Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and / or 4 via ubiquitin proteasome pathway

Bifunctional compounds targeting CDK2 and CDK4 via ubiquitin proteasome pathway address resistance and toxicity issues of CDK4/6 inhibitors by selectively degrading these kinases, enhancing therapeutic efficacy in breast cancer treatment.

WO2026241329A1PCT designated stage Publication Date: 2026-11-19NIKANG THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027893
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-15
Filing Date
2026-05-12
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current CDK4/6 inhibitors face limitations such as primary or acquired resistance due to abnormal activation of CDK2 and exhibit high hematological toxicity, necessitating the development of a molecule that can target both CDK2 and CDK4 to enhance therapeutic efficacy and reduce adverse effects.

Method used

Development of bifunctional compounds that recruit CDK2 and/or CDK4 to ubiquitin ligases for ubiquitylation and proteasomal degradation, utilizing proteolysis-targeting chimeric molecules (PROTACs) to selectively degrade these kinases.

Benefits of technology

The compounds effectively degrade CDK2 and CDK4, potentially overcoming resistance and reducing toxicity, offering enhanced antitumor activity and improved therapeutic outcomes in CDK4/6 inhibitor-refractory breast cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027893_19112026_PF_FP_ABST
    Figure US2026027893_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides certain bifunctional compounds that cause degradation of Cyclin-dependent kinase 2 (CDK2) and / or Cyclin-dependent kinase 4 (CDK4) via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by CDK2 and / or CDK4. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Attorney Docket No. 119005.00357

[0002] Client Ref. No. NKT-25-003PCT

[0003] BIFUNCTIONAL COMPOUNDS CONTAINING 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 AND / OR 4 VIA UBIQUITIN PROTEASOME PATHWAY

[0004] Field of the disclosure

[0005] The present disclosure provides certain bifunctional compounds containing 2, 5 -substituted pyrimidine derivatives that cause degradation of Cyclin-dependent kinase 2 (CDK2) and / or Cyclin-dependent kinase 4 (CDK4) via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by CDK2 and / or CDK4. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

[0006] Background

[0007] Cyclin-dependent kinases (CDKs) are essential cellular serine / threonine kinases that play an important role in orchestrating signaling events, such as DNA replication and protein synthesis, to ensure faithful eukaryotic cell division and proliferation. The regulation of CDK activity is tightly controlled by the fluctuating levels of various cyclins, which form heterodimeric complexes with CDKs to activate them. Out of the 21 identified CDKs, CDKl / Cyclin B, CDK2 / Cyclin E, CDK2 / Cyclin A, CDK4 / Cyclin D, CDK6 / Cyclin D complexes are well known to be vital regulators of cell cycle progression. Other CDKs are involved in regulating gene transcription, DNA repair, differentiation, and apoptosis (see Morgan, D. O. Annu. Rev. Cell. Dev. Biol. (1997) 13: 261-291).

[0008] In the canonical model of cell cycle, mitogenic signaling upregulates D-type cyclins, which directly bind and activate CDK4 / 6. Active CDK4 / 6-cyclin D complexes partially phosphorylate Rb, disrupting the Rb / E2F interaction and de-repressing E2F activity, leading to upregulation of cyclin E, a CDK2 activator. Cdk2-cyclin E further hyper-phosphorylates Rb, releasing E2F to transcribe genes required for S-phase entry. During S-phase, cyclin E is degraded and CDK2 forms a complex with cyclin A to promote phosphorylation of substrates essential for DNA replication and inactivation of E2F, completing S-phase (Asghar et al. Nat. Rev. Drug.

[0009] Discov. (2015) 14: 130-146). CDK1-Cyclin A and CDK1-Cyclin B complexes are activated in late S and G2 phases to drive the transition into and completion of mitosis, respectively (Katsuno et al., 2009; Lindqvist et al., 2009; Lohka et al., 1988).

[0010] Due to their crucial roles in regulating cell cycle and other essential cellular processes, increased activity or temporally abnormal activation of CDKs has been shown to promote tumorigenesis and disease progression (Cordon-Cardo C. Am. J. Pathol. (1995) 147:545-560;

[0011] - 1 - 1107314462\4\AMERICAS

[0012] Attorney Docket No. 119005.00357

[0013] Client Ref. No. NKT-25-003PCT

[0014] Karp JE, Broder S. Nat. Med. (1995) 1:309-320; Hall M, Peters G. Adv. Cancer Res. (1996) 68:67-108). Genetic changes in CDK-cyclin complexes and the proteins that regulate them are widespread in various cancers and are often associated with poor clinical outcomes. Common alterations include amplifications / overexpression of cyclin D, cyclin E, CDK4 and CDK6; loss of Rb; deficiency in CDK inhibitory regulators such as p16, p21, p27, and loss-of-function mutations in FBXW7, a component of SCFFbw7ubiquitin E3 ligase responsible for cyclin E degradation. (Smalley et al. Cancer Res. (2008) 68: 5743-52).

[0015] Over the last two decades, there has been significant interest in developing CDK inhibitors for therapeutic purposes. In combination with endocrine therapies, selective reversible inhibitors of CDK4 and CDK6 e.g., palbociclib, ribociclib, and abemaciclib have revolutionized the therapeutic management for hormone receptor-positive (HR+) metastatic breast cancer (MBC). Ongoing clinical trials are also investigating these CDK4 / 6 inhibitors as single agents or in combination with other therapeutics for various cancers. (O'Leary et al. Nature Reviews (2016) 13:417-430).

[0016] Despite their significant clinical efficacy in ER-positive metastatic breast cancer, CDK4 / 6 inhibitors have some limitations. One major drawback is the development of primary or acquired resistance over time. An important mechanism of resistance involves the abnormal activation of CDK2. This can occur due to an overactivated CDK2 / Cyclin E complex caused by elevated Cyclin E expression (Asghar, U. et al. Clin. Cancer Res. (2017) 23:5561) or formation of the noncanonical CDK2 / cyclin DI complex in response to CDK4 / 6 inhibition (Herrera- Abreu MT et al, Cancer Res. (2006) 15: 2301), which bypasses the need for CDK4 / 6 for cell cycle reentry. Additionally, CDK4 / 6 inhibitors palbociclib and ribociclib exhibit relatively high hematological toxicity, primarily neutropenia. CDK6 is highly expressed in the blood system and plays a role in regulating the growth of hematopoietic cells. Therefore, it is generally believed that the inhibition of CDK6 leads to neutropenia, while breast cancer cells mainly depend on CDK4 for proliferation. Abemaciclib exhibits weaker inhibition of CDK6 than CDK4, resulting in lower hematological toxicity.

[0017] Currently, multiple CDK2 inhibitors are under clinical development in solid tumors, including PF-07104091 (NCT04553133), BLU-222 (NCT05252416), INCB123667 (NCT05238922), INX-315 (NCT05735080), ARTS-021 (NCT05867251), AZD8421

[0018] (NCT06188520) and BG-68501 (NCT06257264). Thus far, PF-07104091 and BLU-222 have demonstrated single agent activities in CDK4 / 6 inhibitor refractory breast cancer patients. In addition, a CDK4 specific inhibitor PF-07220060 (NCT04557449), in combination with endocrine therapy, has demonstrated clinical responses and lower neutropenia adverse events in CDK4 / 6

[0019] - 2 - 1107314462\4\AMERICAS

[0020] Attorney Docket No. 119005.00357

[0021] Client Ref. No. NKT-25-003PCT inhibitor refractory breast cancer patients. Thus, a molecule blocking both CDK2 and CDK4 as single agent or in combination with endocrine therapy, may address the primary and acquired resistance to CDK4 / 6 inhibitors, leading to enhanced antitumor activities and reduced adverse effects to achieve greater therapeutic efficacy in HR+ HER2- breast cancer.

[0022] Considering these factors, developing a small molecule inhibitor or a proteolysis-targeting chimeric molecule (PROTAC) that specifically targets CDK4 and / or CDK2 could represent a therapeutic opportunity with reduced toxicity and improved overall therapeutic efficacy.

[0023] PROTACs are bifunctional molecules comprised of target protein-recruitment moiety and a ligand for E3 ligase, connected by a biocompatible linker. PROTACs bring the protein of interest and the E3 ligase into close proximity and induce ubiquitination and subsequent degradation of the target protein by proteasome.

[0024] Compared to small molecule drugs that typically bind disease-relevant proteins and inhibit their function, PROTACs display several unique and attractive features that make them desirable drug candidates. For example, PROTACs have been shown to be more selective than their inhibitor counterparts, potentially reducing off-target toxicity. Moreover, PROTACs can perform multiple rounds of target ubiquitination and degradation. Due to this catalytic mode of action, PROTACs can function at sub-stoichiometric receptor occupancies. The E3 ligases used in PROTACs mainly include cereblon (CRBN), Von Hippel-Lindau-containing complex (VHL), inhibitor of apoptosis protein (IAP), and mouse double minute 2 (MDM2).

[0025] Therefore, bifunctional compounds that could recruit CDK2 and / or CDK4 to a ubiquitin ligase and thereby causing ubiquitylation and proteasomal degradation of CDK2 andCDK4 are desirable. The present disclosure fulfills this and related needs.

[0026] Summary

[0027] In a first aspect, provided is a compound of Formula (IA):

[0028]

[0029] 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0030] Client Ref. No. NKT-25-003PCT wherein:

[0031] R1is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyloxy, halo, haloalkyl, haloalkoxy, alkoxy, aryloxy, or cyano and wherein cycloalkyl, either alone or as part of cycloalkoxy, is substituted with one to three halo;

[0032] R2and R2aare independently hydrogen or deuterium;

[0033] Hy is cycloalkylene, arylene, heteroarylene, heterocyclylene, bicyclic heterocyclylene, spiro heterocyclylene, bridged heterocyclylene, or fused heterocyclylene, where each of the aforementioned rings is substituted with Ra, Rb, and Rcindependently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, alkoxy, hydroxy, and cyano;

[0034] Degron is an E3 ubiquitin ligase ligand selected from:

[0035] (a) a group of formula (i):

[0036]

[0037] (b) a group of formula (ii):

[0038]

[0039] where:

[0040] Yais CH orN;

[0041] Zais a bond, -CH2-, -NH-, -O-, or -NHC(O)- where NH of -NHC(O)- is attached to Ya;

[0042] ring A is a group of formula (a) or (b):

[0043]

[0044] where:

[0045] Raa, Rbb, Rcc, and Rddare independently selected from hydrogen, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, and cyano;

[0046] - 4 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0047] Client Ref. No. NKT-25-003PCT

[0048] R4and R5are independently hydrogen or alkyl; or R4and R5together with the carbon to which they are attached form > C=O; and

[0049] R6is hydrogen or alkyl;

[0050] ring B is phenylene, cyclylaminylene, a 5- or 6-membered monocyclic heteroarylene, or a 9- or 10-membered fused bicyclic heteroarylene, wherein each heteroarylene ring contains one to three nitrogen ring atoms and further wherein the phenylene, cyclylaminylene, and each heteroarylene are independently substituted with Reeand Rffindependently selected from hydrogen, alkyl, cycloalkyl, alkoxy, halo, haloalkyl, haloalkoxy, and cyano; and

[0051] L is -Z1-Z2-Z3-Z4-Z5-Z6- where:

[0052]

[0053] where:

[0054] n is 0 or 1;

[0055] Z is cycloalkylene, phenylene, monocyclic heteroarylene, heterocyclylene, unsaturated heterocyclylene, bicyclic heterocyclylene, bridged heterocyclylene, unsaturated bridged heterocyclylene, fused heterocyclylene, spiro heterocyclylene, 11 to 13 -membered spiro heterocyclylene, unsaturated spiro heterocyclylene, or 11 to 13 -membered unsaturated spiro heterocyclylene;

[0056] Rdis hydrogen, alkyl, alkoxy, alkoxyalkyl, halo, haloalkyl, haloalkoxy, cyano, and cyanoalkyl;

[0057] Reis hydrogen, alkyl, alkoxy, alkoxyalkyl, halo, haloalkyl, or haloalkoxy;

[0058] Rfis hydrogen, alkyl, alkoxy, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, halo, haloalkyl, haloalkoxy, haloalkoxyalkyl, hydroxy, hydroxyalkyl, alkylsulfonyl, cyano, cyanoalkyl, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonyl, aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclyl, or heterocyclylalkyl where heteroaryl, heteroaryl of heteroaralkyl, heterocyclyl, and heterocyclyl of heterocyclylalkyl are unsubstituted or substituted with one or two substituents independently selected from halo and alkyl;

[0059] Rgis deuterium, alkyl, halo, or haloalkyl; provided that when Z is cycloalkylene, phenylene, monocyclic heteroarylene, heterocyclylene, unsaturated heterocyclylene, bicyclic heterocyclylene, bridged heterocyclylene, unsaturated bridged heterocyclylene, fused heterocyclylene, spiro heterocyclylene, or 11 to 13 -membered spiro heterocyclylene, then at least three of Rd, Re, Rf, and Rgare other than hydrogen;

[0060] - 5 - 1107314462\4\AMERICAS

[0061] Attorney Docket No. 119005.00357

[0062] Client Ref. No. NKT-25-003PCT

[0063] Z2is a bond, alkylene, alkynylene, -C(O)-, -C(O)N(R)-, -NR’ (CO)-, -(O-alkylene)b-, -(alkylene-O)b-, -O(CH2)7-, -O(CH2)8-, cycloalkylene, or heterocyclylene, where each ring is substituted with Rjand Rkindependently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, hydroxy, amino, alkylamino, and dialkylamino;

[0064] Z3is a bond, alkylene, alkynylene, -C(O)NR-, -NR’(CO)-, -O-, -NR”-, -(O-alkylene)c-, -(alkylene-O)c-, cycloalkylene, spiro cycloalkylene, phenylene, -(alkylene)-phenylene-, -phenylene-(alkylene)-, monocyclic heteroarylene, -(alkylene)-monocyclic heteroarylene-, -monocyclic heteroarylene-(alkylene)-, heterocyclylene, -(alkylene)-heterocyclylene-, -heterocyclylene-(alkylene)-, bicyclic heterocyclylene, bridged heterocyclylene, -(alkylene)-bridged heterocyclylene-, -bridged heterocyclylene-(alkylene)-, fused heterocyclylene, spiro heterocyclylene, -(alkyl ene)-spiro heterocyclylene-, -spiro heterocyclylene-(alkylene)-, or 11 to 13 membered spiro heterocyclylene, where each ring, by itself or as part of another group, is substituted with Rmand Rnindependently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, hydroxy, amino, alkylamino, and dialkylamino;

[0065] Z4is a bond, alkylene, alkynylene, -(alkylene-NR”)-, -(NR”-alkylene)-, -O-, -C(O)-, -NR”-, -(O-alkylene)a-, -(alkylene-O)a-, cycloalkylene, -(alkylene)-cycloalkylene-, -cycloalkylene-(alkylene)-, spiro cycloalkylene, phenylene, heteroarylene, heterocyclylene, -(alkylene)-heterocyclylene-, -heterocyclylene-(alkylene)-, fused heterocyclylene, bridged heterocyclylene, -(alkylene)-bridged heterocyclylene-, -bridged heterocyclylene-(alkylene)-, spiro heterocyclylene, -(alkylene)-spiro heterocyclylene, or -spiro heterocyclylene-(alkylene)-, where each ring, by itself or as part of another group, is substituted with R° and Rpindependently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, hydroxy, amino, alkylamino, and dialkylamino;

[0066] Z5is phenylene, monocyclic heteroarylene, or heterocyclylene, where each ring is substituted with Rqand Rrindependently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, hydroxy, amino, alkylamino, and dialkylamino; and

[0067] Z6is -S(O)2-;

[0068] where each R, R’ and R” is independently hydrogen or alkyl, each b, c, and d is independently an integer selected from 1 to 6, and each alkylene of -Z2-, -Z3-, - and

[0069] -Z4-, by itself or as part of another group, is independently substituted with Rsand Rtwhere Rsis hydrogen or deuterium and Rtis hydrogen, deuterium, haloalkyl, hydroxy, alkoxy, cyano, cycloalkyl, heterocyclyl, aryl, or monocyclic heteroaryl, wherein cycloalkyl, heterocyclyl, aryl, monocyclic heteroaryl are substituted with one or two substituents independently selected from

[0070] - 6 - 1107314462\4\AMERICAS

[0071] Attorney Docket No. 119005.00357

[0072] Client Ref. No. NKT-25-003PCT hydrogen, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, or cyano; provided that at least one of -Z2-Z3-Z4- is not a bond;

[0073] or a pharmaceutically acceptable salt thereof.

[0074] In an embodiment of the first aspect, provided is a compound of Formula (I):

[0075]

[0076] wherein:

[0077] R1, R2, R2a, Hy, Degron are as defined in Formula (IA), and

[0078] L is -Z1-Z2-Z3-Z4-Z5-Z6- where:

[0079]

[0080] Z is cycloalkylene, phenylene, monocyclic heteroarylene, heterocyclylene, unsaturated heterocyclylene, bicyclic heterocyclylene, bridged heterocyclylene, unsaturated bridged heterocyclylene, fused heterocyclylene, spiro heterocyclylene, 11 to 13 -membered spiro heterocyclylene, unsaturated spiro heterocyclylene, or 11 to 13 -membered unsaturated spiro heterocyclylene;

[0081] Rdis alkyl, alkoxy, alkoxyalkyl, halo, haloalkyl, haloalkoxy, cyano, and cyanoalkyl;

[0082] Reis alkyl, alkoxy, alkoxyalkyl, halo, haloalkyl, or haloalkoxy;

[0083] Rfis alkyl, alkoxy, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, halo, haloalkyl, haloalkoxy, haloalkoxyalkyl, hydroxy, hydroxyalkyl, alkylsulfonyl, cyano, cyanoalkyl, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonyl, aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclyl, or heterocyclylalkyl where heteroaryl, heteroaryl of heteroaralkyl, heterocyclyl, and heterocyclyl of heterocyclylalkyl are unsubstituted or substituted with one or two substituents selected from halo and alkyl;

[0084] Rgis independently deuterium, alkyl, halo, or haloalkyl; and

[0085] Z2, Z3, Z4, Z5, and Z6are as defined in Formula (IA);

[0086] or a pharmaceutically acceptable salt thereof.

[0087] 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0088] Client Ref. No. NKT-25-003PCT

[0089] In a second aspect, provided is a method of treating a disease mediated by CDK2 and / or CDK4 in a patient, preferably the patient is in need of such treatment, which method comprises administering to the patient a therapeutically effective amount of a compound of Formula (I) of the first aspect (and any of the embodiments thereof described herein), or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition thereof disclosed in the third aspect (or any embodiments thereof described herein). In a first embodiment of the third aspect, the disease is cancer. In a second embodiment of the third aspect the disease is cancer selected from lung cancer (c.g, adenocarcinoma, small cell lung cancer, non-small cell lung carcinomas, parvicellular and non-parvicellular carcinoma, bronchial carcinoma, bronchial adenoma, and / or pleuropulmonary blastoma), skin cancer (c.g, melanoma, squamous cell carcinoma, Kaposi sarcoma, and / or Merkel cell skin cancer), bladder cancer, breast cancer, cervical cancer, colorectal cancer, cancer of the small intestine, colon cancer, rectal cancer, cancer of the anus, endometrial cancer, gastric cancer, head and neck cancer (c.g, cancers of the larynx, hypopharynx, nasopharynx, oropharynx, lips, and / or mouth), liver cancer (e.g., hepatocellular carcinoma and / or cholangiocellular carcinoma), ovarian cancer, prostate cancer, testicular cancer, uterine cancer, esophageal cancer, gall bladder cancer, pancreatic cancer (e.g., exocrine pancreatic carcinoma), stomach cancer, thyroid cancer, parathyroid cancer, bone cancer, biliary tract cancer, vaginal cancer, astrocytoma, liposarcomas, glioblastoma, neuroblastoma and / or kidney cancer. In a third embodiment of the third aspect, the cancers are those that are resistant to CDK4 / 6 inhibitors through CDK2 -mediated mechanisms e.g., breast cancer. In a fourth embodiment of the third aspect, the disease is an autoimmune disease or a condition associated with an autoimmune disease. In some embodiments of the third aspect, the autoimmune disease or condition associated with an autoimmune disease is selected from rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), primary Sjogren’s syndrome (pSS), multiple sclerosis (MS), Crohn’s disease (CD), uveitis, pemphigus vulgaris, and sepsis. In a fifth embodiment of the third aspect, the disease is gout.

[0090] In a third aspect, provided is a pharmaceutical composition comprising a compound of Formula (I) (or any of the embodiments thereof described herein), or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.

[0091] In a fourth aspect, provided is a compound of Formula (I) (or any of the embodiments thereof described herein), or a pharmaceutically acceptable salt thereof for use as a medicament. In one embodiment of the fourth aspect, the compound of Formula (I) (or any embodiments thereof disclosed herein), or a pharmaceutically acceptable salt thereof is useful for the treatment of one or more of diseases disclosed in the second aspect above.

[0092] - 8 - 1107314462\4\AMERICAS

[0093] Attorney Docket No. 119005.00357

[0094] Client Ref. No. NKT-25-003PCT

[0095] In a fifth aspect, provided is the use of a compound of Formula (I) (or any of the embodiments thereof described herein), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease in a patient in which the activity of CDK2 and / or CDK4 contributes to the pathology and / or symptoms of the disease. In one embodiment of the fifth aspect, the disease is one or more of diseases disclosed in the second aspect above.

[0096] In an embodiment of any one of the above aspects, CDK2 and / or CDK4 are selectively degraded over CDK1.

[0097] The ability of compounds of Formula (I) to degrade CDK2 and CDK4 selectively over CDK1 was measured by determining potency of the compounds in inhibiting retinoblastoma protein (Rb) phosphorylation in OVCAR3 (CDK2 dependent cell line), T47D (CDK4 dependent cell line) and KYSE520 (CDK1 dependent cell line) as described in Biological Example 1 below, and then determining the ratio of pRb IC50 from OVCAR3 and KYSE520 and T47D and KYSE520, respectively. Additionally, although the compounds of Formula (I) degrade both CDK2 and CDK4, they can, however, selectively degrade CDK2 over CDK4 or visa-versa by determining the ratio of Rb IC50 from OVCAR3 and T47D. For the sake of clarity, selectively degrade as used herein means the compound disclosed herein may cause degradation of CDK2 to a greater extent than CDK4 or vice-versa.

[0098] In the aforementioned aspects involving the treatment of cancer, further embodiments are provided comprising administering the compound Formula (I), or a pharmaceutically acceptable salt thereof (or any embodiments thereof disclosed herein) or the pharmaceutical composition of the third aspect, in combination with at least one additional anticancer agent. When combination therapy is used, the agents can be administered simultaneously or sequentially.

[0099] Detailed Description

[0100] Definitions:

[0101] Unless otherwise stated, the following terms used in the specification and claims are defined for the purposes of this Application and have the following meaning:

[0102] “Alkyl” means a linear or branched saturated monovalent hydrocarbon radical of one to six carbon atoms, e.g., methyl, ethyl, propyl, 2-propyl, butyl, pentyl, and the like.

[0103] “Alkenyl” means a linear or branched monovalent hydrocarbon radical of two to six carbon atoms containing a double bond e.g., ethenyl, propenyl, 2-propenyl, butenyl, pentenyl, and the like.

[0104] “Alkynyl” means a linear or branched monovalent hydrocarbon radical of two to six carbon atoms containing a triple bond e.g., ethynyl, propynyl, 2-propynyl, butynyl, and the like.

[0105] - 9 - 1107314462\4\AMERICAS

[0106] Attorney Docket No. 119005.00357

[0107] Client Ref. No. NKT-25-003PCT

[0108] “Alkylene” means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms unless otherwise stated e.g., methylene, ethylene, propylene, 1 -methylpropylene, 2-methylpropylene, butylene, pentylene, and the like.

[0109] “Alkynylene” means a linear unsaturated divalent hydrocarbon radical of two to six carbon atoms or a branched unsaturated divalent hydrocarbon radical of three to six carbon atom containing a triple bond, e.g.,

[0110]

[0111] ,, and the like.

[0112] “Alkoxy” means a -ORZradical where Rzis alkyl as defined above, e.g., methoxy, ethoxy, propoxy, or 2-propoxy, n-, iso-, or Zc / V-butoxy, and the like.

[0113] “Alkoxyalkyl” means alkyl as defined above that is substituted with alkoxy as defined above e.g., methoxy methyl, methoxy ethyl, ethoxy ethyl, and the like.

[0114] “Alkyl sulfonyl” means an -SChR2radical where Rzis alkyl as defined above, e.g., methylsulfonyl, and the like.

[0115] “Alkoxycarbonyl” means a -C(O)ORZradical where Rzis alkyl as defined above, e.g., methoxycarbonyl, ethoxycarbonyl, and the like.

[0116] “Amino” means -NH2.

[0117] “Aminoalkyl” means alkyl as defined above that is substituted with -NH2 e.g., NEfcmethyl, NEhethyl, and the like.

[0118] “Aminocarbonyl” means -C(O)NH2.

[0119] “Alkylaminocarbonyl” means -C(O)NHRZradical where Rzis alkyl as defined above e.g., methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, and the like.

[0120] “Dialkylaminocarbonyl” means -C(O)NRzlRzradical where Rzand Rzlare independently alkyl as defined above e.g., dimethylaminocarbonyl, di ethylaminocarbonyl, dipropylaminocarbonyl, and the like.

[0121] “Alkylamino” means -NHRZradical where Rzis alkyl as defined above e.g., methylamino, ethylamino, propylamino, and the like.

[0122] “Alkylaminoalkyl” means alkyl as defined above that is substituted with alkylamino as defined above e.g., methyaminomethyl, methylaminoethyl, ethylaminoethyl, and the like.

[0123] “Aryl” means a monovalent monocyclic or bicyclic aromatic hydrocarbon radical of 6 to 10 ring atoms e.g., phenyl or naphthyl.

[0124] “Aralkyl” and “arylalkyl” means an -(alkylene)-Rzradical where Rzis aryl as defined above e.g. benzyl.

[0125] “Arylene” means a divalent aryl (as defined above) radical e.g., phenylene or naphthylene.

[0126] - 10 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0127] Client Ref. No. NKT-25-003PCT

[0128] “Aryloxy” means a -ORzradical where Rzis aryl as defined above e.g., phenyloxy (or phenoxy) and naphthyloxy.

[0129] “Bicyclic heterocyclylene” means a saturated or unsaturated, divalent fused bicyclic group of 8 to 12 ring atoms in which one, two, or three ring atoms are heteroatoms independently selected from N, O, and S(O)n, where n is an integer selected from 0 to 2, the remaining ring atoms being carbon, unless stated otherwise. Additionally, one or two ring carbon atoms of the bicyclic heterocyclylene ring can optionally be replaced by a -CO- group. More specifically the term bicyclic heterocyclylene includes, but is not limited to,, decahydro-2,6-naphthyridin-diyl, octahydrocyclopenta[c]pyrrol-diyl, octahydro-lH-pyrrolo[3,4-c]pyridin-diyl, hexahydrofuro[3,2-b]furan-3,6-diyl, and the like. When the heterocyclylene ring is unsaturated it can contain one or two ring double bonds provided that the ring is not aromatic.

[0130] “Bridged heterocyclylene” means a saturated divalent bicyclic ring having 5 to 9 ring carbon ring atoms in which two non-adjacent ring atoms are linked by a (CRzRz’)ngroup where n is an integer selected from 1 to 3 and Rzand Rz’ are independently H or methyl (also may be referred to herein as “bridging” group) and further wherein one or two ring carbon atoms, including an atom in the bridging group, is replaced by a heteroatom selected from N, O, and S(O)n, where n is an integer selected from 0 to 2. Bridged heterocyclylene is optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, and cyano unless stated otherwise. Examples include, but are not limited to, 3,8-diazabicyclo[3.2.1]octa-3,8-diyl, 7-oxabicyclo[2.2.1]heptan-diyl, 2,5-diazabicyclo[2.2.1]heptan-diyl, 3,6-diazabicyclo-[3.1.1]heptan-diyl, 2,5-diazabicyclo[2.2.2]octan-diyl, 3,8-diazabicyclo[3.2.1]octan-diyl,

[0131] 6-azabicyclo[3.1.1]heptan-diyl, 8-azabicyclo[3.2.1]octan-diyl, and the like.

[0132] “Cycloalkyl” means a monocyclic saturated monovalent hydrocarbon radical of three to ten carbon atoms. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

[0133] “Cycloalkyloxy or cycloalkoxy” means a -ORZradical where Rzis cycloalkyl as defined above. Examples include, but are not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.

[0134] “Cycloalkylalkyl” means an -(alkylene)-Rzradical where Rzis cycloalkyl as defined above. Examples include, but are not limited to, cyclopropylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclohexylmethyl, and the like.

[0135] “Cycloalkylene” means a divalent saturated hydrocarbon radical of three to six carbon atoms, unless stated otherwise e.g., 1,1 -cyclopropylene, 1,1 -cyclobutylene, 1,4-cyclohexylene, and the like.

[0136] - 11 - 1107314462\4\AMERICAS

[0137] Attorney Docket No. 119005.00357

[0138] Client Ref. No. NKT-25-003PCT

[0139] “Carbonyl” means -C(O)-.

[0140] “Carboxy” means -COOH.

[0141] “Cyclylaminylene” means a saturated divalent monocyclic ring of 4 to 8 ring atoms in which one or two ring atoms are nitrogen, the remaining ring atoms being carbon. More specifically, the term cyclylaminyl includes, but is not limited to, pyrrolidinylene (pyrrolidin-diyl), piperidinylene (piperidin-diyl), homopiperidinylene (homopiperidin-diyl), piperazinylene (piperazin-diyl), and the like.

[0142] “Cyanoalkyl” means alkyl radical as defined above that is substituted with a cyano e.g., cyanomethyl, cyanoethyl, and the like.

[0143] “Deuterium” means refers to2H or D.

[0144] “Dialkylamino” means a -NRZRZradical where each Rzis alkyl as defined above, e.g., dimethylamino, methylethylamino, n-propylmethylamino, 2-propylmethylamino, n-, iso-, or / c / V-butylmethylamino, and the like.

[0145] “Dialkylaminoalkyl” means alkyl as defined above that is substituted with dialkylamino as defined above e.g., dimethyaminomethyl, dimethylaminoethyl, ethylmethylaminoethyl, and the like.

[0146] “Fused heterocyclylene” means a divalent bicyclic ring in which two adjacent ring atoms of a saturated or partially unsaturated (but not aromatic) monocyclic ring of 4 to 7 ring atoms having one or two heteroatoms independently selected from N, O, and S(O)n (where n is 0, 1, or 2) and the remaining ring atoms being carbon, are fused to two adjacent ring members of a phenyl, or a five or six membered heteroaryl, each as defined herein, unless stated otherwise. The nitrogen atom is optionally oxidized or quatemized. The fused heterocyclylene can be attached to the remainder of the molecule at any two atoms of the ring. Representative examples include, but are not limited to, l,2,3,4-tetrahydroquinolin-l,4-diyl, 3,4-dihydro-2H-benzo[b][l,4]oxazin-5,8-diyl, 3,4-dihydro-2H-pyrido[3,2-b][l,4]oxazin-diyl, 4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-diyl, and the like.

[0147] “Halo” means fluoro, chloro, bromo, or iodo, preferably fluoro or chloro.

[0148] “Haloalkyl” means alkyl radical as defined above, which is substituted with one or more halogen atoms, e.g., one to five halogen atoms, such as fluorine or chlorine, including those substituted with different halogens, e.g., -CH2CI, -CF3, -CHF2, -CH2CF3, -CF2CF3, -CF(CH3)2, and the like. When the alkyl is substituted with only fluoro, it can be referred to in this Application as fluoroalkyl.

[0149] “Haloalkoxy” means a -ORZradical where Rzis haloalkyl as defined above e.g., -OCF3,

[0150] - 12 - 1107314462\4\AMERICAS

[0151] Attorney Docket No. 119005.00357

[0152] Client Ref. No. NKT-25-003PCT

[0153] -OCHF2, and the like. When Rzis haloalkyl where the alkyl is substituted with only fluoro (in some examples, one or more fluoro), it is referred to in this Application as fluoroalkoxy.

[0154] “Haloalkoxyalkyl” means a -(alkylene)ORzradical where Rzis haloalkyl as defined above e.g, -CH2OCF3, - CH2CH2OCF3and the like.

[0155] “Hydroxyalkyl” means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with one or two hydroxy groups, provided that if two hydroxy groups are present, they are not both present on the same carbon atom. Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxy-ethyl, 2-hydroxypropyl, 3 -hydroxypropyl, l-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3 -hydroxybutyl, 4-hydroxybutyl, 2,3 -dihydroxypropyl, l-(hydroxymethyl)-2-hydroxyethyl, 2,3 -dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl, preferably 2-hydroxyethyl, 2,3-dihydroxypropyl, and l-(hydroxymethyl)-2 -hydroxy ethyl.

[0156] “Heteroaryl” means a monovalent monocyclic or fused bicyclic aromatic radical of 5 to 10 ring atoms, unless otherwise stated, where one or more, (in one embodiment, one, two, or three), ring atoms are heteroatom selected from N, O, and S, the remaining ring atoms being carbon. Representative examples include, but are not limited to, pyrrolyl, thienyl, thiazolyl, imidazolyl, furanyl, indolyl, isoindolyl, indazolyl, imidazo[l,2-a]pyridinyl, imidazo[l,2-a]pyrazinyl, oxazolyl, isoxazolyl, oxadiazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl, and the like. As defined herein, the terms “heteroaryl” and “aryl” are mutually exclusive. When the heteroaryl ring contains 5- or 6 ring atoms and is a monocyclic ring, it is also referred to herein as 5-or 6-membered monocyclic heteroaryl or monocyclic heteroarylene. When the heteroaryl ring contains 9- or 10 ring atoms and is a fused bicyclic ring, it is also referred to herein as 9-or 10-membered fused bicyclic heteroaryl.

[0157] “Heteroarylene” means a divalent heteroaryl radical as defined above, unless stated otherwise. Representative examples include, but are not limited to, benzimidazoldiyl e.g., benzimidazole-l,5-diyl, and the like. When the heteroarylene ring contains 5- or 6 ring atoms and is a monocyclic ring, it is also referred to herein as monocyclic heteroarylene or as 5-or 6-membered monocyclic heteroarylene e.g., pyrazolyl-1.4-diyl. When the heteroarylene ring contains 9- or 10 ring atoms and is a fused bicyclic ring, it is also referred to herein as 9-or 10-membered fused bicyclic heteroarylene.

[0158] “Heteroarylalkyl” or “heteroaralkyl” means an -(alkylene)-Rzradical where Rzis heteroaryl as defined above.

[0159] - 13 - 1107314462\4\AMERICAS

[0160] Attorney Docket No. 119005.00357

[0161] Client Ref. No. NKT-25-003PCT

[0162] “Heterocyclyl” means a saturated, monovalent monocyclic group of 4 to 10 ring atoms in which one or two ring atoms are heteroatom independently selected from N, O, and S(O)n, where n is an integer selected from 0 to 2, the remaining ring atoms being C, unless stated otherwise. Additionally, one or two ring carbon atoms in the heterocyclyl ring can optionally be replaced by a -CO- group. More specifically the term heterocyclyl includes, but is not limited to, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, 2-oxopyrrolidinyl, 2-oxopiperidinyl, morpholinyl, piperazinyl, tetrahydro-furanyl, tetrahydro-pyranyl, thiomorpholinyl, and the like. When the heterocyclyl group contains at least one nitrogen atom, it is also referred to herein as heterocycloamino and is a subset of the heterocyclyl group.

[0163] “Heterocyclylalkyl” means an -(alkylene)-Rzradical where Rzis heterocyclyl as defined above e.g. piperidinylmethyl and piperazinylmethyl.

[0164] “Heterocyclylene” means a saturated, divalent, monocyclic group of 4 to 10 ring atoms in which one or two ring atoms are heteroatom independently selected from N, O, and S(O)n, where n is an integer selected from 0 to 2, the remaining ring atoms being C, unless stated otherwise. Additionally, one or two ring carbon atoms in the heterocyclylene ring can optionally be replaced by a -CO- group. More specifically, the term heterocyclylene includes, but is not limited to,

[0165]

[0166] , piperidin-l,4-diyl, azeti din-1, 3-diyl, and the like.

[0167] “Phenylene” means divalent phenyl.

[0168] The term “oxo,” as used herein, alone or in combination, means =(O).

[0169] The phrase “optionally” or “optional” as used herein means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, the phrase “alkylene optionally substituted with halo” is intended to cover alkylene that is unsubstituted and alkylene that is substituted with halo.

[0170] “Spiro cycloalkylene” means a saturated bicyclic divalent hydrocarbon ring having 6 to 12 ring atoms wherein the rings are connected through only one atom, the connecting atom is also called the spiroatom, most often a quaternary carbon (“spiro carbon”). Spiro cycloalkylene is optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, and cyano, unless stated otherwise. Representative examples include, but are not limited to, spiro[3,5]nonandiyl e.g., spiro[3.5]nonane-2,7-diyl, and the like.

[0171] “Spiro heterocyclylene" means a saturated bicyclic divalent ring having 6 to 10 ring atoms in which one, two, or three ring atoms are heteroatom selected from N, O, and S(O)n, where n is an integer selected from 0 to 2, the remaining ring atoms being C and the rings are connected

[0172] - 14 - 1107314462\4\AMERICAS

[0173] Attorney Docket No. 119005.00357

[0174] Client Ref. No. NKT-25-003PCT through only one atom, the connecting atom is also called the spiroatom, most often a quaternary carbon (“spiro carbon”). Spiro heterocyclylene is optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, and cyano, unless stated otherwise. Representative examples include, but are not limited to, 2-azaspiro[3.3]heptan-diyl, 2,6-diazaspiro[3.3]heptan-diyl, l,7-diazaspiro[3.5]nonan-diyl, 2,7-diazaspiro[3.5]nonan-diyl, 3,9-diazaspiro[5.5]undecan-diyl, and the like.

[0175] “11 to 13 membered spiro heterocyclylene” means a saturated bicyclic divalent ring having 11 to 13 ring atoms in which one, two, or three ring atoms are heteroatom(s) selected from N, O, and S(O)n, where n is an integer selected from 0 to 2, the remaining ring atoms being C and the rings are connected through only one atom, the connecting atom is also called the spiroatom, most often a quaternary carbon (“spiro carbon”). The 11 to 13 membered spiro heterocyclylene is optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, and cyano, unless stated otherwise. Representative examples include, but are not

[0176] limited to,

[0177]

[0178] diazaspiro[5.5]undecan-diyl, 1-oxa-diazaspiro[5.5]undecan-diyl, and the like.

[0179] “Unsaturated bridged heterocyclylene” means a nonaromatic divalent bicyclic ring of 5 to

[0180] 9 ring carbon ring atoms containing one double bond in which two non-adjacent ring atoms are linked by a (CRzRz’)ngroup where n is an integer selected from 1 to 3 and Rzand Rz’ are independently H or methyl (also may be referred to herein as “bridging” group) and further wherein one or two ring carbon atoms, including an atom in the bridging group, is replaced by a heteroatom selected from N, O, and S(O)n, where n is an integer selected from 0 to 2. Bridged heterocyclylene is optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, and cyano unless stated otherwise. Examples include, but are not

[0181]

[0182] limited to, and the like.

[0183] “Unsaturated heterocyclylene” means a nonaromatic, divalent, monocyclic group of 5 to 10 ring atoms containing one double bond in which one or two ring atoms are heteroatom independently selected from N, O, and S(O)n, where n is an integer selected from 0 to 2, the remaining ring atoms being C, unless stated otherwise. Additionally, one or two ring carbon atoms in the heterocyclylene ring can optionally be replaced by a -CO- group. More specifically, the term unsaturated heterocyclylene includes, but is not limited to, tetrahydropiperidin-l,4-diyl, tetrahydropiperazindiyl, and the like.

[0184] - 15 - 1107314462\4\AMERICAS

[0185] Attorney Docket No. 119005.00357

[0186] Client Ref. No. NKT-25-003PCT

[0187] “Unsaturated spiro heterocyclylene" means a nonaromatic bicyclic divalent ring of 6 to 10 ring atoms containing one or two double bonds in which one, two, or three ring atoms are heteroatom selected from N, O, and S(O)n, where n is an integer selected from 0 to 2, the remaining ring atoms being C and the rings are connected through only one atom, the connecting atom is also called the spiroatom, most often a quaternary carbon (“spiro carbon”). Spiro heterocyclylene is optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, and cyano, unless stated otherwise. Representative examples include,

[0188]

[0189] “Unsaturated 11 to 13 membered spiro heterocyclylene” means a nonaromatic bicyclic divalent ring of 11 to 13 ring atoms containing one or two double bonds in which one, two, or three ring atoms are heteroatom(s) selected from N, O, and S(O)n, where n is an integer selected from 0 to 2, the remaining ring atoms being C and the rings are connected through only one atom, the connecting atom is also called the spiroatom, most often a quaternary carbon (“spiro carbon”). The 11 to 13 membered spiro heterocyclylene is optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, and cyano, unless stated

[0190] otherwise. Representative examples include, but are not limited to,

[0191]

[0192]

[0193] the like.

[0194] The present disclosure also includes protected derivatives of compounds of Formula (I) (or any embodiments thereof disclosed herein), or a pharmaceutically acceptable salt thereof. For example, when compounds of Formula (I) contain groups such as hydroxy, carboxy, or any group containing a nitrogen atom(s), these groups can be protected with suitable protecting groups. A comprehensive list of suitable protective groups can be found in T. W. Greene, Protective Groups in Organic Synthesis, 5thEd., John Wiley & Sons, Inc. (2014), the disclosure of which is incorporated herein by reference in its entirety. The protected derivatives of compounds of the present disclosure can be prepared by methods well known in the art.

[0195] The present disclosure also includes polymorphic forms and deuterated forms of the compound of Formula (I) (or any embodiments thereof disclosed herein), or a pharmaceutically acceptable salt thereof.

[0196] The term “prodrug” refers to a compound that is made more active in vivo. Certain compounds Formula (I) (and any embodiment thereof disclosed herein including specific

[0197] - 16 - 1107314462\4\AMERICAS

[0198] Attorney Docket No. 119005.00357

[0199] Client Ref. No. NKT-25-003PCT compounds) may also exist as prodrugs, as described in Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003). Prodrugs of the compounds described herein are structurally modified forms of the compound that readily undergo chemical changes under physiological conditions to provide the active compound. Prodrugs are often useful because, in some situations, they may be easier to administer than the compound, or parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. A wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. An example, without limitation, of a prodrug would be a compound which is administered as an ester (the “prodrug”), but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound.

[0200] A “pharmaceutically acceptable salt” of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include:

[0201] acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as formic acid, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxy ethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid,

[0202] 4-toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4,4’-methylenebis-(3-hydroxy-2-ene-l -carboxylic acid), 3 -phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or

[0203] salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine,

[0204] A-methylglucamine, and the like. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington’s Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, which is incorporated herein by reference in its entirety.

[0205] - 17 - 1107314462\4\AMERICAS

[0206] Attorney Docket No. 119005.00357

[0207] Client Ref. No. NKT-25-003PCT

[0208] The compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may have asymmetric centers. Compounds of Formula (I), (and any embodiment thereof disclosed herein including specific compounds) containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art. All chiral, diastereomeric, all mixtures of chiral or diastereomeric forms, and racemic forms are within the scope of this disclosure, unless the specific stereochemistry or isomeric form is specifically indicated. It will also be understood by a person of ordinary skill in the art that when a compound is denoted as (R) stereoisomer, it may contain the corresponding (S) stereoisomer as an impurity and vice versa.

[0209] Certain compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) can exist as tautomers and / or geometric isomers. All possible tautomers and cis and trans isomers, as individual forms and mixtures thereof are within the scope of this disclosure. Additionally, as used herein the term alkyl includes all the possible isomeric forms of said alkyl group albeit only a few examples are set forth. Furthermore, when the cyclic groups such as aryl is substituted, it includes all the positional isomers albeit only a few examples are set forth. Furthermore, all hydrates of a compound of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) are within the scope of this disclosure.

[0210] The compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may also contain unnatural amounts of isotopes at one or more of the atoms that constitute such compounds. Unnatural amounts of an isotope may be defined as ranging from the amount found in nature to an amount 100% of the atom in question, that differ only in the presence of one or more isotopically enriched atoms. Exemplary isotopes that can be incorporated into compounds of the present disclosure, such as a compound of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, such as2H,3H,11C,13C,14C,13N,15N,15O,17O,18O,32P,33P,35S,18F,36Cl,123I, and125I, respectively. Isotopically labeled compounds (e.g., those labeled with3H and14C) can be useful in compound or substrate tissue distribution assays. Tritiated (i.e.,3H) and carbon-14 (i.e.,14C) isotopes can

[0211] - 18 - 1107314462\4\AMERICAS

[0212] Attorney Docket No. 119005.00357

[0213] Client Ref. No. NKT-25-003PCT be useful for their ease of preparation and detectability. Further, substitution with (or isotopically enriched for) heavier isotopes such as deuterium (i.e.,2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements). In some embodiments, in compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds, including in Table 1 below, one or more hydrogen atoms are replaced by2H or3H, or one or more carbon atoms are replaced by13C- or14C-enriched carbon. Positron emitting isotopes such as15O,13N,11C, and15F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds can generally be prepared by following procedures analogous to those disclosed in the Schemes or in the Examples herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.

[0214] A “pharmaceutically acceptable carrier or excipient” means a carrier or an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier or an excipient that is acceptable for veterinary use as well as human pharmaceutical use.

[0215] “A pharmaceutically acceptable carrier / excipienf ’ as used in the specification and claims includes both one and more than one such excipient.

[0216] The term “about,” as used herein, is intended to qualify the numerical values which it modifies, denoting such a value as variable within a margin of error. When no particular margin of error, such as a standard deviation to a mean value given in a chart or table of data, is recited, the term “about” should be understood to mean that range which would encompass ± 10%, preferably ± 5%, the recited value and the range is included.

[0217] Certain structures provided herein are drawn with one or more floating substituents. Unless provided otherwise or otherwise clear from the context, the substituent(s) may be present on any atom of the ring to which it is attached, where chemically feasible and valency rules permitting.

[0218] For example, in the structure:

[0219]

[0220] , the Raasubstituent, and similarly the Rbband X1substituents, can replace hydrogen of any CH that is part of the benzo portion of the bicyclic ring that is not already substituted with Rbband X1(in the case of Raa), and similarly with Raaand X1(in the case of Rbb), and with Raaand Rbb(in the case of X1).

[0221] Additionally, as used throughout the application, including in the embodiments, when a group is drawn out as divalent, the left bond of the divalent group is attached to the group which is

[0222] - 19 - 1107314462\4\AMERICAS

[0223] Attorney Docket No. 119005.00357

[0224] Client Ref. No. NKT-25-003PCT to its left in the remainder of the molecule, and the right bond of the divalent group is attached to the group which is to its right in the remainder of the molecule. For example, in Formula (I), in the following divalent groups:

[0225]

[0226] the bond on the left of (a) and(b) is attached to the following ring:

[0227] right side of (a) and (b) is attached to Z1of L of the following structure:

[0228]

[0229] The term “disease” as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder,” “syndrome,” and “condition” (as in medical condition), in that all reflect an abnormal condition of the human or animal body or of one of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced duration or quality of life.

[0230] The term “combination therapy” means the administration of two or more therapeutic agents to treat a disease or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.

[0231] The term “patient” is generally synonymous with the term “subject” and includes all mammals including humans. Examples of patients include humans, livestock such as cows, goats, sheep, pigs, and rabbits, and companion animals such as dogs, cats, rabbits, and horses. In one embodiment, the patient is a human.

[0232] - 20 - 1107314462\4\AMERICAS

[0233] Attorney Docket No. 119005.00357

[0234] Client Ref. No. NKT-25-003PCT

[0235] “Treating” or “treatment” of a disease includes:

[0236] (1) preventing the disease, i.e., causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease;

[0237] (2) inhibiting the disease, i.e., delaying, arresting, or reducing the development or severity of the disease or its clinical symptoms; or

[0238] (3) relieving the disease, i.e., causing regression of the disease or its clinical symptoms.

[0239] In one embodiment, treating or treatment of a disease includes inhibiting the disease, i.e., delaying, arresting or reducing the development or severity of the disease or its clinical symptoms; or relieving the disease, i.e., causing regression of the disease or its clinical symptoms.

[0240] A “therapeutically effective amount” means the amount of a compound of the present disclosure and / or a pharmaceutically acceptable salt thereof that, when administered to a patient for treating a disease, is sufficient to affect such treatment for the disease. The “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.

[0241] A “condition associated with an autoimmune disease” means a condition that a patient with an autoimmune disease is susceptible to, e.g., sepsis, or a condition that is caused by the autoimmune disease, e.g., uveitis.

[0242] The compounds of Formula (I) can also inhibit CDK2 and / or CDK4. The term “inhibiting” and “reducing,” or any variation of these terms in relation to CDK2 and / or CDK4, includes any measurable decrease or complete inhibition of enzymatic activity of CDK2 and / or CDK4, respectively, to achieve a desired result. For example, the compound of Formula (I) may decrease about, at most about, or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, or any range derivable therein, of CDK2 and / or CDK4 activities, compared to their / its normal activity. In some embodiments, the CDK2 and / or CDK4 activity is reduced by at least 40% in the presence of a compound disclosed herein in the Summary, Embodiments, and Compound Table 1 disclosed herein as compared to an equivalent sample comprising CDK2 and / or CDK4, respectively, in the absence of said compound. The inhibitory activity of a compound of Formula (I) can be measure using Biological Example 1, by converting a compound of Formula (I) to a corresponding compound of Formula (I) that cannot be degraded by the ubiquitin proteosome pathway e.g., by methylating the nitrogen

[0243] H

[0244] atom in

[0245]

[0246] group of ligase ligand (i) or (ii) present in the compound of Formula (I).

[0247] - 21 - 1107314462\4\AMERICAS

[0248] Attorney Docket No. 119005.00357

[0249] Client Ref. No. NKT-25-003PCT

[0250] The term “degrading” and “degrade,” or any variation of these terms in relation to CDK2 and CDK4, means any measurable decrease in the concentration of CDK2 and CDK4, respectively, over time in a sample containing a compound of Formula (I). For example, there may be a decrease of about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, or any range derivable therein, in CDK2 and / or CDK4 concentration in a sample containing CDK2 and CDK4, respectively and a compound disclosed herein in the Summary, Embodiments, and Compound Table 1 disclosed herein as compared to an equivalent sample comprising CDK2 and CDK4 respectively, in the absence of said compound. The % degradation can be determined as described in Biological Example 2 below. In one embodiment, the decrease in the concentration of CDK2 and / or CDK4 is > 20%. In another embodiment, the decrease in the concentration of CDK2 and / or CDK4 is > 40%. In another embodiment, the decrease in the concentration of CDK2 and / or CDK4 is > 50%. In another embodiment, the decrease in the concentration of CDK2 and / or CDK4 is > 60%. In another embodiment, the decrease in the concentration of CDK2 and / or CDK4 > 70%. In another embodiment, the decrease in the concentration of CDK2 and / or CDK4 is > 80%.

[0251] “E3 ubiquitin ligase” refers to a family of proteins that operate in conjunction with El ubiquitin-activating enzyme and E2 ubiquitin-conjugating enzyme, assist or directly catalyze the covalent ligation of ubiquitin to a lysine residue of a substrate protein. E3 ubiquitin ligases directly bind to substrate proteins and thus confer substrate specificity for the ubiquitination process. Ubiquitination can serve as a versatile signal mark for substrate proteins, which are targeted to degradation by proteasome or other regulations ranging from translocation to transcription. The cereblon (CRBN) and von Hippel-Lindau (VHL) proteins are substrate recognition subunits of two ubiquitously expressed and biologically important Cullin RING E3 ubiquitin ligase complexes. Cereblon forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1), Cullin-4A (CUL4A), and regulator of cullins 1 (ROC1). VHL is part of the E3 ligase complex VCB, which also consists of elongins B and C, Cul2 and Rbxl.

[0252] Embodiments:

[0253] In embodiments Al A to A206, the present disclosure includes:

[0254] - 22 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0255] Client Ref. No. NKT-25-003PCT

[0256] Al A. In embodiment Al A, provided is a compound of Formula (IA) or a pharmaceutically acceptable salt thereof, as provided in the first aspect in the Summary.

[0257] Al. In embodiment Al, provided is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, as provided in the first embodiment of the first aspect in the Summary.

[0258] A2. In embodiment A2, the compound of embodiment Al A or Al, or a pharmaceutically acceptable salt thereof, is wherein R1is alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, cycloalkyl, or cycloalkyl substituted with one to three halo.

[0259] A3. In embodiment A3, the compound of embodiment Al A, Al or A2, or a pharmaceutically acceptable salt thereof, is wherein R1is halo, haloalkyl, or haloalkoxy.

[0260] A4. In embodiment A4, the compound of any one of embodiments Al A to A3, or a pharmaceutically acceptable salt thereof, is wherein R1is halo.

[0261] A5. In embodiment A5, the compound of any one of embodiments Al A to A3, or a pharmaceutically acceptable salt thereof, is wherein R1is haloalkyl.

[0262] A6. In embodiment A6, the compound of any one of embodiments Al A to A3, or a pharmaceutically acceptable salt thereof, is wherein R1is haloalkoxy.

[0263] A7. In embodiment A7, the compound of any one of embodiments Al A to A6, or a pharmaceutically acceptable salt thereof, is wherein R1is chloro, bromo, fluoro, difluoromethyl, trifluoromethyl, di fluoroethyl, trifluoroethyl, difluoromethoxy, trifluoromethoxy, difluoroethoxy, or trifluoroethoxy unless stated otherwise.

[0264] A8. In embodiment A8, the compound of any one of embodiments Al A to A7, or a pharmaceutically acceptable salt thereof, is wherein R1is chloro, bromo, difluoromethyl, trifluoromethyl, difluoromethoxy, or trifluoromethoxy unless stated otherwise.

[0265] A9. In embodiment A9, the compound of any one of embodiments Al A to A4, A7, and A8, or a pharmaceutically acceptable salt thereof, is wherein R1is chloro or bromo.

[0266] A10. In embodiment A10, the compound of any one of embodiments Al A to A3, A5, A7, and A8, or a pharmaceutically acceptable salt thereof, is wherein R1is difluoromethyl or tri fluoromethyl.

[0267] All. In embodiment All, the compound of any one of embodiments Al A to A3, A5, A7, A8, and A10, or a pharmaceutically acceptable salt thereof, is wherein R1is trifluoromethyl.

[0268] A12. In embodiment A12, the compound of embodiment Al A, Al or A2, or a pharmaceutically acceptable salt thereof, is wherein R1is alkyl, alkenyl, or alkynyl.

[0269] A13. In embodiment A13, the compound of embodiment A1A, Al, A2, or A12, or a pharmaceutically acceptable salt thereof, is wherein R1is methyl, ethyl, propyl, vinyl, propenyl, ethynyl, or propynyl.

[0270] - 23 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0271] Client Ref. No. NKT-25-003PCT

[0272] A14. In embodiment A14, the compound of embodiment Al A, Al, A2, A12, or A13, or a pharmaceutically acceptable salt thereof, is wherein R1is methyl, ethyl, or propyl.

[0273] A15. In embodiment A15, the compound of embodiment A1A, Al, A2, A12, or A13, or a pharmaceutically acceptable salt thereof, is wherein R1is vinyl, propenyl, ethynyl, or propynyl.

[0274] A16. In embodiment A16, the compound of embodiment Al A, Al or A2, or a pharmaceutically acceptable salt thereof, is wherein R1is alkoxy.

[0275] A17. In embodiment 17, the compound of embodiment Al A, Al, A2, or A16, or a pharmaceutically acceptable salt thereof, is wherein R1is methoxy, ethoxy, or propoxy.

[0276] A18. In embodiment A18, the compound of embodiment A1A, Al, A2, or A16, or a pharmaceutically acceptable salt thereof, is wherein R1is methoxy.

[0277] A19. In embodiment A19, the compound of embodiment Al A, Al or A2, or a pharmaceutically acceptable salt thereof, is wherein R1is cyano.

[0278] A20. In embodiment A20, the compound of embodiment Al A, Al or A2, or a pharmaceutically acceptable salt thereof, is wherein R1is cycloalkyl.

[0279] A21. In embodiment A21, the compound of embodiment Al A, Al, A2, or A20, or a pharmaceutically acceptable salt thereof, is wherein R1is cyclopropyl.

[0280] A22. In embodiment A22, the compound of embodiment Al A, Al or A2, or a pharmaceutically acceptable salt thereof, is wherein R1is cycloalkyl substituted with one to three halo which are independently selected (in one embodiment, R1is fluorocyclopropyl or difluorocyclopropyl).

[0281] A23. In embodiment A23, the compound of any one of embodiments Al A, Al to A22, or a pharmaceutically acceptable salt thereof, is wherein R2and R2aare hydrogen.

[0282] A24. In embodiment A24, the compound of any one of embodiments Al A to A22, or a pharmaceutically acceptable salt thereof, is wherein one of R2and R2ais deuterium and the other of R2and R2ais hydrogen or both R2and R2aare deuterium.

[0283] A25. In embodiment A25, the compound of any one of embodiments Al A to A24, or a pharmaceutically acceptable salt thereof, is wherein Hy is heterocyclylene, phenylene, spiro heterocyclylene, bridged heterocyclylene, or cycloalkylene, wherein each of the aforementioned rings is substituted with Ra, Rb, and Rcwhere Raand Rbare independently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, alkoxy, hydroxy, and cyano, and Rcis hydrogen.

[0284] A26. In embodiment A26, the compound of any one of embodiments Al A to A25, or a pharmaceutically acceptable salt thereof, is wherein Hy is heterocyclylene substituted with Ra, Rb, and Rcwhere Raand Rbare independently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, alkoxy, hydroxy, and cyano, and Rcis hydrogen.

[0285] - 24 - 1107314462\4\AMERICAS

[0286] Attorney Docket No. 119005.00357

[0287] Client Ref. No. NKT-25-003PCT

[0288] A27. In embodiment A27, the compound of any one of embodiments Al A to A26, or a pharmaceutically acceptable salt thereof, is wherein the heterocyclylene of Hy is pyrrolidin-1,3-diyl or piperidin-l,4-diyl, where Hy is substituted with Ra, Rb, and Rcwhere Raand Rbare independently hydrogen, deuterium, methyl, fluoro, methoxy, or hydroxy, Rcis hydrogen, and Z6of L is attached to the nitrogen atom of the piperidin-l,4-diyl or pyrrolidin-l,3-diyl ring of Hy.

[0289] A28. In embodiment A28, the compound of any one of embodiments Al A to 1, or a pharmaceutically acceptable salt thereof, is wherein the heterocyclylene of Hy is:

[0290]

[0291] where the N atom of the pyrrolidin- 1,3 -diyl or piperidin-l,4-diyl rings is attached to Z6of L.

[0292] A29. In embodiment A29, the compound of any one of embodiments Al A to A28, or a pharmaceutically acceptable salt thereof, is wherein the heterocyclylene of Hy is:

[0293]

[0294] where the N atom of the pyrrolidin- 1,3 -diyl or piperidin-l,4-diyl rings is attached to Z6of L.

[0295] A30. In embodiment A30, the compound of any one of embodiments Al A to A29, or a pharmaceutically acceptable salt thereof, is wherein the heterocyclylene of Hy is:

[0296]

[0297] where the N atom of the piperidin-l,4-diyl ring is attached to Z6of L.

[0298] A31. In embodiment A31, the compound of any one of embodiments Al A to A25, or a pharmaceutically acceptable salt thereof, is wherein Hy is bridged heterocyclylene substituted with Ra, Rb, and Rcindependently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, alkoxy, hydroxy, and cyano.

[0299] A32. In embodiment A32, the compound of any one of embodiments Al A to A25, and A31, or a pharmaceutically acceptable salt thereof, is wherein the bridged heterocyclylene of Hy is a ring of formula:

[0300] - 25 - 1107314462\4\AMERICAS

[0301] Attorney Docket No. 119005.00357

[0302] Client Ref. No. NKT-25-003PCT

[0303]

[0304] and each ring is substituted with Ra, Rb, and Rcwhere Rcis hydrogen, and Z6of L is attached to the nitrogen atom of each ring.

[0305] A33. In embodiment A33, the compound of embodiment A31 or A32, or a pharmaceutically acceptable salt thereof, is wherein Raand Rbare independently hydrogen, deuterium, methyl, fluoro, methoxy, or hydroxy.

[0306] A34. In embodiment A34, the compound of embodiment A31, A32, or A33, or a pharmaceutically acceptable salt thereof, is wherein Rbis hydrogen.

[0307] A35. In embodiment A35, the compound of any one of embodiments Al A to A25, or a pharmaceutically acceptable salt thereof, is wherein Hy is cycloalkylene substituted with Ra, Rb, and Rcwhere Rais deuterium, methyl, fluoro, methoxy, or hydroxy and Rband Rcare hydrogen.

[0308] A36. In embodiment A36, the compound of any one of embodiments Al to A25, and A35, or a pharmaceutically acceptable salt thereof, is wherein the cycloalkylene of Hy is cyclohexylene.

[0309] A37. In embodiment A37, the compound of any one of embodiments Al A to A25, A35, and A36, or a pharmaceutically acceptable salt thereof, is wherein the cycloalkylene of Hy is

[0310]

[0311] denotes the bond to Z6of L.

[0312] A38. In embodiment A38, the compound of any one of embodiments Al A to A25, or a pharmaceutically acceptable salt thereof, is wherein Hy is arylene substituted with Ra, Rb, and Rcwherein the arylene is phenylene substituted with Ra, Rb, and Rcwhere Raand Rbare independently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, alkoxy, hydroxy, and cyano, and Rcis hydrogen.

[0313] A39. In embodiment A39, the compound of any one of embodiments Al A to A25, or a pharmaceutically acceptable salt thereof, is wherein Hy is spiro heterocyclylene (such as

[0314] 2-azaspiro[3.3]heptan-2-yl) substituted with Ra, Rb, and Rcwhere Raand Rbare independently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, alkoxy, hydroxy, and cyano, and Rcis hydrogen.

[0315] A40. In embodiment A40, the compound of any one of embodiments Al A to A25 and A38, or a pharmaceutically acceptable salt thereof, is wherein the phenylene of Hy is

[0316] - 26 - 1107314462\4\AMERICAS

[0317] Attorney Docket No. 119005.00357

[0318] Client Ref. No. NKT-25-003PCT

[0319] 1,4-phenylene according to structure

[0320]

[0321] denotes the bond to NH and

[0322]

[0323] denotes the bond to Z6of L.

[0324] A41. In embodiment A41, the compound of any one of embodiments Al A to A40, or a pharmaceutically acceptable salt thereof, is wherein the Degron is an E3 ubiquitin ligase ligand of formula (i) or (ii).

[0325] A42. In embodiment A42, the compound of any one of embodiments Al A to A41, or a pharmaceutically acceptable salt thereof, is wherein the Degron is an E3 ubiquitin ligase ligand of formula (i):

[0326]

[0327] (i).

[0328] A43. In embodiment A43, the compound of any one of embodiments Al A to A42, or a pharmaceutically acceptable salt thereof, is wherein the ring A of the E3 ubiquitin ligase ligand of formula (i) is a group of formula (a):

[0329]

[0330] A44. In embodiment A44, the compound of any one of embodiments Al A to A43, or a pharmaceutically acceptable salt thereof, is wherein R4and R5are independently hydrogen or alkyl.

[0331] A45. In embodiment A45, the compound of any one of embodiments Al A to A44, or a pharmaceutically acceptable salt thereof, is wherein R4and R5are hydrogen.

[0332] A46. In embodiment A46, the compound of any one of embodiments Al A to A44, or a pharmaceutically acceptable salt thereof, is wherein R4is hydrogen and R5is methyl.

[0333] A47. In embodiment A47, the compound of any one of embodiments Al A to A43, or a pharmaceutically acceptable salt thereof, is wherein R4and R5together with the carbon to which they are attached form > C=O.

[0334] - 27 - 1107314462\4\AMERICAS

[0335] Attorney Docket No. 119005.00357

[0336] Client Ref. No. NKT-25-003PCT

[0337] A48. In embodiment A48, the compound of any one of embodiments Al A to A42, or a pharmaceutically acceptable salt thereof, is wherein the ring A of the E3 ubiquitin ligase ligand of formula (i) is a group of formula (b):

[0338]

[0339] A49. In embodiment A49, the compound of any one of embodiments Al A to A42, and

[0340] A48, or a pharmaceutically acceptable salt thereof, is wherein R6is hydrogen.

[0341] A50. In embodiment A50, the compound of any one of embodiments Al A to A42, and A48, or a pharmaceutically acceptable salt thereof, wherein R6is alkyl, in one embodiment methyl.

[0342] A51. In embodiment A51, the compound of any one of embodiments Al A to A50, or a pharmaceutically acceptable salt thereof, is wherein ring A of the E3 ubiquitin ligase ligand of formula (i) is:

[0343]

[0344] unless stated otherwise.

[0345] A52. In embodiment A52, the compound of any one of embodiments A1A to A51, or a pharmaceutically acceptable salt thereof, is wherein ring A of the E3 ubiquitin ligase ligand of formula (i) is:

[0346] - 28 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0347] Client Ref. No. NKT-25-003PCT

[0348]

[0349] unless stated otherwise.

[0350] A53. In embodiment A53, the compound of any one of embodiments Al A to A52, or a pharmaceutically acceptable salt thereof, is wherein ring A of the E3 ubiquitin ligase ligand of

[0351]

[0352] unless stated otherwise.

[0353] A54. In embodiment A54, the compound of any one of embodiments Al A to A43, A47, and A51 to A53, or a pharmaceutically acceptable salt thereof, is wherein ring A of the E3 ubiquitin ligase ligand of formula (i) is:

[0354]

[0355] A55. In embodiment A55, the compound of any one of embodiments Al A to A43, A47, and A51 to A53, or a pharmaceutically acceptable salt thereof, is wherein ring A of the E3 ubiquitin ligase ligand of formula (i) is:

[0356] - 29 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0357] Client Ref. No. NKT-25-003PCT

[0358]

[0359] A56. In embodiment A56, the compound of any one of embodiments Al A to A45 and A51 to A53, or a pharmaceutically acceptable salt thereof, is wherein ring A of the E3 ubiquitin ligase ligand of formula (i) is:

[0360]

[0361] A57. In embodiment A57, the compound of any one of embodiments Al A to A45 and A51 to A53, or a pharmaceutically acceptable salt thereof, is wherein ring A of the E3 ubiquitin ligase ligand of formula (i) is:

[0362]

[0363] A58. In embodiment A58, the compound of any one of embodiments Al A to A42, A48, and A50 to A53, or a pharmaceutically acceptable salt thereof, is wherein ring A of the E3 ubiquitin ligase ligand of formula (i) is:

[0364]

[0365] A59. In embodiment A59, the compound of any one of embodiments Al A to A42, A48, and A50 to A53, or a pharmaceutically acceptable salt thereof, is wherein ring A of the E3 ubiquitin ligase ligand of formula (i) is:

[0366]

[0367] A60. In embodiment A60, the compound of any one of embodiments Al A to A56, or a pharmaceutically acceptable salt thereof, is wherein Raa, Rbb, Rcc, and Rddare independently selected from hydrogen, alkyl, alkoxy, halo, haloalkyl, and haloalkoxy. For sake of clarity, Raa,

[0368] - 30 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0369] Client Ref. No. NKT-25-003PCT

[0370] Rbb, Rcc, and / or Rddare hydrogen when they are not specifically drawn out in structures of formula (i) and (ii), respectively.

[0371] A61. In embodiment A61, the compound of any one of embodiments Al A to A56, or a pharmaceutically acceptable salt thereof, is wherein Raa, Rbb, Rcc; and Rddare independently selected from hydrogen, alkyl, alkoxy, halo, haloalkyl, and cyano.

[0372] A62. In embodiment A62, the compound of any one of embodiments Al A to A56, A60, and A61, or a pharmaceutically acceptable salt thereof, is wherein Raa, Rbb, Rcc; and Rddare independently selected from hydrogen, methyl, methoxy, ethoxy, fluoro, trifluoromethyl, difluoromethyl, and trifluoromethoxy.

[0373] A63. In embodiment A63, the compound of any one of Al A to A56 and A60 to A62, or a pharmaceutically acceptable salt thereof, is wherein Raa, Rbb, Rcc; and Rddare independently selected from hydrogen and methyl.

[0374] A64. In embodiment A64, the compound of any one of embodiments Al A to A56 and A60 to A62, or a pharmaceutically acceptable salt thereof, is wherein Raa, Rbb, Rcc; and Rddare independently selected from hydrogen and methoxy.

[0375] A65. In embodiment A65, the compound of any one of embodiments Al A to A56 and A60 to A62, or a pharmaceutically acceptable salt thereof, is wherein Raa, Rbb, Rcc; and Rddare independently selected from hydrogen and fluoro.

[0376] A66. In embodiment A66, the compound of any one of embodiments Al A to A56 and A60 to A62, or a pharmaceutically acceptable salt thereof, is wherein Raa, Rbb, Rcc; and Rddare independently selected from hydrogen, trifluoromethyl, and difluoromethyl.

[0377] A67. In embodiment A67, the compound of any one of embodiments Al A to A56, A60, and A62, or a pharmaceutically acceptable salt thereof, is wherein Raa, Rbb, Rcc; and Rddare independently selected from hydrogen and trifluoromethoxy.

[0378] A68. In embodiment A68, the compound of any one of embodiments Al A to A56 and A60 to A62, or a pharmaceutically acceptable salt thereof, is wherein Raa, Rbb, Rcc; and Rddare independently selected from hydrogen, fluoro, and trifluoromethyl.

[0379] A69. In embodiment A69, the compound of any one of embodiments Al A to A41, or a pharmaceutically acceptable salt thereof, is wherein the Degron is an E3 ubiquitin ligase ligand of formula (ii):

[0380]

[0381] - 31 - 1107314462\4\AMERICAS

[0382] Attorney Docket No. 119005.00357

[0383] Client Ref. No. NKT-25-003PCT

[0384] A70. In embodiment A70, the compound of any one of embodiments Al A to A41, and A69, or a pharmaceutically acceptable salt thereof, is wherein Yais CH.

[0385] A71. In embodiment A71, the compound of any one of embodiments Al A to A41, and A69, or a pharmaceutically acceptable salt thereof, is wherein Yais N.

[0386] A72. In embodiment A72, the compound of any one of embodiments Al A to A41, and A69 to A71, or a pharmaceutically acceptable salt thereof, is wherein Zais a bond, -NH-, -O-, or -NHC(O)-.

[0387] A73. In embodiment A73, the compound of any one of embodiments A1A to A41, and A69 to A72, or a pharmaceutically acceptable salt thereof, is wherein Zais a bond, -NH-, or -NHC(O)-.

[0388] A74. In embodiment A74, the compound of any one of embodiments Al A to A41, and A69 to A73, or a pharmaceutically acceptable salt thereof, is wherein Zais a bond.

[0389] A75. In embodiment A75, the compound of any one of embodiments Al A to A41, and A69 to A73, or a pharmaceutically acceptable salt thereof, is wherein Zais -NH-, or -NHC(O)-.

[0390] A76. In embodiment A76, the compound of any one of embodiments Al A to A41, A69 to A73, and A75, or a pharmaceutically acceptable salt thereof, is wherein Zais -NH-.

[0391] A77. In embodiment A77, the compound of any one of embodiments Al A to A41, A69 to A73, and A75, or a pharmaceutically acceptable salt thereof, is wherein Zais -NHC(O)-.

[0392] A78. In embodiment A78, the compound of any one of embodiments Al A to A41and A69 to A77, or a pharmaceutically acceptable salt thereof, is wherein ring B is phenylene substituted with Reeand Rff.

[0393] A79. In embodiment A79, the compound of any one of embodiments Al A to A41and A69 to A77, or a pharmaceutically acceptable salt thereof, is wherein ring B is cyclylaminylene substituted with Reeand Rff.

[0394] A80. In embodiment A80, the compound of any one of embodiments Al A to A41 and A69 to A77, or a pharmaceutically acceptable salt thereof, is wherein ring B is 5- or 6-membered monocyclic heteroarylene or a 9- or 10-membered fused bicyclic heteroarylene, wherein each heteroarylene ring contains one to three nitrogen ring atoms and each ring is substituted with Reeand Rff.

[0395] A81. In embodiment A81, the compound of any one of embodiments A1A to A41, A69 to A77, and A80, or a pharmaceutically acceptable salt thereof, is wherein ring B is 5- or 6-membered monocyclic heteroarylene containing one or two nitrogen ring atoms substituted with Reeand Rff.

[0396] - 32 - 1107314462\4\AMERICAS

[0397] Attorney Docket No. 119005.00357

[0398] Client Ref. No. NKT-25-003PCT

[0399] A82. In embodiment A82, the compound of any one of embodiments Al A to A41, A69 to A77, and A80, or a pharmaceutically acceptable salt thereof, is wherein ring B is a 9- or 10-membered fused bicyclic heteroarylene containing one to three nitrogen ring atoms (and not containing any additional heteroatoms) and substituted with Reeand Rff.

[0400] A83. In embodiment A83, the compound of any one of embodiments A1A to A41, A69 to A77, A80, and A82, or a pharmaceutically acceptable salt thereof, is wherein ring B is a 9- or 10-membered fused bicyclic heteroarylene containing one or two nitrogen ring atoms and substituted with Reeand Rff.

[0401] A84. In embodiment A84, the compound of any one of embodiments Al A to A41 and A69 to A83, or a pharmaceutically acceptable salt thereof, is wherein the E3 ubiquitin ligase ligand of formula (ii) is:

[0402]

[0403] unless stated otherwise.

[0404] A85. In embodiment A85, the compound of any one of embodiments A1A to A41and

[0405] A69 to A84, or a pharmaceutically acceptable salt thereof, is wherein the E3 ubiquitin ligase ligand of formula (ii) is:

[0406]

[0407] - 33 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0408] Client Ref. No. NKT-25-003PCT

[0409]

[0410] where

[0411]

[0412] is cyclylaminylene unless stated otherwise.

[0413] A86. In embodiment A86, the compound of any one of embodiments Al A to A41, A69, A70, A72, A73, A80, and A82 to A85, or a pharmaceutically acceptable salt thereof, is wherein

[0414]

[0415] A87. In embodiment A87, the compound of any one of embodiments Al A to A41 and A69 to A85, or a pharmaceutically acceptable salt thereof, is wherein the E3 ubiquitin ligase ligand of formula (ii) is:

[0416]

[0417] - 34 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0418] Client Ref. No. NKT-25-003PCT

[0419]

[0420] unless otherwise stated.

[0421] A88. In embodiment A88, the compound of any one of embodiments Al A to A41, A69, A71 to A73, A80, A82 to A85, and A87, or a pharmaceutically acceptable salt thereof, is wherein

[0422] the E3 ubiquitin ligase ligand of formula

[0423]

[0424] A89. In embodiment A89, the compound of any one of embodiments Al A to A41 and

[0425] A69 to A88, or a pharmaceutically acceptable salt thereof, is wherein each Reeand Rffare independently selected from hydrogen, alkyl, alkoxy, halo, cyano, haloalkyl, and haloalkoxy.

[0426] A90. In embodiment A90, the compound of any one of embodiments Al A to A41 and A69 to A88, or a pharmaceutically acceptable salt thereof, is wherein Reeand Rffare independently selected from hydrogen, alkyl, cycloalkyl, alkoxy, halo, haloalkyl, and cyano.

[0427] A91. In embodiment A91, the compound of any one of embodiments Al A to A41 and A69 to A90, or a pharmaceutically acceptable salt thereof, is wherein Reeand Rffare independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, methoxy, ethoxy, fluoro, chloro, trifluoromethyl, 2,2,2-trifluoroethyl, difluoromethyl, difluoromethoxy, trifluoromethoxy, and cyano unless stated otherwise.

[0428] A92. In embodiment A92, the compound of any one of embodiments Al A to A41 and A69 to A91, or a pharmaceutically acceptable salt thereof, is wherein Reeand Rffare independently selected from hydrogen, methyl, ethyl, and isopropyl.

[0429] A93. In embodiment A93, the compound of any one of embodiments A1A to A41 and A69 to A91, or a pharmaceutically acceptable salt thereof, is wherein Reeand Rffare independently selected from hydrogen and methoxy.

[0430] A94. In embodiment A94, the compound of any one of embodiments Al A to A41 and A69 to A91, or a pharmaceutically acceptable salt thereof, is wherein Reeand Rffare independently selected from hydrogen, methyl, ethyl, isopropyl, chloro, and fluoro.

[0431] A95. In embodiment A95, the compound of any one of embodiments Al A to A41 and A69 to A91, or a pharmaceutically acceptable salt thereof, is wherein one of Reeand Rffis

[0432] - 35 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0433] Client Ref. No. NKT-25-003PCT hydrogen or fluoro and the other of Reeand Rffis selected from hydrogen, trifluoromethyl, 2,2,2-trifluoroethyl, and difluoromethyl.

[0434] A96. In embodiment A96, the compound of any one of embodiments Al A to A41, A69 to A89, and A91, or a pharmaceutically acceptable salt thereof, is wherein Reeand Rffare independently selected from hydrogen, difluoromethoxy, and trifluoromethoxy.

[0435] A97. In embodiment A97, the compound of any one of embodiments A1A to A41and A69 to A91, or a pharmaceutically acceptable salt thereof, is wherein Reeand Rffare independently selected from hydrogen, chloro, fluoro, and trifluoromethyl.

[0436] A98. In embodiment A98, the compound of any one of embodiments Al A to A41and A69 to A91, or a pharmaceutically acceptable salt thereof, is wherein Reeand Rffare hydrogen.

[0437] A99. In embodiment A99, the compound of any one of embodiments Al A to A41and A69 to A91, or a pharmaceutically acceptable salt thereof, is wherein Reeand Rffare chloro.

[0438] A100. In embodiment A100, the compound of any one of embodiments Al A to A41 and A69 to A91, or a pharmaceutically acceptable salt thereof, is wherein Reeand Rffare fluoro.

[0439] A101. In embodiment A101, the compound of any one of embodiments Al A to A41and A69 to A91, or a pharmaceutically acceptable salt thereof, is wherein Reeand Rffare independently trifluoromethyl or 2,2,2-trifluoroethyl.

[0440] A102. In embodiment A102, the compound of any one of embodiments Al A to A101, or

[0441] a pharmaceutically acceptable salt thereof, is wherein

[0442]

[0443] phenylene, heterocyclylene, unsaturated heterocyclylene, bridged heterocyclylene, unsaturated bridged heterocyclylene, spiro heterocyclylene, unsaturated spiro heterocyclylene, 11 to 13-membered spiro heterocyclylene, or 11 to 13-membered unsaturated spiro heterocyclylene, Rdis alkyl, alkoxy, alkoxyalkyl, halo, haloalkyl, haloalkoxy, cyano, and cyanoalkyl; Reis alkyl, alkoxy, alkoxyalkyl, halo, haloalkyl, or haloalkoxy; Rfis alkyl, alkoxy, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, halo, haloalkyl, haloalkoxy, haloalkoxyalkyl, hydroxy, hydroxyalkyl, alkylsulfonyl, cyano, cyanoalkyl, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl where heteroaryl, heteroaryl of heteroaralkyl, heterocyclyl, and heterocyclyl of heterocyclylalkyl are unsubstituted or substituted with one or two substituents selected from halo and alkyl; and Rgis deuterium, alkyl, halo, or haloalkyl.

[0444] - 36 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0445] Client Ref. No. NKT-25-003PCT

[0446] A103. In embodiment A103, the compound of embodiment A102, or a pharmaceutically acceptable salt thereof, is wherein Z is heterocyclylene.

[0447] Al 04. In embodiment Al 04, the compound of embodiment Al 02, or a pharmaceutically acceptable salt thereof, is wherein Z is bridged heterocyclylene.

[0448] Al 05. In embodiment Al 05, the compound of embodiment Al 02, or a pharmaceutically acceptable salt thereof, is wherein Z is spiro heterocyclylene.

[0449] A106. In embodiment A106, the compound of embodiment A102, or a pharmaceutically acceptable salt thereof, is wherein Z is unsaturated heterocyclylene, unsaturated bridged heterocyclylene, unsaturated spiro heterocyclylene, 11 to 13-membered spiro heterocyclylene, or 11 to 13-membered unsaturated spiro heterocyclylene.

[0450] A107. In embodiment A107, the compound of embodiment A102 or A106, or a pharmaceutically acceptable salt thereof, is wherein Z is unsaturated heterocyclylene.

[0451] A108. In embodiment A108, the compound of embodiment A102 or A106, or a pharmaceutically acceptable salt thereof, is wherein Z is unsaturated bridged heterocyclylene.

[0452] A109a. In embodiment A109a, the compound of embodiment A102 or A106, or a pharmaceutically acceptable salt thereof, is wherein Z is unsaturated spiro heterocyclylene.

[0453] A109b. In embodiment A109b, the compound of embodiment A102 or A106, or a pharmaceutically acceptable salt thereof, is wherein Z is 11 or 12 membered spiro heterocyclylene.

[0454] A109. In embodiment A109, the compound of embodiment A102 or A106, or a pharmaceutically acceptable salt thereof, is wherein Z is 11 or 12 membered unsaturated spiro heterocyclylene.

[0455] A110. In embodiment Al 10, the compound of any one of embodiments A102 to A109, or a pharmaceutically acceptable salt thereof, is wherein Rdis alkyl, halo, or cyano.

[0456] Al 11. In embodiment Al 11, the compound of any one of embodiments A102 to Al 10, or a pharmaceutically acceptable salt thereof, is wherein Reis alkyl, alkoxy, alkoxyalkyl, halo, or haloalkyl.

[0457] Al 12. In embodiment Al 12, the compound of any one of embodiments A102 to Al 11, or a pharmaceutically acceptable salt thereof, is wherein Reis alkyl, halo, or haloalkyl.

[0458] Al 13. In embodiment Al 13, the compound of any one of embodiments A102 to Al 12, or a pharmaceutically acceptable salt thereof, is wherein Rfis alkyl, alkoxy, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, halo, haloalkyl, haloalkoxyalkyl, hydroxy, alkylsulfonyl, cyano, cyanoalkyl, alkylaminocarbonyl, alkoxycarbonyl, aryl, arylalkyl, heteroaryl, heterocyclyl, or heterocyclylalkyl where heteroaryl, heteroaryl of heteroaralkyl, heterocyclyl, and heterocyclyl of heterocyclylalkyl

[0459] - 37 - 1107314462\4\AMERICAS

[0460] Attorney Docket No. 119005.00357

[0461] Client Ref. No. NKT-25-003PCT are unsubstituted or substituted with one or two substituents independently selected from halo or alkyl.

[0462] Al 14. In embodiment Al 14, the compound of any one of embodiments A102 to Al 13, or a pharmaceutically acceptable salt thereof, is wherein n is 0.

[0463] Al 15. In embodiment Al 15, the compound of any one of embodiments A102 to Al 13, or a pharmaceutically acceptable salt thereof, is wherein n is 1.

[0464] Al 16. In embodiment Al 16, the compound of any one of embodiments Al 02 to Al 13 and Al 15, or a pharmaceutically acceptable salt thereof, is wherein Rg, when present, is alkyl.

[0465] Al 17. In embodiment Al 17, the compound of any one of embodiments Al 02 to Al 16, or a pharmaceutically acceptable salt thereof, is wherein at least one of Rd, Re, and Rfis other than alkyl.

[0466] Al 18. In embodiment Al 18, the compound of any one of embodiments A102 to Al 17, or a pharmaceutically acceptable salt thereof, is wherein one of Rd, Re, and Rfis other than alkyl.

[0467] Al 19. In embodiment Al 19, the compound of any one of embodiments Al 02 to Al 17, or a pharmaceutically acceptable salt thereof, is wherein two of Rd, Re, and Rfare other than alkyl.

[0468] A120. In embodiment A120, the compound of embodiment Al 18 or Al 19, or a pharmaceutically acceptable salt thereof, is wherein the one or two of Rd, Re, and Rfthat is other than alkyl is / are independently halo.

[0469] A121. In embodiment A121, the compound of any one of embodiments A102 to A120, or a pharmaceutically acceptable salt thereof, is wherein each of Rd, Re, and Rfthat is not other than alkyl is independently alkyl.

[0470] A122. In embodiment A122, the compound of any one of embodiments A102 to A121, or a pharmaceutically acceptable salt thereof, is wherein Rdis methyl, ethyl, isopropyl, fluoro, or cyano unless stated otherwise e.g., in Al 16 and A121, each of Rd, Re, and Rfthat is alkyl is independently selected from methyl, ethyl, and isopropyl.

[0471] A123. In embodiment A123, the compound of any one of embodiments A102 to A122, or a pharmaceutically acceptable salt thereof, is wherein Reis methyl, ethyl, fluoro, difluoromethyl, or trifluoromethyl unless stated otherwise.

[0472] A124. In embodiment A124, the compound of any one of embodiments A102 to A123, or a pharmaceutically acceptable salt thereof, is wherein Rfis methyl, ethyl, methoxy, methoxymethyl, cyclopropyl, cyclopropylmethyl, fluoro, difluoromethyl, trifluoromethyl, difluoromethoxymethyl, trifluoromethoxymethyl, hydroxy, methylsulfonyl, cyano, cyanomethyl, methylaminocarbonyl, phenyl, phenylmethyl, pyrazolyl, pyrazolylmethyl, oxetanyl, or oxetanylmethyl, where phenyl, phenylmethyl, pyrazolyl, and pyrazolylmethyl are unsubstituted or

[0473] - 38 - 1107314462\4\AMERICAS

[0474] Attorney Docket No. 119005.00357

[0475] Client Ref. No. NKT-25-003PCT substituted with one or two substituents independently selected from methyl or fluoro unless stated otherwise.

[0476] A125. In embodiment A125, the compound of any one of embodiments A102 to Al 13 and Al 15 to A124, or a pharmaceutically acceptable salt thereof, is wherein Rg, when present, is methyl or ethyl.

[0477] A126. In embodiment A126, the compound of any one of embodiments A102 to Al 13 and Al 15 to A125, or a pharmaceutically acceptable salt thereof, is wherein Rg, when present, is methyl.

[0478] A127. In embodiment A127, the compound of any one of embodiments A102 to Al 13, Al 15 to A121, or a pharmaceutically acceptable salt thereof, is wherein:

[0479] Rdis alkyl;

[0480] Reis alkyl or halo;

[0481] Rfis alkyl, halo, cyano, cyanoalkyl, or haloalkyl; and

[0482] Rg, when present, is alkyl;

[0483] unless stated otherwise.

[0484] A128. In embodiment A128, the compound of any one of embodiments A102 to Al 13, Al 15 to A127, or a pharmaceutically acceptable salt thereof, is wherein:

[0485] Rdis methyl;

[0486] Reis methyl, or fluoro;

[0487] Rfis methyl, fluoro, cyano, cyanomethyl, difluoromethyl, trifluoromethyl, or 2,2,2-trifluoroethyl; and

[0488] Rg, when present, is methyl.

[0489] A129. In embodiment A129, the compound of any one of embodiments A102 to A128, or a pharmaceutically acceptable salt thereof, is wherein at least two of Rd, Re, and Rfare attached to a carbon atom of Z that is adjacent to the carbon atom of Z that is attached to ring A or ring B of E3 ubiquitin ligand of formula (i) and (ii), respectively.

[0490] A130. In embodiment A130, the compound of any one of embodiments Al to A128, or a pharmaceutically acceptable salt thereof, is wherein at least two of Rd, Re, and Rfare attached to a carbon atom of Z that is adjacent to the carbon atom of Z that is attached to alk.

[0491] A131. In embodiment A131, the compound of any one of embodiments A102 to A129, or a pharmaceutically acceptable salt thereof, is wherein Z is:

[0492]

[0493] - 39 - 1107314462\4\AMERICAS

[0494] Attorney Docket No. 119005.00357

[0495] Client Ref. No. NKT-25-003PCT

[0496] Al 32. In embodiment Al 32, the compound of any one of embodiments Al 02 to A131, or a pharmaceutically acceptable salt thereof, is wherein Z is:

[0497]

[0498] A133. In embodiment A133, the compound of any one of embodiments A102 to A132, or

[0499] a pharmaceutically acceptable salt thereof, is wherein

[0500]

[0501] is:

[0502]

[0503] - 40 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0504] Client Ref. No. NKT-25-003PCT

[0505]

[0506] where Rd, Re, Rf, and Rgare as defined herein, unless stated otherwise. For sake of clarity, the

[0507] phrase “unless stated otherwise” applies t

[0508]

[0509] addition to Rd, Re, Rf, and, when present, Rg.

[0510] A134. In embodiment A134, the compound of any one of embodiments A102 to A133, or a

[0511]

[0512] - 41 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0513] Client Ref. No. NKT-25-003PCT

[0514]

[0515] where Rd, Re, Rf, and Rgare as defined therein.

[0516] A135. In embodiment A135, the compound of any one of embodiments A102 to A134, or

[0517] a pharmaceutically acceptable salt thereof, is wherein

[0518]

[0519] is:

[0520]

[0521] - 42 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0522] Client Ref. No. NKT-25-003PCT

[0523]

[0524] - 43 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0525] Client Ref. No. NKT-25-003PCT

[0526]

[0527] where Rd, Re, Rf, and Rgare as defined therein.

[0528] A136. In embodiment A136, the compound of any one of embodiments A102 to A135, or

[0529] a pharmaceutically acceptable salt thereof, is wherein

[0530]

[0531] is:

[0532] - 44 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0533] Client Ref. No. NKT-25-003PCT

[0534]

[0535] - 45 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0536] Client Ref. No. NKT-25-003PCT

[0537]

[0538] where Rd, Re, Rf, and Rgare as defined therein.

[0539] A137. In embodiment A137, the compound of any one of embodiments A102 to A136, or

[0540] a pharmaceutically acceptable salt thereof, is wherein

[0541]

[0542] is:

[0543] - 46 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0544] Client Ref. No. NKT-25-003PCT

[0545]

[0546] - 47 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0547] Client Ref. No. NKT-25-003PCT

[0548]

[0549] - 48 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0550] Client Ref. No. NKT-25-003PCT

[0551]

[0552] - 49 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0553] Client Ref. No. NKT-25-003PCT

[0554]

[0555] unless stated otherwise.

[0556] - 50 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0557] Client Ref. No. NKT-25-003PCT

[0558] A138 In embodiment A138, the compound of any one of embodiments A102 to A137, or

[0559] a pharmaceutically acceptable salt thereof, is wherein

[0560]

[0561]

[0562] - 51 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0563] Client Ref. No. NKT-25-003PCT

[0564] A139. In embodiment A139, the compound of any one of embodiments A102 to A138, or

[0565] a pharmaceutically acceptable salt thereof, is wherein

[0566]

[0567]

[0568] A140. In embodiment A140, the compound of any one of embodiments A102 to A139, or

[0569]

[0570] - 52 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0571] Client Ref. No. NKT-25-003PCT

[0572] A141. In embodiment A141, the compound of any one of embodiments A102 to A140, or

[0573] a pharmaceutically acceptable salt thereof, is wherein

[0574]

[0575]

[0576] A142. In embodiment A142, the compound of any one of embodiments A102 to A140, or

[0577] a pharmaceutically acceptable salt thereof, is wherein

[0578]

[0579] is:

[0580]

[0581] A143. In embodiment A143, the compound of any one of embodiments A102 to A140, or

[0582] a pharmaceutically acceptable salt thereof, is wherein

[0583]

[0584]

[0585] - 53 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0586] Client Ref. No. NKT-25-003PCT

[0587] A144. In embodiment A144, the compound of any one of embodiments A102 to A140

[0588]

[0589] A145. In embodiment A145, the compound of any one of embodiments A102 to A140

[0590]

[0591] A146. In embodiment A146, the compound of any one of embodiments A102 to A140,

[0592]

[0593] A147a. In embodiment A147a, the compound of any one of embodiments A102 to A140,

[0594] A143, and A145, or a pharmaceutically acceptable salt thereof, is wherein

[0595]

[0596] is:

[0597] - 54 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0598] Client Ref. No. NKT-25-003PCT

[0599]

[0600] A147b. In embodiment A147b, the compound of any one of embodiments Al A and

[0601] A2 to A101, or a pharmaceutically acceptable salt thereof, is wherein

[0602]

[0603] unsaturated spiro heterocycylene where each of Rd, Re, Rf, and Rgis hydrogen.

[0604] A147c. In embodiment A147c, the compound of any one of embodiments Al A, A2

[0605] to A101, and A147b, or a pharmaceutically acceptable salt thereof, is wherein

[0606]

[0607]

[0608] A147d. In embodiment A147d, the compound of any one of embodiments Al A and

[0609] A2 to A101, A147b, and A147c, or a pharmaceutically acceptable salt thereof, is wherein

[0610]

[0611] - 55 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0612] Client Ref. No. NKT-25-003PCT

[0613] A147. In embodiment A147, the compound of any one of embodiments Al A and A2 to

[0614] A101, A147b, and A147c, or a pharmaceutically acceptable salt thereof, is wherein

[0615]

[0616]

[0617] A148. In embodiment A148, the compound of any one of embodiments Al to A147 is wherein at least one of -Z2-Z3-Z4- is not a bond. In a sub-embodiment of A148, the compound is wherein at least two of -Z2-Z3-Z4-are not a bond.

[0618] A150. In embodiment A150, the compound of any one of embodiments A1 to A148, or a pharmaceutically acceptable salt thereof, is wherein:

[0619] Z2is a bond;

[0620] Z3is a bond, alkylene, -C(O)NR-, -NR’ (CO)-, -O-, -NR”-, cycloalkylene, phenylene, monocyclic heteroarylene, heterocyclylene, bicyclic heterocyclylene, bridged heterocyclylene, fused heterocyclylene, or spiro heterocyclylene, where each ring is substituted with Rmand Rn; and

[0621] Z4is a bond, alkylene, -O-, cycloalkylene, phenylene, monocyclic heteroarylene, heterocyclylene, fused heterocyclylene, or spiro heterocyclylene, where each ring is substituted with R° and Rp; and

[0622] wherein each alkylene in Z3and Z4is independently substituted with Rsand Rt.

[0623] A151. In embodiment A151, the compound of any one of embodiments A1 to A148 and A150, or a pharmaceutically acceptable salt thereof, is wherein:

[0624] Z2is a bond;

[0625] Z3is cycloalkylene, phenylene, monocyclic heteroarylene, heterocyclylene, bicyclic heterocyclylene, bridged heterocyclylene, fused heterocyclylene, or spiro heterocyclylene, where each ring is substituted with Rmand Rn; and

[0626] Z4is a bond, alkylene, -O-, cycloalkylene, phenylene, monocyclic heteroarylene, heterocyclylene, fused heterocyclylene, or spiro heterocyclylene, where each ring is substituted with R° and Rpindependently selected from hydrogen, deuterium, alkyl, alkoxy, hydroxy, cyano, halo, haloalkyl, and haloalkoxy; and

[0627] wherein alkylene in Z4is substituted with Rsand Rt

[0628] A152. In embodiment A152, the compound of any one of embodiments A1 to A147, and A150, or a pharmaceutically acceptable salt thereof, is wherein:

[0629] - 56 - 1107314462\4\AMERICAS

[0630] Attorney Docket No. 119005.00357

[0631] Client Ref. No. NKT-25-003PCT

[0632] Z2and Z3are each a bond;

[0633] Z4is alkylene, -O-, cycloalkylene, monocyclic heteroarylene, heterocyclylene, fused heterocyclylene, or spiro heterocyclylene, where each ring is substituted with R° and Rpindependently selected from hydrogen, deuterium, alkyl, alkoxy, hydroxy, cyano, halo, haloalkyl, and haloalkoxy; and

[0634] wherein alkylene in Z4is substituted with substituted with Rsand Rt

[0635] A153. In embodiment A153, the compound of any one of embodiments A1 to A147 and A150, or a pharmaceutically acceptable salt thereof, is wherein:

[0636] Z2is a bond;

[0637] Z3is heterocyclylene, bridged heterocyclylene, or spiro heterocyclylene, where each ring is substituted with Rmand Rnindependently selected from hydrogen, deuterium, alkyl, alkoxy, hydroxy, cyano, halo, haloalkyl, and haloalkoxy;

[0638] Z4is alkylene, -O-, cycloalkylene, or heterocyclylene, where each ring is substituted with R° and Rpindependently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, and hydroxy, preferably hydrogen, deuterium, alkyl, alkoxy, hydroxy, cyano, halo, haloalkyl, and haloalkoxy; and

[0639] wherein alkylene in Z4is substituted with Rsand Rt.

[0640] A154. In embodiment A154, the compound of any one of embodiments A1 to A147, A150, and A152, or a pharmaceutically acceptable salt thereof, is wherein:

[0641] Z2and Z3are each a bond;

[0642] Z4is alkylene, -O-, cycloalkylene, or heterocyclylene, where each ring is substituted with R° and Rpindependently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, and hydroxy, preferably hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, and haloalkoxy, preferably Z4is alkylene or -O-;

[0643] Z5is phenylene or monocyclic heteroarylene, each ring substituted with Rqand Rrindependently selected from hydrogen, deuterium, alkyl, alkoxy, hydroxy, cyano, halo, haloalkyl, and haloalkoxy; and

[0644] wherein alkylene in Z4is substituted with Rsand Rt.

[0645] A155. In embodiment A155, the compound of any one of embodiments A1 to A147 and A150, or a pharmaceutically acceptable salt thereof, is wherein:

[0646] Z2is a bond;

[0647] Z3is cycloalkylene, phenylene, monocyclic heteroarylene, heterocyclylene, bicyclic heterocyclylene, bridged heterocyclylene, fused heterocyclylene, or spiro heterocyclylene, where

[0648] - 57 - 1107314462\4\AMERICAS

[0649] Attorney Docket No. 119005.00357

[0650] Client Ref. No. NKT-25-003PCT each ring is substituted with Rmand Rnindependently selected from hydrogen, deuterium, alkyl, alkoxy, hydroxy, cyano, halo, haloalkyl, and haloalkoxy;

[0651] Z4is a bond, alkylene, or -O-; and

[0652] wherein alkylene in Z4is substituted with Rsand Rt.

[0653] A156. In embodiment A156, the compound of any one of embodiments A1 to A147, A150, and A155, or a pharmaceutically acceptable salt thereof, is wherein:

[0654] Z2is a bond;

[0655] Z3is heterocyclylene substituted with Rmand Rnindependently selected from hydrogen, deuterium, alkyl, alkoxy, hydroxy, cyano, halo, haloalkyl, and haloalkoxy;

[0656] Z4is a bond, alkylene, or -O-;

[0657] Z5is phenylene or monocyclic heteroarylene, each ring substituted with Rqand Rrindependently selected from hydrogen, deuterium, alkyl, alkoxy, hydroxy, cyano, halo, haloalkyl, and haloalkoxy; and

[0658] wherein alkylene in Z4is substituted with Rsand Rt.

[0659] A157. In embodiment A157, the compound of any one of embodiments A1 to A147, and A150, or a pharmaceutically acceptable salt thereof, is wherein:

[0660] Z2is a bond;

[0661] Z3is a bond, alkylene, or -O-;

[0662] Z4is heterocyclylene, bridged heterocyclylene, or spiro heterocyclylene, where each ring is substituted with R° and Rp, preferably R° and Rpare independently selected from hydrogen, deuterium, alkyl, alkoxy, hydroxy, cyano, halo, haloalkyl, and haloalkoxy;

[0663] Z5is phenylene or monocyclic heteroarylene, each ring substituted with Rqand Rr, preferably Rqand Rrare independently selected from hydrogen, deuterium, alkyl, alkoxy, hydroxy, cyano, halo, haloalkyl, and haloalkoxy; and

[0664] wherein alkylene in Z3is substituted with Rsand Rt.

[0665] A158. In embodiment A158, the compound of any one of embodiments A1 to A147, A151, A152, and A157, or a pharmaceutically acceptable salt thereof, is wherein Z4is heterocyclylene or spiro heterocyclylene, where each ring is substituted with R° and Rp, preferably R° and Rpare independently selected from hydrogen, deuterium, alkyl, alkoxy, hydroxy, cyano, halo, haloalkyl, and haloalkoxy.

[0666] A159. In embodiment A159, the compound of any one of embodiments A1 to A147, or a pharmaceutically acceptable salt thereof, is wherein Z2is heterocyclylene or bridged heterocyclylene, each ring substituted with Rjand Rk.

[0667] - 58 - 1107314462\4\AMERICAS

[0668] Attorney Docket No. 119005.00357

[0669] Client Ref. No. NKT-25-003PCT

[0670] A160. In embodiment A160, the compound of any one of embodiments Al to A147, or a pharmaceutically acceptable salt thereof, is wherein Z2is a bond.

[0671] A161. In embodiment A161, the compound of any one of embodiments Al to A147, or a pharmaceutically acceptable salt thereof, is wherein:

[0672] Z3is alkylene, cycloalkylene, phenylene, -(alkylene)-phenylene-, -phenylene-(alkylene)-, monocyclic heteroarylene, -(alkylene)-monocyclic heteroarylene-, -monocyclic heteroarylene-(alkylene)-, heterocyclylene, -(alkylene)-heterocyclylene-, -heterocyclylene-(alkylene)-, bicyclic heterocyclylene, bridged heterocyclylene, -(alkylene)-bridged heterocyclylene-, -bridged heterocyclylene-(alkylene)-, fused heterocyclylene, spiro heterocyclylene, -(alkylene)-spiro heterocyclylene-, or -spiro heterocyclylene-(alkylene), where each ring, by itself or as part of another group, is substituted with Rmand Rn;

[0673] Z4is alkylene, -(alkylene-NR”)-, -(NR”-alkylene)-, -O-, -NR”-, -(O-alkylene)a-, -(alkylene-O)a-, cycloalkylene, -(alkylene)-cycloalkylene-, -cycloalkylene-(alkylene)-, spiro cycloalkylene, phenylene, heteroarylene, heterocyclylene, -(alkylene)-heterocyclylene-, -heterocyclylene-(alkylene)-, fused heterocyclylene, bridged heterocyclylene, -(alkylene)-bridged heterocyclylene-, -bridged heterocyclylene-(alkylene)-, spiro heterocyclylene, -(alkylene)-spiro heterocyclylene, or -spiro heterocyclylene-(alkylene)-, where each ring, by itself or as part of another group, is substituted with R° and Rp; and

[0674] and each alkylene in Z3and Z4, itself or as part of another group (e.g., -(alkylene)-phenylene-), is independently substituted with Rsand Rt.

[0675] A162. In embodiment A162, the compound of any one of embodiments Al to A147, or a pharmaceutically acceptable salt thereof, is wherein:

[0676] Z2is each a bond;

[0677] Z3is -(alkylene)-heterocyclylene-, where heterocyclylene is substituted with Rmand Rnand alkylene is substituted with Rsand Rt;

[0678] Z4is a bond; and

[0679] Z5is phenylene substituted with Rqand Rr.

[0680] A163. In embodiment A163, the compound of A147, or a pharmaceutically acceptable salt thereof, is wherein:

[0681] Z2is a bond;

[0682] Z3is alkylene- Rt;

[0683] Z4is a bond; and

[0684] Z5is phenylene substituted with Rqand Rr.

[0685] - 59 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0686] Client Ref. No. NKT-25-003PCT

[0687] A164. In embodiment A164, the compound of any one of embodiments Al to A163, or a

[0688] pharmaceutically acceptable salt thereof, is wherein -Z5- is

[0689]

[0690] (i.e., Z5is phenylene where Z4and Z6are attached at meta position of the phenylene ring) substituted with Rqand Rrindependently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, cyano, and haloalkoxy.

[0691] A165. In embodiment A165, the compound of any one of embodiments A1 to A164, or a

[0692] pharmaceutically acceptable salt thereof, is wherein -Z5- is

[0693]

[0694] substituted with Rqand Rrindependently selected from hydrogen, deuterium, methyl, methoxy, fluoro, chloro, difluoromethyl, trifluoromethyl, difluoromethoxy, cyano, and trifluoromethoxy.

[0695] A166. In embodiment A166, the compound of any one of embodiments A1 to A165, or a

[0696] pharmaceutically acceptable salt thereof, is wherein -Z5- is

[0697]

[0698] substituted with Rqand Rrindependently selected from hydrogen, deuterium, or fluoro.

[0699] A167. In embodiment A167, the compound of any one of embodiments A1 to A166, or a pharmaceutically acceptable salt thereof, is wherein -Z5- is

[0700]

[0701] A168. In embodiment A168, the compound of any one of embodiments Al to A165, or a pharmaceutically acceptable salt thereof, is wherein -Z5- is

[0702]

[0703] A169. In embodiment A169, the compound of any one of embodiments A1 to A161, or a pharmaceutically acceptable salt thereof, is wherein -Z5- is monocyclic heteroarylene (such as imidazol-1,5-diyl, pyridin-2,4-diyl, pyridin-2,6-diyl, or pyridin-3,5-diyl) substituted with Rqand Rrindependently selected from hydrogen, alkyl, alkoxy, halo, haloalkyl, and haloalkoxy.

[0704] A170. In embodiment A170, the compound of any one of embodiments A1 to A161, or a pharmaceutically acceptable salt thereof, is wherein -Z5- is imidazol-2,5-diyl, pyridin-2,4-diyl, pyridin-2,6-diyl, or pyridin-3,5-diyl, each ring substituted with Rqand Rrindependently selected

[0705] - 60 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0706] Client Ref. No. NKT-25-003PCT from hydrogen, methyl, methoxy, fluoro, chloro, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, difluorom ethoxy, and trifluoromethoxy.

[0707] A171. In embodiment A171, the compound of any one of embodiments Al to A161, and Al 70, or a pharmaceutically acceptable salt thereof, is wherein -Z5- is imidazol-2,5-diyl, pyridin-2,4-diyl, pyridin-2,6-diyl, or pyridin-3,5-diyl, each ring substituted with Rqand Rrindependently selected from hydrogen, methyl, methoxy, fluoro, chloro, difluoromethyl, trifluoromethyl, difluorom ethoxy, and trifluoromethoxy.

[0708] Al 72. In embodiment Al 72, the compound of any one of embodiments Al to A161, or a pharmaceutically acceptable salt thereof, is wherein -Z5- is heterocyclylene substituted with Rqand Rrindependently selected from hydrogen, methyl, methoxy, fluoro, chloro, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, difluoromethoxy, and trifluoromethoxy.

[0709] A173. In embodiment A173, the compound of any one of embodiments Al to A161, and Al 72, or a pharmaceutically acceptable salt thereof, is wherein -Z5- is azetidinyl, pyrrolidinyl, piperazinyl, or piperidinyl.

[0710] A174. In embodiment A174, the compound of any one of embodiments Al to A163, or a pharmaceutically acceptable salt thereof, is wherein each alkylene of Z2, Z3, Z4, by itself and when present, is methylene, ethylene, or propylene, each substituted with Rsand Rf

[0711] A175. In embodiment A175, the compound of any one of embodiments Al to A163, and Al 74, or a pharmaceutically acceptable salt thereof, is wherein each alkylene of Z2, Z3, and Z4, by itself and when present, is methylene substituted with Rsand R1.

[0712] A176. In embodiment A176, the compound of any one of embodiments Al to A148, A161, A162, and A164 to A173, or a pharmaceutically acceptable salt thereof, is wherein each alkylene of Z2, Z3, and Z4, as part of -(O-alkylene)b- in Z2, -(alkylene-O)b- in Z2, -(O-alkylene)c- in Z3, -(alkyl ene-O)c- in Z3, -(O-alkylene)a- in Z4, and -(alkylene-O)a- in Z4and when present, is ethylene or propylene; as part of -(alkylene-NR”)- and -(NR”-alkylene)- in Z4and when present, is methylene, ethylene or propylene; and as part of -(alkylene)-cycloalkylene-, -cycloalkylene-(alkylene)-, -(alkylene)-phenylene-, -phenylene-(alkylene)-, -(alkylene)-monocyclic heteroarylene-, -monocyclic heteroarylene-(alkylene)-, -(alkylene)-heterocyclylene-, -heterocyclylene-(alkylene)-, -(alkylene)-bridged heterocyclylene-, -bridged heterocyclylene-(alkylene)-, -(alkylene)-spiro heterocyclylene-, and -spiro heterocyclylene-(alkylene)- is methylene, ethylene, propylene, or butylene, preferably methylene, wherein each of above alkylene group is substituted with Rsand R1.

[0713] A177. In embodiment A177, the compound of any one of embodiments Al to A148, A161, A162, A164 to A173, and A176, or a pharmaceutically acceptable salt thereof, is wherein

[0714] - 61 - 1107314462\4\AMERICAS

[0715] Attorney Docket No. 119005.00357

[0716] Client Ref. No. NKT-25-003PCT each alkylene of Z2, Z3, and Z4, as part of -(O-alkylene)b- in Z2, -(alkylene-O)b- in Z2, -(O-alkylene)c- in Z3, -(alkyl ene-O)c- in Z3, -(O-alkylene)a- in Z4, and -(alkylene-O)a- in Z4, and when present, is ethylene; as part of -(alkylene-NR”)-) and -(NR”-alkylene)- and when present, is methylene; and as part of -(alkylene)-cycloalkylene-, -cycloalkylene-(alkylene)-, -(alkylene)-phenylene-, -phenylene-(alkylene)-, -(alkylene)-monocyclic heteroarylene-, -monocyclic heteroarylene-(alkylene)-, -(alkylene)-heterocyclylene-, -heterocyclylene-(alkylene)-, -(alkylene)-bridged heterocyclylene-, -bridged heterocyclylene-(alkylene)-, -(alkylene)-spiro heterocyclylene-, and -spiro heterocyclylene-(alkylene)- and when present, is methylene.

[0717] A178. In embodiment A178, the compound of any one of embodiments Al to A177 or a pharmaceutically acceptable salt thereof, is wherein each R, R’ and R” of Z2, Z3, and Z4, when present, is independently hydrogen or methyl.

[0718] Al 79. In embodiment Al 79, the compound of any one of embodiments Al to Al 78, or a pharmaceutically acceptable salt thereof, is wherein each R, R’ and R” of Z2, Z3, and Z4, when present, is hydrogen.

[0719] Al 80. In embodiment Al 80, the compound of any one of embodiments Al to Al 78, or a pharmaceutically acceptable salt thereof, is wherein each R, R’ and R” of Z2, Z3, and Z4, when present, is methyl.

[0720] A181. In embodiment Al 81 the compound of any one of embodiments Al to Al 80, or a pharmaceutically acceptable salt thereof, is wherein each cycloalkylene of Z2, Z3, and Z4, when present, is independently selected from cyclopropylene, cyclobutylene, cyclopentylene, and cyclohexylene.

[0721] Al 82. In embodiment Al 82, the compound of any one of embodiments Al to Al 81, or a pharmaceutically acceptable salt thereof, is wherein each cycloalkylene of Z2, Z3, and Z4, when present, is independently selected from 1,3 -cyclopentylene, 1,3-cyclohexylene, and

[0722] 1,4-cyclohexylene.

[0723] Al 83. In embodiment Al 83, the compound of any one of embodiments Al to Al 82, or a pharmaceutically acceptable salt thereof, is wherein heteroarylene is monocyclic heteroarylene and each monocyclic heteroarylene of Z3, Z4, and Z5, when present, is independently selected from imidazoldiyl, pyridindiyl and pyrimidindiyl unless stated otherwise in any of the embodiments above.

[0724] Al 84. In embodiment Al 84, the compound of any one of embodiments Al to Al 83, or a pharmaceutically acceptable salt thereof, is wherein heteroarylene of Z3, Z4, and Z5, when present, is monocyclic heteroarylene and each monocyclic heteroarylene of Z3, Z4, and Z5, when present, is

[0725] - 62 - 1107314462\4\AMERICAS

[0726] Attorney Docket No. 119005.00357

[0727] Client Ref. No. NKT-25-003PCT independently selected from imidazol-2,5-diyl, pyridin-2,4-diyl, pyridin-2,6-diyl, and pyridin-3,5-diyl, unless stated otherwise in any of the embodiments above.

[0728] Al 85. In embodiment Al 85, the compound of any one of embodiments Al to Al 84, or a pharmaceutically acceptable salt thereof, is wherein each phenylene of Z3, Z4, and Z5, when present, is independently selected from 1,3 -phenylene and 1,4-phenylene unless stated otherwise in any of the embodiments above.

[0729] Al 86. In embodiment Al 86, the compound of any one of embodiments Al to Al 85, or a pharmaceutically acceptable salt thereof, is wherein each heterocyclylene, bridged heterocyclylene, and spiro heterocyclylene, of Z2, Z3, Z4, and Z5, when present, are independently selected from:

[0730]

[0731] wherein each ring is optionally substituted with 1, 2, or 3 fluoro, unless stated otherwise in any of the embodiments above.

[0732] Al 87. In embodiment Al 87, the compound of any one of embodiments Al to Al 86, or a pharmaceutically acceptable salt thereof, is wherein each heterocyclylene, bridged heterocyclylene, and spiro heterocyclylene, of Z2, Z3, Z4, and Z5, when present, are independently selected from:

[0733]

[0734] wherein each ring is optionally substituted with 1 or 2 fluoro, unless stated otherwise in any of the embodiments above.

[0735] - 63 - 1107314462\4\AMERICAS

[0736] Attorney Docket No. 119005.00357

[0737] Client Ref. No. NKT-25-003PCT

[0738] Al 88. In embodiment Al 88, the compound of any one of embodiments Al to A148, Al 50, and Al 57, or a pharmaceutically acceptable salt thereof, is wherein -Z3-Z4-Z5-Z6- is:

[0739]

[0740] wherein Rqis selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano, preferably Rqis selected from hydrogen, methyl, fluoro, chloro, cyano, methoxy, difluoromethoxy, difluoromethyl, and trifluorom ethyl.

[0741] Al 89. In embodiment Al 89, the compound of embodiment Al 88, or a pharmaceutically

[0742] acceptable salt thereof, is wherein

[0743]

[0744] is:

[0745]

[0746] A190. In embodiment A190, the compound of embodiment A188 and A189, or a pharmaceutically acceptable salt thereof, is wherein alkylene of Z3is methylene or ethylene.

[0747] A191. In embodiment A191, the compound of any one of embodiment A188 to A190, or a pharmaceutically acceptable salt thereof, is wherein alkylene of Z3is methylene.

[0748] Al 92. In embodiment Al 90, the compound of any one of embodiments Al 88 to A191, or a pharmaceutically acceptable salt thereof, is wherein Z4is alkylene substituted with Rsand R1where Rsand R1are hydrogen.

[0749] A193. In embodiment A193, the compound of any one of embodiments A188 to A192, or a pharmaceutically acceptable salt thereof, is wherein the alkylene of Z4is -CH2-,

[0750] -(CH2)2-, -(CH2)3-, -CH(CH3)-, -CH(CH3)-CH2-, -CH2-CH(CH3)-CH2-, or -CH2-C(CH3)2-CH2-.

[0751] A194. In embodiment A194, the compound of any one of embodiments A188 to A193, or a pharmaceutically acceptable salt thereof, is wherein the alkylene of Z4is -CH(CH3)-CH2-.

[0752] Al 95. In embodiment Al 95, the compound of any one of embodiments Al 88 to A191, or a pharmaceutically acceptable salt thereof, is wherein Z4is alkylene substituted with Rsand R1where Rsis hydrogen or deuterium and R1is hydrogen, deuterium, haloalkyl, hydroxy, alkoxy, or cyano.

[0753] A196. In embodiment A196, the compound of any one of embodiments A188 to A191 and Al 95, or a pharmaceutically acceptable salt thereof, is wherein Z4is alkylene substituted with Rsand R1where Rsis hydrogen and R1is haloalkyl.

[0754] - 64 - 1107314462\4\AMERICAS

[0755] Attorney Docket No. 119005.00357

[0756] Client Ref. No. NKT-25-003PCT

[0757] Al 97. In embodiment Al 97, the compound of any one of embodiments Al 88 to Al 91 and Al 95, or a pharmaceutically acceptable salt thereof, is wherein Z4is alkylene substituted with Rsand R1where Rsis hydrogen and R1is hydroxy.

[0758] A198. In embodiment A198, the compound of any one of embodiments A188 to A191 and Al 95, or a pharmaceutically acceptable salt thereof, is wherein Z4is alkylene substituted with Rsand R1where Rsis hydrogen and R1is alkoxy.

[0759] Al 99. In embodiment Al 99, the compound of any one of embodiments Al 88 to Al 91 and Al 95 to Al 98, or a pharmaceutically acceptable salt thereof, is wherein Z4is -CH(CHF2)-, -CH(CF3)-, -C(CH3)(CF3)-, -CH(CH2CF3)-, -CH(CH2CH2CF3)-, -CH(CH(CF3)2)-, -CH(CH2OH)-, -CH(CH2OCH3)-, -CH(CH2O-ethyl)-, -CH(CH2CN)-, -CH(CF3)-CH2-, -CH(OH)-CH2-, or -CH(OCH3)-CH2-.

[0760] A200. In embodiment A200, the compound of any one of embodiments Al 88 to A191, or a pharmaceutically acceptable salt thereof, is wherein Z4is heterocyclylene substituted with R° and Rp.

[0761] A201. In embodiment A201, the compound of any one of embodiments Al 88 to Al 91 and A200, or a pharmaceutically acceptable salt thereof, is wherein Z4is:

[0762]

[0763] A202. In embodiment A202, the compound of any one of embodiments Al 88 to A191, A200 and A201,or a pharmaceutically acceptable salt thereof, is wherein -Z3-Z4-Z5-Z6- is:

[0764]

[0765] - 65 - 1107314462\4\AMERICAS

[0766] Attorney Docket No. 119005.00357

[0767] Client Ref. No. NKT-25-003PCT

[0768] A203. In embodiment A203, the compound of any one of embodiments Al to A45, A47, A48, A50-A58, A60-A76, A78, and A80 to A202, or a pharmaceutically acceptable salt thereof, is wherein Degron is the E3 ubiquitin ligase ligand selected from:

[0769]

[0770] where Reeis hydrogen, methyl, ethyl, cyclopropyl, or 2,2,2-trifluoroethyl and Rffis hydrogen, methyl, cyclopropyl, fluoro, cyano, methoxy, difluoromethoxy, trifluorom ethoxy, or trifluoromethyl unless stated otherwise.

[0771] A204. In embodiment A204, the compound of embodiment A203, or a pharmaceutically acceptable salt thereof, is wherein Degron is the E3 ubiquitin ligase ligand selected from:

[0772]

[0773] - 66 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0774] Client Ref. No. NKT-25-003PCT

[0775]

[0776] where Reeis hydrogen, methyl, ethyl, cyclopropyl, or 2,2,2-trifluoroethyl and Rffis hydrogen, methyl, cyclopropyl, fluoro, cyano, methoxy, difluoromethoxy, trifluoromethoxy, or trifluoromethyl unless stated otherwise.

[0777] A205. In embodiment A205, the compound of embodiment A203 or A204, or a pharmaceutically acceptable salt thereof, is wherein Degron is the E3 ligase ligand selected from:

[0778]

[0779] A206. In embodiment A206, the compound of A203, or a pharmaceutically acceptable

[0780] salt thereof, is wherein Degron is the E3 ubiquitin ligase ligand i

[0781]

[0782] each

[0783] Reeis hydrogen, methyl, ethyl, cyclopropyl, or 2,2,2-trifluoroethyl (in an embodiment methyl) and each Rff, when specifically drawn is hydrogen, methyl, cyclopropyl, fluoro, cyano, methoxy, difluoromethoxy, trifluoromethoxy, or trifluoromethyl unless stated otherwise.

[0784] For sake of clarity, when an embodiment refers to more than one preceding embodiment of varying scopes, only those groups that fall within the scope of group(s) recited in a preceding embodiment s) should be selected from the embodiment referring thereto. For example, of the groups recited in embodiment A7, while all the recited groups in A7 should be selected for embodiment Al, only fluoro, chloro, and bromo should be selected for embodiment A4 as scope of R1in A4 is limited to halo; and only difluoromethyl, trifluoromethyl, difluoroethyl, and trifluoroethyl should be selected for embodiment A5 as scope of R1in A5 is limited to haloalkyl.

[0785] - 67 - 1107314462\4\AMERICAS

[0786] Attorney Docket No. 119005.00357

[0787] Client Ref. No. NKT-25-003PCT

[0788] Representative compounds of Formula (I) are shown in Compound Table 1 below:

[0789] Table 1

[0790]

[0791] - 68 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0792] Client Ref. No. NKT-25-003PCT

[0793]

[0794] In another embodiment, provided are representative compounds of Formula (I) as follows:

[0795]

[0796] - 69 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0797] Client Ref. No. NKT-25-003PCT

[0798]

[0799] or a pharmaceutically acceptable salt thereof.

[0800] General Synthetic Scheme

[0801] Compounds Formulas (I) (and any embodiment thereof disclosed herein including specific compounds) can be made by the methods depicted in the reaction schemes shown below.

[0802] The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), Bachem (Torrance, Calif.), or Sigma (St. Louis, Mo.) or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser’s Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd’s Chemistry of Carbon Compounds,

[0803] - 70 - 1107314462\4\AMERICAS

[0804] Attorney Docket No. 119005.00357

[0805] Client Ref. No. NKT-25-003PCT

[0806] Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March’s Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition) and Larock’s Comprehensive Organic Transformations (VCH Publishers Inc., 1989). These schemes are merely illustrative of some methods by which the compounds Formula (I) (and any embodiment thereof disclosed herein including specific compounds) can be synthesized, and various modifications to these schemes can be made and will be suggested to one skilled in the art reading this disclosure. The starting materials and the intermediates, and the final products of the reaction may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography and the like. Such materials may be characterized using conventional means, including physical constants and spectral data.

[0807] Unless specified to the contrary, the reactions described herein take place at atmospheric pressure over a temperature range from about -78 °C to about 150 °C, such as from about 0 °C to about 125 °C and further such as at about room (or ambient) temperature, e.g., about 20 °C.

[0808] Compounds of Formula (I), where Degron is an E3 ligase ligand of formula (i) and (ii) where R2ais hydrogen, ring Hy, R1, R2, R2a, and L are as defined in the first aspect, can be prepared as described in Scheme 1 below.

[0809] Scheme 1

[0810]

[0811] Treatment of a pyrimidine of formula 1-1 where A1is a halogen such as chlorine, or bromine, with an amine of formula 1-2, where Hy is as defined in the Summary and FG1is a suitable functional group such as an acid or amine, under conditions well known in the art (such as in the presence of TEA and ZnCl2in tert-butanol), provides a compound of formula 1-3. A compound of formula 1-4 with a suitable functional group (FG2), such as acid, amine, or alkyl halide, reacts with FG1in 1-3 to afford compound of Formula (I). For example, the reaction is a peptide coupling reaction, where the resulting amide bond is part of L as defined in the Summary, and FG1and FG2are a combination of carboxylic acid and an amine, in the presence of suitable coupling reagents, such as a combination of HATU and DIPEA in DMF.

[0812] Alternatively, a compound of Formula (I) such as where R2ais hydrogen, Hy is 1,4-piperidindiyl, Degron is a group of formula (i) and L is attached to Degron (i) where Z1is

[0813] - 71 - 1107314462\4\AMERICAS

[0814] Attorney Docket No. 119005.00357

[0815] Client Ref. No. NKT-25-003PCT heterocyclylene wherein Rd. Re, Rf, Rgand n are as defined in the Summary and L’ is -Z2-Z3-Z4-Z5- as defined in the Summary, and other groups are as defined in the Summary can be synthesized as illustrated and described in Scheme 2.

[0816] Scheme 2

[0817]

[0818] Treatment of a pyrimidine of formula 1-1 where A1is a halogen such as chlorine, or bromine, with a piperidine amine of formula 2-2 under conditions well known in the art, such as in the presence of TEA, and ZnCl2in tert-butanol, provides a compound of formula 2-3. An amine compound of formula 2-4, prepared by removal of the Boc protecting group of 2-3 in the presence of an acid, such as TFA, is converted to a sulfonamide compound of formula 2-6 by treating it with a sulfonyl halide of formula 2-5 where L’ is -Z2-Z3-Z4-Z5- in the compound of Formula (I) and A2is halogen such as chlorine and LG is a suitable leaving group such as halo or methylsulfonyl.

[0819] Treatment of a compound of formula 2-6 with an amine compound of formula 2-7, where ring A is defined as in Embodiment A3, under basic conditions such as in the presence of DIPEA, provides a compound of formula (I).

[0820] Compounds of formula 1-1, 1-4, 2-5, and 2-7 are either commercially available or they can be prepared by methods known in the art.

[0821] Alternatively, a compound of Formula (I) such as where R2ais hydrogen, Degron is a group of formula (i) and L is attached to Degron of formula (i) via heterocyclylene, such as 4-piperidin-l-yl where Rd. Re, Rf, Rgand n are as defined in the Summary, L’ is -Z2-Z3-Z4-Z5- as defined in the Summary and other groups are as defined in the Summary, can be synthesized as illustrated and described in Scheme 3 below.

[0822] - 72 - 1107314462\4\AMERICAS

[0823] Attorney Docket No. 119005.00357

[0824] Client Ref. No. NKT-25-003PCT

[0825]

[0826] Cross coupling of a compound of formula 3-1, where A1is a halogen and ring A as defined in the Summary, with a tetrahydropiperidinyl of formula 3-2 where M is a metal, such as boronic ester or zinc, provides a compound of formula 3-3. The reaction typically proceeds in the presence of a palladium catalyst; for example, when M is a boronic ester, a Suzuki reaction is conducted in the presence of Pd(dppf)Cl2and Na2CO3, in 1,4-di oxane and water.

[0827] Reduction of the double bond in compound 3-3 under conditions well known in the art, such as in the presence of a palladium catalyst and under hydrogen atmosphere, provides compound of formula 3-4. Removal of the Boc protection group of 3-4 under acidic conditions provides an amine compound of formula 3-5. Reaction of 3-5 with a compound of formula 3-6, where LG1is a leaving group, such as halogen or -OSO2Me, Hy is as defined in the Summary and L’ is -Z2-Z3-Z4-Z5- as defined in the Summary, provides compound of formula 3-7. Removal of the Boc protecting group in compound 3-7 using an acid like TFA provides an amine compound of formula 3-8. Treatment of compound 3-8 with a compound of formula 1-1 under suitable conditions such as acidic, basic or transition metal catalyzed reaction conditions well known in the art, provides a compound of Formula (I).

[0828] - 73 - 1107314462\4\AMERICAS

[0829] Attorney Docket No. 119005.00357

[0830] Client Ref. No. NKT-25-003PCT

[0831] Alternatively, compounds of Formula (I) where R2ais hydrogen, R1, R2, Hy, L, and Degron are as defined in the Summary can be prepared as described in Scheme 4 below:

[0832] Scheme 4

[0833]

[0834] Treatment of a pyrimidine of formula 1-1 with an amine of formula 4-1, where R1, R2, Hy, L and Degron are as defined in the Summary, under suitable conditions such as acidic, basic or transition metal catalyzed reaction conditions well known in the art, provides a compound of Formula (I).

[0835] Utility

[0836] The compound of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) could cause degradation of CDK2 and CDK4 proteins and hence are useful in the treatment of diseases mediated by CDK2 and / or CDK4.

[0837] Increasing evidence suggests that overactivated CDK2 and / or CDK4 leads to abnormal cell cycle regulation and proliferation in cancer cells. While CDK2 / 4 mutations are rarely found, the kinase activity of CDK4 / Cyclin D, CDK2 / Cyclin E or CDK2 / Cyclin A complexes is elevated via several mechanisms in human cancers. Aberrations of CDK4 / cyclin D regulation have been identified in many human cancers. For example, amplification or overexpression of cyclin DI has been found in many cancers, including breast invasive ductal carcinoma, invasive breast carcinoma, bladder urothelial carcinoma, breast invasive lobular carcinoma, and lung adenocarcinoma. Translocation of cyclin DI Amplification of CDK4 is common in liposarcoma. CDK4 amplification has also been observed at lower frequency in other solid tumors and hematologic malignancies. Loss of the CDK4 inhibitor pl6 (CDKN2A) is also a common event in many cancers, including glioblastoma multiforme, head and neck squamous cell carcinoma, pancreatic adenocarcinoma, esophageal adenocarcinoma, mesothelioma, lung squamous cell carcinoma, bladder urothelial carcinoma, skin cutaneous melanoma, diffuse large B-cell lymphoma, cholangiocarcinoma, lung adenocarcinoma, and stomach adenocarcinoma.

[0838] Cyclin E has been found to be frequently amplified in cancers, for example, in uterine cancer, ovarian cancer, stomach cancer, and breast cancer. In some cancer types, loss-of-function mutations in FBXW7 or overexpression of USP28, which control the turnover of cyclin E, leads to cyclin E overexpression and CDK2 activation. Alternatively, certain cancer cells express a hyperactive, truncated form of cyclin E or cyclin A. In addition, cyclin A amplification and

[0839] - 74 - 1107314462\4\AMERICAS

[0840] Attorney Docket No. 119005.00357

[0841] Client Ref. No. NKT-25-003PCT overexpression have also been reported in various cancers such as hepatocellular carcinomas, colorectal and breast cancers. In some tumors, catalytic activity of CDK2 is increased following loss of the expression or alteration of the location of the endogenous CDK2 inhibitor p27 or p21, or overexpression of SKP2, a negative regulator of p27. In addition, CDC25A and CDC25B, protein phosphatases responsible for the dephosphorylations that activate the CDK2, are overexpressed in various tumors. These various mechanisms of CDK2 activation have been validated using cancer cells or mouse cancer models. Furthermore, CDK2 / cyclin E phosphorylates oncogenic Myc to oppose ras-induced senescence, highlighting the importance of CDK2 in myc / ras-induced tumorigenesis. Inactivation of CDK2 has been shown to be synthetically lethal to myc over-expressing cancer cells. In aneuploid cancer cells, for example KRAS-mutant lung cancer, CDK2 inhibition resulted in anaphase catastrophe and apoptosis. Moreover, inhibiting CDK2 effectively induced granulocytic differentiation in AML cell lines and arrested tumor growth in AML mice models.

[0842] CDK2 activation as a result of cyclin E amplification or overexpression has also been identified as a key primary or acquired resistance pathway to HR+ or HER2+ breast cancers treated by CDK4 / 6 inhibitors or trastuzumab. Accordingly, compounds of Formula (I) can be used in combination with CDK4 / 6 inhibitors or anti-HER2 therapies for the treatment of cancers that become refractory to CDK4 / 6 inhibitors or anti-HER2 therapies.

[0843] Therefore, a compound of this disclosure may be useful for treating tumors characterized by 1) overexpression of CDK2 and / or CDK4; 2) amplification / overexpression of cyclin D, cyclin E or cyclin A; 3) hyperphosphorylation of CDK2 (Thr160) or CDK4 (Thr172); 4) loss-of-function of mutation in FBXW7, depletion of AMBRA1, overexpression of USP28, or amplification / overexpression of CDC25A or / and CDC25B; 5) expression of truncated cyclin E or cyclin A, 6) dysregulation of pl 6, p21 or p27, or overexpression of SKP2;and 7) hyperactive MYC / RAS; 8) Aneuploid cancers, and 9) CDK4 and / or CDK6 inhibitor refractory cancers.

[0844] In some embodiments, the cancer is ovarian cancer (e.g. serous, clear cell, endometrioid, and mucinous ovarian carcinomas), uterine cancer (e.g. endometrial cancer and uterine sarcoma), stomach cancer (i.e. gastric cancer), lung cancer (e.g., adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas, parvicellular and non-parvicellular carcinoma, bronchial carcinoma, bronchial adenoma, pleuropulmonary blastoma), renal cancer (e.g. clear cell renal cell carcinomas, papillary renal cell carcinomas, and chromophobe renal cell carcinomas), brain cancer (including astrocytoma, meningioma and glioblastoma), neuroblastoma, paraganglioma, pheochromocytoma, pancreatic neuroendocrine tumors, somatostatinomas, hemangioblastomas, gastrointestinal stromal tumors, pituitary tumors, leiomyomas, leiomyosarcomas, polycythaemia,

[0845] - 75 - 1107314462\4\AMERICAS

[0846] Attorney Docket No. 119005.00357

[0847] Client Ref. No. NKT-25-003PCT retinal cancers, hereditary leiomyomatosis, renal cell cancer, astrocytoma, skin cancer (e.g. melanoma, squamous cell carcinoma, Kaposi sarcoma, Merkel cell skin cancer), bladder cancer (including bladder urothelial carcinoma), cervical cancer, colorectal cancer (e.g., cancer of the small intestine, colon cancer, rectal cancer, cancer of the anus), head and neck cancer (e.g., cancers of the larynx, hypopharynx, nasopharynx, oropharynx, lips, tongue and mouth), liver cancer (e.g., hepatocellular carcinoma and cholangiocellular carcinoma), prostate cancer, testicular cancer, gall bladder cancer, pancreatic cancer (e.g. exocrine pancreatic carcinoma and neuroendocrine pancreatic cancer), thyroid cancer, and parathyroid cancer, fallopian tube cancer, peritoneal cancer, vaginal cancer, biliary tract cancer, esophageal cancer (e.g. esophageal squamous cell carcinoma and esophageal adenocarcinoma), sarcoma (e.g. liposarcoma and osteosarcoma), bone cancer, chondrosarcoma, leukemia (including acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, and chronic lymphocytic leukemia), lymphoma (e.g. non-Hodgkin lymphoma NHL including mantel cell lymphoma, MCL and Hodgkin lymphoma) and multiple myeloma.

[0848] In other embodiments, the cancer is breast cancer, including, e.g., ER-positive / HR-positive breast cancer, HER2-negative breast cancer; ER-positive / HR-positive breast cancer, HER2-positive breast cancer; ER-negative / HR-negative, HER2-positive breast cancer, triple negative breast cancer (TNBC); or inflammatory breast cancer. In some embodiments, the breast cancer is endocrine resistant breast cancer, anti-HER2 therapy (e.g. trastuzumab) resistant breast cancer, or breast cancer demonstrating primary or acquired resistance to CDK4 / CDK6 inhibition. In some embodiments, the breast cancer is advanced or metastatic breast cancer. In some embodiments of each of the foregoing, the breast cancer is characterized by amplification or overexpression of CCNE1 and / or CCNE2.

[0849] Besides cancer, compounds of Formula (I) as described in the Summary as described in the first aspect (or any of the embodiments thereof herein above) are useful in treating autoimmune diseases autoimmune diseases e.g., rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), primary Sjogren’s syndrome (pSS), multiple sclerosis (MS), Crohn’s disease (CD), gout, uveitis, pemphigus vulgaris, and sepsis, and can also be used as a promising preventive treatment for noise-, cisplatin-, or antibiotic-induced or age-related hearing loss.

[0850] Testing

[0851] CDK2 / 4 potency and CDK2 / 4 degradation activities of the compounds of the present disclosure can be tested using the in vitro assays described in Biological Examples below.

[0852] - 76 - 1107314462\4\AMERICAS

[0853] Attorney Docket No. 119005.00357

[0854] Client Ref. No. NKT-25-003PCT

[0855] Pharmaceutical Compositions

[0856] In general, the compounds Formula (I) (unless stated otherwise, reference to compound / compounds of Formula (I) wherein includes any embodiments thereof described herein or a pharmaceutically acceptable salt thereof) will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Therapeutically effective amounts of compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may range from about 0.01 to about 500 mg per kg patient body weight per day, which can be administered in single or multiple doses. A suitable dosage level may be from about 0.1 to about 250 mg / kg per day; about 0.5 to about 100 mg / kg per day. A suitable dosage level may be about 0.01 to about 250 mg / kg per day, about 0.05 to about 100 mg / kg per day, or about 0.1 to about 50 mg / kg per day. Within this range the dosage can be about 0.05 to about 0.5, about 0.5 to about 5 or about 5 to about 50 mg / kg per day. For oral administration, the compositions can be provided in the form of tablets containing about 1.0 to about 1000 milligrams of the active ingredient, particularly about 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900, and 1000 milligrams of the active ingredient. The actual amount of the compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds), i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the patient, the potency of the compound being utilized, the route and form of administration, and other factors.

[0857] In general, compounds Formula (I) (and any embodiment thereof disclosed herein including specific compounds) will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration. The preferred manner of administration is oral using a convenient daily dosage regimen, which can be adjusted according to the degree of affliction. Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.

[0858] The choice of formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules, including enteric coated or delayed release tablets, pills or capsules are preferred) and the bioavailability of the drug substance.

[0859] The compositions are comprised of in general, a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are generally non-toxic, aid

[0860] - 77 - 1107314462\4\AMERICAS

[0861] Attorney Docket No. 119005.00357

[0862] Client Ref. No. NKT-25-003PCT administration, and do not adversely affect the therapeutic benefit of the compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds). Such excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.

[0863] Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols.

[0864] The compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi -dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and / or dispersing agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in powder form or in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

[0865] Formulations for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compounds which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

[0866] In addition to the formulations described previously, the compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may also be

[0867] - 78 - 1107314462\4\AMERICAS

[0868] Attorney Docket No. 119005.00357

[0869] Client Ref. No. NKT-25-003PCT formulated as a depot preparation. Such long -acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

[0870] For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, pastilles, or gels formulated in conventional manner. Such compositions may comprise the active ingredient in a flavored basis such as sucrose and acacia or tragacanth.

[0871] The compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.

[0872] Certain compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may be administered topically, that is by non-systemic administration. This includes the application of a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream. In contrast, systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.

[0873] Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as gels, liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient for topical administration may comprise, for example, from 0.001% to 10% w / w (by weight) of the formulation. In certain embodiments, the active ingredient may comprise as much as 10% w / w. In other embodiments, it may comprise less than 5% w / w. In certain embodiments, the active ingredient may comprise from 2% w / w to 5% w / w. In other embodiments, it may comprise from 0.1% to 1% w / w of the formulation.

[0874] For administration by inhalation, compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may be conveniently delivered from an insufflator, nebulizer pressurized packs or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Alternatively, for administration by inhalation or insufflation, the compounds of

[0875] - 79 - 1107314462\4\AMERICAS

[0876] Attorney Docket No. 119005.00357

[0877] Client Ref. No. NKT-25-003PCT

[0878] Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator. Other suitable pharmaceutical excipients and their formulations are described in Remington’s Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 20th ed., 2000).

[0879] The level of the compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (wt. %) basis, from about 0.01-99.99 wt. % of a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. For example, the compound is present at a level of about 1-80 wt. %.

[0880] Combinations and Combination Therapies

[0881] The compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may be used in combination with one or more other drugs in the treatment of diseases or conditions for which compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) or the other drugs may have utility. Such other drug(s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds). When a compound of Formula (I)(or any embodiment thereof disclosed herein including specific compounds) is used contemporaneously with one or more other drugs, a pharmaceutical composition in unit dosage form containing such other drugs and the compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) is preferred. However, the combination therapy may also include therapies in which the compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) and the other active ingredients may be used in lower doses than when each is used singly.

[0882] - 80 - 1107314462\4\AMERICAS

[0883] Attorney Docket No. 119005.00357

[0884] Client Ref. No. NKT-25-003PCT

[0885] Accordingly, the pharmaceutical compositions of the present disclosure also include those that contain one or more other drugs, in addition to a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds).

[0886] The above combinations include combinations of a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) not only with one other drug, but also with two or more other active drugs. Likewise, a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) may be used in combination with other drugs that are used in the prevention, treatment, control, amelioration, or reduction of risk of the diseases or conditions for which a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) is useful. Such other drugs may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds). When a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) can be used. Accordingly, the pharmaceutical compositions of the present disclosure also include those that also contain one or more other active ingredients, in addition to a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds). The weight ratio of the compound of this disclosure to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used.

[0887] Where the subject in need is suffering from or at risk of suffering from cancer, the subject can be treated with a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) in any combination with one or more other anti-cancer agents including but not limited to: MAP kinase pathway (RAS / RAF / MEK / ERK) inhibitors including but not limited to: Vemurafanib (PLX4032), Dabrafenib, Encorafenib (LGX818), TQ-B3233, XL-518 (Cas No. 1029872-29-4, available from ACC Corp); trametinib, selumetinib (AZD6244), TQ-B3234, PD184352, PD325901, TAK-733, pimasertinib, binimetinib, refametinib, cobimetinib (GDC-0973), AZD8330, BVD-523, LTT462, Ulixertinib, AMG510, ARS853, and any RAS inhibitors disclosed in patents WO2016049565, WO2016164675, WO2016168540, WO2017015562, WO2017058728, WO2017058768, WO2017058792, W02017058805, W02017058807, W02017058902, WO2017058915, W02017070256,

[0888] - 81 - 1107314462\4\AMERICAS

[0889] Attorney Docket No. 119005.00357

[0890] Client Ref. No. NKT-25-003PCT

[0891] WO2017087528, WO2017100546, WO2017172979, W02017201161, WO2018064510, W02018068017, WO2018119183;

[0892] CSF1R inhibitors (PLX3397, LY3022855, etc.) and CSF1R antibodies (IMC-054, RG7155) TGF beta receptor kinase inhibitor such as LY2157299;

[0893] BTK inhibitor such as ibrutinib; BCR-ABL inhibitors: Imatinib (Gleevec®); Inilotinib hydrochloride; Nilotinib (Tasigna®); Dasatinib (BMS-345825); Bosutinib (SKI-606); Ponatinib (AP24534); Bafetinib (INNO406); Danusertib (PHA-739358), AT9283 (CAS 1133385-83-7); Saracatinib (AZD0530); and N-[2-[(lS,4R)-6-[[4-cyclobutylarmno)-5-(trifluoromethyl)-2-pyrimidinyl]amino]-l, 2,3,4-tetrahydronaphthalen-l,4-imin-9-yl]-2-oxoethyl]-acetamide

[0894] (PF-03814735, CAS 942487-16-3);

[0895] ALK inhibitors: PF-2341066 (XALKOPJ ®; crizotinib); 5-chloro-N4-(2- (isopropyl-sulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiper azin-l-yl)piperi din-1- yl)phenyl)pyrimidine-2,4-diamine; GSK1838705 A; CH5424802; Ceritinib (ZYKADIA); TQ-B3139, TQ-B3101 PI3K inhibitors: 4-[2-(lH-indazol-4-yl)-6-[[4-(methylsulfonyl)piperazin-l- yl]methyl]thieno[3,2-d]-pyrimidin-4-yl]morholine (also known as GDC 0941 and described in PCT Publication Nos. WO 09 / 036082 and WO 09 / 055730), 2-methyl-2-[4-[3-methyl-2-oxo-8- (quinolin-3-yl)-2,3-dihydro-imidazo[4,5-c]quinolin-l-yl]phenyl]propionitrile (also known as BEZ 235 or NVP-BEZ 235, and described in PCT Publication No. WO 06 / 122806);

[0896] Vascular Endothelial Growth Factor (VEGF) receptor inhibitors: Bevacizumab (sold under the trademark Avastin® by Genentech / Roche), axitinib, (N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-lH-indazol-6-yl]sulfanyl]benzamide, also known as AG013736, and described in PCT Publication No. WO 01 / 002369), Brivanib Alaninate ((S)-((R)-l-(4-(4-fluoro-2-methyl-lH-indol-5-yloxy)-5-methylpyrrolo[2,l-f][l,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate, also known as BMS-582664), motesanib (N-(2,3-dihydro-3,3-dimethyl-lH-indol-6-yl)-2-[(4- pyridinyl-methyl)amino]-3-pyridinecarboxamide, and described in PCT Publication No. WO 02 / 066470), pasireotide (also known as SOM230, and described in PCT Publication No. WO 02 / 010192), sorafenib (sold under the tradename Nexavar®); AL-2846 MET inhibitor such as foretinib, carbozantinib, or crizotinib;

[0897] FLT3 inhibitors - sunitinib malate (sold under the tradename Sutent® by Pfizer); PKC412 (midostaurin); tanutinib, sorafenib, lestaurtinib, KW-2449, quizartinib (AC220) and crenolanib;

[0898] Epidermal growth factor receptor (EGFR) inhibitors: Gefitnib (sold under the tradename Iressa®), N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3" S")-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide, sold under the tradename Tovok® by Boehringer

[0899] - 82 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0900] Client Ref. No. NKT-25-003PCT

[0901] Ingelheim), cetuximab (sold under the tradename Erbitux® by Bristol-Myers Squibb), panitumumab (sold under the tradename Vectibix® by Amgen);

[0902] HER2 receptor inhibitors: Trastuzumab (sold under the trademark Herceptin® by Genentech / Roche), neratinib (also known as HKI-272, (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide, and described PCT Publication No. WO 05 / 028443), lapatinib or lapatinib ditosylate (sold under the trademark Tykerb® by GlaxoSmithKline); Trastuzumab emtansine (in the United States, ado-trastuzumab emtansine, trade name Kadcyla) - an antibody-drug conjugate consisting of the monoclonal antibody trastuzumab (Herceptin) linked to the cytotoxic agent mertansine (DM1); Trastuzumab deruxtecan (trade name Enhertu);

[0903] HER dimerization inhibitors: Pertuzumab (sold under the trademark Omnitarg®, by Genentech);

[0904] CD20 antibodies: Rituximab (sold under the trademarks Rituxan® and Mab Thera® by Genentech / Roche), tositumomab (sold under the trademarks Bexxar® by GlaxoSmithKline), ofatumumab (sold under the trademark Arzerra® by GlaxoSmithKline);

[0905] Tyrosine kinase inhibitors: Erlotinib hydrochloride (sold under the trademark Tarceva® by Genentech / Roche), Linifanib (N-[4-(3-amino-lH-indazol-4-yl)phenyl]-N'-(2-fluoro-5-methylphenyl)urea, also known as ABT 869, available from Genentech), sunitinib malate (sold under the tradename Sutent® by Pfizer), bosutinib (4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-l-yl)propoxy]quinoline-3-carbonitrile, also known as SKI-606, and described in US Patent No. 6,780,996), dasatinib (sold under the tradename Sprycel® by Bristol-Myers Squibb), armala (also known as pazopanib, sold under the tradename Votrient® by GlaxoSmithKline), imatinib and imatinib mesylate (sold under the tradenames Gilvec® and Gleevec® by Novartis);

[0906] DNA Synthesis inhibitors: Capecitabine (sold under the trademark Xeloda® by Roche), gemcitabine hydrochloride (sold under the trademark Gemzar® by Eli Lilly and Company), nelarabine ((2R3S,4R,5R)-2-(2-amino-6-methoxy-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, sold under the tradenames Arranon® and Atriance® by GlaxoSmithKline);

[0907] Antineoplastic agents: oxaliplatin (sold under the tradename Eloxatin® ay Sanofi -Aventis and described in US Patent No. 4,169,846);

[0908] Human Granulocyte colony-stimulating factor (G-CSF) modulators: Filgrastim (sold under the tradename Neupogen® by Amgen);

[0909] - 83 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0910] Client Ref. No. NKT-25-003PCT

[0911] Immunomodulators: Afutuzumab (available from Roche®), pegfilgrastim (sold under the tradename Neulasta® by Amgen), lenalidomide (also known as CC-5013, sold under the tradename Revlimid®), thalidomide (sold under the tradename Thalomid®);

[0912] CD40 inhibitors: Dacetuzumab (also known as SGN-40 or huS2C6, available from Seattle Genetics, Inc); Pro-apoptotic receptor agonists (PARAs): Dulanermin (also known as AMG-951, available from Amgen / Genentech);

[0913] Hedgehog antagonists: 2-chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)-benzamide (also known as GDC-0449, and described in PCT Publication No. WO 06 / 028958);

[0914] Phospholipase A2 inhibitors: Anagrelide (sold under the tradename Agrylin®);

[0915] BCL-2 inhibitors: 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-l-cyclohexen-l-yl]methyl]-l-piperazinyl]-N-[[4-[[(lR)-3-(4-morpholinyl)-l-[(phenylthio)m ethyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide (also known as ABT-263 and described in PCT Publication No. WO 09 / 155386);

[0916] MC1-1 inhibitors: MIK665, S64315, AMG 397, and AZD5991;

[0917] Aromatase inhibitors: Exemestane (sold under the trademark Aromasin® by Pfizer), letrozole (sold under the tradename Femara® by Novartis), anastrozole (sold under the tradename Arimidex®);

[0918] Topoisomerase I inhibitors: Irinotecan (sold under the trademark Camptosar® by Pfizer), topotecan hydrochloride (sold under the tradename Hycamtin® by GlaxoSmithKline);

[0919] Topoisomerase II inhibitors: etoposide (also known as VP-16 and Etoposide phosphate, sold under the tradenames Toposar®, VePesid® and Etopophos®), teniposide (also known as VM-26, sold under the tradename Vumon®);

[0920] mTOR inhibitors: Temsirolimus (sold under the tradename Torisel® by Pfizer), ridaforolimus (formally known as deferolimus, (lR,2R,4S)-4-[(2R)-2[(lR,9S,12S,15R,16E, 18R,19R,21R, 23S,24E,26E,28Z,30S,32S,35R)-l,18-dihydroxy-19,30- dimethoxy-15, 17, 21, 23, 29, 35-hexamethyl-2,3, 10, 14,20-pentaoxo-l 1, 36-dioxa-4- azatri cyclo[30.3.1.04 ' 9] hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate, also known as AP23573 and MK8669, and described in PCT Publication No. WO 03 / 064383), everolimus (sold under the tradename Afinitor® by Novartis);

[0921] Proteasome inhibitor such as carfilzomib, MLN9708, delanzomib, or bortezomib;

[0922] BET inhibitors such as INCB054329, OTX015, and CPI-0610;

[0923] LSD1 inhibitors such as GSK2979552, and INCB059872;

[0924] KAT6 inhibitors such as PF-07248144;

[0925] HIF-2a inhibitors such as PT2977, PT2385, imdatifan, and casdatifan;

[0926] - 84 - 1107314462\4\AMERICAS

[0927] Attorney Docket No. 119005.00357

[0928] Client Ref. No. NKT-25-003PCT

[0929] Osteoclastic bone resorption inhibitors: l-Hydroxy-2-imidazol-l-yl-phosphonoethyl) phosphonic acid monohydrate (sold under the tradename Zometa® by Novartis); CD33 Antibody Drug Conjugates: Gemtuzumab ozogamicin (sold under the tradename Mylotarg® by Pfizer / Wyeth);

[0930] CD22 Antibody Drug Conjugates: Inotuzumab ozogamicin (also referred to as CMC-544 and WAY-207294, available from Hangzhou Sage Chemical Co., Ltd.);

[0931] CD20 Antibody Drug Conjugates: Ibritumomab tiuxetan (sold under the tradename Zevalin®);

[0932] Somatostatin analogs: octreotide (also known as octreotide acetate, sold under the tradenames Sandostatin® and Sandostatin LAR®);

[0933] Synthetic Interleukin- 11 (IL-11): oprelvekin (sold under the tradename Neumega® by Pfizer / Wyeth);

[0934] Synthetic erythropoietin: Darbepoetin alfa (sold under the tradename Aranesp® by Amgen);

[0935] Receptor Activator for Nuclear Factor K B (RANK) inhibitors: Denosumab (sold under the tradename Prolia® by Amgen);

[0936] Thrombopoietin mimetic peptibodies: Romiplostim (sold under the tradename Nplate® by Amgen);

[0937] Cell growth stimulators: Palifermin (sold under the tradename Kepivance® by Amgen);

[0938] Anti-Insulin-like Growth Factor-1 receptor (IGF-1R) antibodies: Figitumumab (also known as CP-751,871, available from ACC Corp), robatumumab (CAS No. 934235-44-6);

[0939] Anti-CSl antibodies: Elotuzumab (HuLuc63, CAS No. 915296-00-3);

[0940] CD52 antibodies: Alemtuzumab (sold under the tradename Campath®);

[0941] Histone deacetylase inhibitors (HDI): Vorinostat (sold under the tradename Zolinza® by Merck);

[0942] Alkylating agents: Temozolomide (sold under the tradenames Temodar® and Temodal® by Schering-Plough / Merck), dactinomycin (also known as actinomycin-D and sold under the tradename Cosmegen®), melphalan (also known as L-PAM, L-sarcolysin, and phenylalanine mustard, sold under the tradename Alkeran®), altretamine (also known as hexamethylmelamine (HMM), sold under the tradename Hexal en®), carmustine (sold under the tradename BiCNU®), bendamustine (sold under the tradename Treanda®), busulfan (sold under the tradenames Busulfex® and Myleran®), carboplatin (sold under the tradename Paraplatin®), lomustine (also known as CCNU, sold under the tradename CeeNU®), cisplatin (also known as CDDP, sold under the tradenames Platinol® and Platinol®-AQ), chlorambucil (sold under the tradename

[0943] - 85 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0944] Client Ref. No. NKT-25-003PCT

[0945] Leukeran®), cyclophosphamide (sold under the tradenames Cytoxan® and Neosar®), dacarbazine (also known as DTIC, DIC and imidazole carboxamide, sold under the tradename DTIC-Dome®), altretamine (also known as hexamethylmelamine (HMM) sold under the tradename Hexalen®), ifosfamide (sold under the tradename Ifex®), procarbazine (sold under the tradename Matulane®), mechlorethamine (also known as nitrogen mustard, mustine and mechloroethamine hydrochloride, sold under the tradename Mustargen®), streptozocin (sold under the tradename Zanosar®), thiotepa (also known as thiophosphoamide, TESPA and TSP A, sold under the tradename Thioplex®; Biologic response modifiers: bacillus calmette-guerin (sold under the tradenames theraCys® and TICE® BCG), denileukin diftitox (sold under the tradename Ontak®);

[0946] Anti-tumor antibiotics: doxorubicin (sold under the tradenames Adriamycin® and Rubex®), bleomycin (sold under the tradename lenoxane®), daunorubicin (also known as dauorubicin hydrochloride, daunomycin, and rubidomycin hydrochloride, sold under the tradename Cerubidine®), daunorubicin liposomal (daunorubicin citrate liposome, sold under the tradename DaunoXome®), mitoxantrone (also known as DHAD, sold under the tradename Novantrone®), epirubicin (sold under the tradename Ellence™), idarubicin (sold under the tradenames Idamycin®, Idamycin PFS®), mitomycin C (sold under the tradename Mutamycin®);

[0947] Anti -microtubule agents: Estramustine (sold under the tradename Emcyl®);

[0948] Cathepsin K inhibitors: Odanacatib (also known as MK-0822, N-(l-cyanocyclopropyl)-4-fluoro-N-2-{(lS)-2,2,2-trifluoro-l-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-L-leucinamide, available from Lanzhou Chon Chemicals, ACC Corp., and ChemieTek, and described in PCT Publication no. WO 03 / 075836); Epothilone B analogs: Ixabepilone (sold under the tradename Lxempra® by Bristol-Myers Squibb);

[0949] Heat Shock Protein (HSP) inhibitors: Tanespimycin (17-allylamino-17-demethoxy-geldanamycin, also known as KOS-953 and 17-AAG, available from SIGMA, and described in US Patent No. 4,261,989), NVP-HSP990, AUY922, AT13387, STA-9090, Debio 0932,

[0950] KW-2478, XL888, CNF2024, TAS-116

[0951] TpoR agonists: Eltrombopag (sold under the tradenames Promacta® and Revolade® by GlaxoSmithKline);

[0952] Anti-mitotic agents: Docetaxel (sold under the tradename Taxotere® by Sanofi -Aventis); Adrenal steroid inhibitors: aminoglutethimide (sold under the tradename Cytadren®);

[0953] Anti-androgens: Nilutamide (sold under the tradenames Nilandron® and Anandron®), bicalutamide (sold under tradename Casodex®), flutamide (sold under the tradename Fulexin™);

[0954] Androgens: Fluoxymesterone (sold under the tradename Halotestin®);

[0955] - 86 - 1107314462\4\AMERICAS

[0956] Attorney Docket No. 119005.00357

[0957] Client Ref. No. NKT-25-003PCT

[0958] CDK (CDK1, CDK2, CDK3, CDK5, CDK7, CDK8, CDK9, CDK11 / 12, or CDK16) inhibitors including but not limited to Alvocidib (pan-CDK inhibitor, also known as flovopirdol or HMR-1275, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-l-methyl-4-piperidinyl]-4-chromenone, and described in US Patent No. 5,621,002);

[0959] CDK4 / 6 inhibitors pabociclib, ribociclib, abemaciclib, and Trilaciclib; CDK9 inhibitors AZD 4573, P276-00, AT7519M, TP-1287; CDK2 / 4 / 6 inhibitor such as PF-06873600;

[0960] SHP-2 inhibitor such as TNO155;

[0961] MDM2 / MDMX, MDM2 / p53 and / or MDMX / p53 modulators;

[0962] Gonadotropin-releasing hormone (GnRH) receptor agonists: Leuprolide or leuprolide acetate (sold under the tradenames Viadure® by Bayer AG, Eligard® by Sanofi -Aventis and Lupron® by Abbott Lab);

[0963] Taxane anti -neoplastic agents: Cabazitaxel (l-hydroxy-7, 10 -dimethoxy-9-oxo-5,20-epoxytax-1 l-ene-2a,4,13a-triyl-4-acetate-2-benzoate-13-[(2R,3S)-3-{ [(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate), larotaxel ((2a,3^,4a,5p,7a,10p,13a)-4, 10-bis(acetyloxy)-13-({(2R,3 S)-3-[(tert-butoxy carbonyl) amino] -2-hydroxy-3-phenylpropanoyl}oxy)-l-hydroxy-9-oxo-5,20-epoxy-7, 19-cyclotax-l l-en-2-yl benzoate);

[0964] 5HTla receptor agonists: Xaliproden (also known as SR57746, l-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-l,2,3,6-tetrahydropyridine, and described in US Patent No.

[0965] 5,266,573); HPC vaccines: Cervarix® sold by GlaxoSmithKline, Gardasil® sold by Merck; Iron Chelating agents: Deferasinox (sold under the tradename Exjade® by Novartis);

[0966] Anti-metabolites: Claribine (2-chlorodeoxyadenosine, sold under the tradename leustatin®), 5 -fluorouracil (sold under the tradename Adrucil®), 6-thioguanine (sold under the tradename Purinethol®), pemetrexed (sold under the tradename Alimta®), cytarabine (also known as arabinosylcytosine (Ara-C), sold under the tradename Cytosar-U®), cytarabine liposomal (also known as Liposomal Ara-C, sold under the tradename DepoCyt™), decitabine (sold under the tradename Dacogen®), hydroxyurea (sold under the tradenames Hydrea®, Droxia™ and Mylocel™), fludarabine (sold under the tradename Fludara®), floxuridine (sold under the tradename FUDR®), cladribine (also known as 2-chlorodeoxyadenosine (2-CdA) sold under the tradename Leustatin™), methotrexate (also known as amethopterin, methotrexate sodium (MTX), sold under the tradenames Rheumatrex® and Trexall™), pentostatin (sold under the tradename Nipent®);

[0967] Bisphosphonates: Pamidronate (sold under the tradename Aredia®), zoledronic acid (sold under the tradename Zometa®); Demethylating agents: 5-azacitidine (sold under the tradename Vidaza®), decitabine (sold under the tradename Dacogen®);

[0968] - 87 - 1107314462\4\AMERICAS

[0969] Attorney Docket No. 119005.00357

[0970] Client Ref. No. NKT-25-003PCT

[0971] Plant Alkaloids: Paclitaxel protein-bound (sold under the tradename Abraxane®), vinblastine (also known as vinblastine sulfate, vincaleukoblastine and VLB, sold under the tradenames Alkaban-AQ® and Velban®), vincristine (also known as vincristine sulfate, LCR, and VCR, sold under the tradenames Oncovin® and Vincasar Pfs®), vinorelbine (sold under the tradename Navelbine®), paclitaxel (sold under the tradenames Taxol and Onxal™);

[0972] Retinoids: Ali tretinoin (sold under the tradename Panretin®), tretinoin (all -trans retinoic acid, also known as ATRA, sold under the tradename Vesanoid®), Isotretinoin (13-cis-retinoic acid, sold under the tradenames Accutane®, Amnesteem®, Claravis®, Clarus®, Decutan®, Isotane®, Izotech®, Oratane®, Isotret®, and Sotret®), bexarotene (sold under the tradename Targretin®);

[0973] Glucocorticosteroids: Hydrocortisone (also known as cortisone, hydrocortisone sodium succinate, hydrocortisone sodium phosphate, and sold under the tradenames Ala-Cort®, Hydrocortisone Phosphate, Solu-Cortef®, Hydrocort Acetate® and Lanacort®), dexamethazone ((8S,9R,10S,l lS,13S,14S,16R,17R)-9-fluoro-l l,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,1 l,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one), prednisolone (sold under the tradenames Delta-Cortel®, Orapred®, Pediapred® and Prelone®), prednisone (sold under the tradenames Deltasone®, Liquid Red®, Meticorten® and Orasone®), methylprednisolone (also known as 6-Methylprednisolone, Methylprednisolone Acetate, Methylprednisolone Sodium Succinate, sold under the tradenames Duralone®, Medralone®, Medrol®, M-Prednisol® and Solu-Medrol®);

[0974] Cytokines: interleukin-2 (also known as aldesleukin and IL-2, sold under the tradename Proleukin®), interleukin- 11 (also known as oprevelkin, sold under the tradename Neumega®), alpha interferon alfa (also known as IFN-alpha, sold under the tradenames Intron® A, and Roferon-A®); Estrogen receptor downregulators: Fulvestrant (sold under the tradename Faslodex®); elacestrant and camizestrant.

[0975] Anti-estrogens: tamoxifen (sold under the tradename Novaldex®); Toremifene (sold under the tradename Fareston®);

[0976] Selective estrogen receptor modulators (SERMs): Raloxifene (sold under the tradename Evista®);

[0977] Estrogen receptor PRO T AC s: Vepdegestrant (ARV-471);

[0978] Leutinizing hormone releasing hormone (LHRH) agonists: Goserelin (sold under the tradename Zoladex®); Progesterones: megestrol (also known as megestrol acetate, sold under the tradename Megace®);

[0979] - 88 - 1107314462\4\AMERICAS

[0980] Attorney Docket No. 119005.00357

[0981] Client Ref. No. NKT-25-003PCT

[0982] Miscellaneous cytotoxic agents: Arsenic trioxide (sold under the tradename Trisenox®), asparaginase (also known as L-asparaginase, Erwinia L-asparaginase, sold under the tradenames Elspar® and Kidrolase®);

[0983] One or more immune checkpoint inhibitors CD27, CD28, CD40, CD 122, CD96, CD73, CD39, CD47, 0X40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM kinase, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, A2BR, HIF-2a, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, CD96, TIGIT, PD-1, PD-L1 and PD-L2. In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, 0X40, GITR, CD137 and STING. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from B7-H3, B7-H4, BTLA, CTLA-4, IDO, TDO, Arginase, KIR, LAG3, PD-1, TIM3, CD96, TIGIT and VISTA. In some embodiments, the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD 160 inhibitors, 2B4 inhibitors and TGFR beta inhibitors.

[0984] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, e.g., an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, or pembrolizumab or PDR001. In some embodiments, the anti-PDl antibody is pembrolizumab.

[0985] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-Ll monoclonal antibody. In some embodiments, the anti-PD-Ll monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-Ll monoclonal antibody is MPDL3280A (atezolizumab) or MEDI4736 (durvalumab).

[0986] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody. In some embodiments, the anti -CTLA-4 antibody is ipilimumab or tremelimumab. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016 or LAG525. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of GITR, e.g., an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518 or, MK-4166, INCAGN01876 or MK-1248. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of 0X40, e.g., an anti-OX40 antibody or OX40L fusion protein. In some embodiments, the anti-OX40 antibody is

[0987] - 89 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[0988] Client Ref. No. NKT-25-003PCT

[0989] MEDI0562 or, INCAGN01949, GSK2831781, GSK-3174998, MOXR-0916, PF-04518600 or LAG525. In some embodiments, the OX40L fusion protein is MEDI6383

[0990] Compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) can also be used to increase or enhance an immune response, including increasing the immune response to an antigen; to improve immunization, including increasing vaccine efficacy; and to increase inflammation. In some embodiments, the compounds of the invention can be used to enhance the immune response to vaccines including, but not limited, Listeria vaccines, oncolytic viral vaccines, and cancer vaccines such as GV AX® (granulocytemacrophage colony-stimulating factor (GM-CF) gene-transfected tumor cell vaccine). Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines and recombinant viruses. Other immune-modulatory agents also include those that block immune cell migration such as antagonists to chemokine receptors, including CCR2 and CCR4; Sting agonists and Toll receptor agonists.

[0991] Other anti-cancer agents also include those that augment the immune system such as adjuvants or adoptive T cell transfer. Compounds of this application may be effective in combination with CAR (Chimeric antigen receptor) T cell treatment as a booster for T cell activation.

[0992] A compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) can also be used in combination with the following adjunct therapies: antinausea drugs: NK-1 receptor antagonists: Casopitant (sold under the tradenames Rezonic® and Zunrisa® by GlaxoSmithKline); and

[0993] Cytoprotective agents: Amifostine (sold under the tradename Ethyol®), leucovorin (also known as calcium leucovorin, citrovorum factor and folinic acid).

[0994] Examples

[0995] The following preparations of Intermediates (References) and compounds of Formula (I) (Examples) are given to enable those skilled in the art to more clearly understand and to practice the present disclosure. They should not be considered as limiting the scope of the disclosure, but merely as being illustrative and representative thereof.

[0996] Reference 1

[0997] Synthesis of 2-chloro-5-(difluoromethyl)pyrimidine

[0998]

[0999] - 90 - 1107314462\4\AMERICAS

[1000] Attorney Docket No. 119005.00357

[1001] Client Ref. No. NKT-25-003PCT

[1002] To a solution of 2-chloropyrimidine-5-carbaldehyde (250 mg, 1.60 mmol) in DCM (3.0 mL) was added DAST (45 mg, 31.93 mmol) at 0 °C and the mixture was stirred at rt overnight. The mixture was diluted with water and extracted DCM. The organic layer was washed with brine, dried over Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (PE / EtOAc, 10 / 1) to give the title compound as a white solid.

[1003] Reference compound la was prepared by proceeding analogously as described in Reference 1.

[1004]

[1005] Reference 2

[1006] Synthesis of 2-chloro-5-(difluoromethoxy)pyrimidine

[1007]

[1008] A mixture of 2-chloropyrimidin-5-ol (1.00 g, 7.69 mmol), methyl 2-chloro-2,2-difluoroacetate (3.32 g, 23.08 mmol) and CS2CO3 (3.01 g, 9.23 mmol) in DMF (10.0 mL) was stirred at 100 °C under N2 lh. The mixture was poured into water, and the resulting mixture was extracted with DCM. The combined organic layers were dried over Na2SC>4, and concentrated. The residue was purified by silica gel column chromatography (PE / EtOAc, 20 / 1) give the title compound as yellow oil.

[1009] Reference 3

[1010] Synthesis of 5-chloro-N-(piperidin-4-yl)pyrimidin-2-amine hydrogen chloride

[1011]

[1012] Step 1: tert-Butyl 4-((5-chloropyrimidin-2-yl)amino)piperidine-l -carboxylate

[1013]

[1014] i

[1015] Boc

[1016] A mixture of tert-butyl 4-aminopiperidine-l -carboxylate (3.50 g, 23.49 mmol), 2,5-dichloropyrimidine (5.17 g, 25.84 mmol) and DIEA (6.06 g, 46.98 mmol) in DMSO (50.0 mL) was stirred at 90 °C under N2 for 3 h. The mixture was diluted with water and extracted with

[1017] - 91 - 1107314462\4\AMERICAS

[1018] Attorney Docket No. 119005.00357

[1019] Client Ref. No. NKT-25-003PCT

[1020] EtOAc. The organic layer was washed with brine, dried over Na2SC>4, concentrated and the residue was purified by silica gel column chromatography (PEZEtOAc, 8 / 1) to give the title compound as white solid.

[1021] Step 2: 5-Chloro-N-(piperidin-4-yl)pyrimidin-2-amine hydrogen chloride

[1022]

[1023] A mixture of tert-butyl 4-((5-chloropyrimidin-2-yl)amino)piperidine-l -carboxylate (500 mg, 1.60 mmol) and 4 M hydrogen chloride in dioxane (5.0 mL) was stirred at rt for 2 h. The mixture was concentrated to give the title compound.

[1024] The following reference compounds were synthesized by proceeding analogously as described in Reference 3.

[1025]

[1026] Reference 4

[1027] Synthesis of 3-(2,6-bis(benzyloxy)pyridin-3-yl)-6-iodo-l-methyl-lH-indazole

[1028]

[1029] Step 1: 3-(2,6-Bis(benzyloxy)pyridin-3-yl)-6-bromo-l-methyl-lH-indazole

[1030]

[1031] To a solution of 6-bromo-3-iodo-l-methyl-lH-indazole (5.00 g, 14.84 mmol) and 2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (6.81 g, 16.32 mmol) in dioxane / water = 5 / 1 (70.0 mL) was added Pd(dppf)Cl2 (1.08g, 1.48 mmol) and Cs2CO3 (12.09 g,

[1032] - 92 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[1033] Client Ref. No. NKT-25-003PCT

[1034] 37.10 mmol). The mixture was stirred at 80 °C under nitrogen for 12 h. After cooling to rt, the mixture was filtrated and the filtrate was concentrated. The residue was purified by silica gel column chromatography (PE / ethyl acetate, 7 / 1) to give the title compound as a yellow solid.

[1035] Step 2: 3-(2,6-Bis(benzyloxy)pyridin-3-yl)-6-iodo-l-methyl-lH-indazole

[1036]

[1037] To a solution of 3-(2,6-bis(benzyloxy)pyridin-3-yl)-6-bromo-l-methyl-lH-indazole (4.50 g, 8.99 mmol), KI (7.46 g, 44.95 mmol) and Cui (1.71 g, 8.99 mmol) in DMF (50.0 mL) was added N, N' -dimethylethylenediamine (1.58 g, 17.98 mmol) and the resulting mixture was stirred at 110 °C for 16 h. The mixture was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2SC>4 and concentrated. The residue was purified by silica gel column chromatography (PE / ethyl acetate, 8 / 1) to give the title compound as a yellow solid.

[1038] Reference 5

[1039] Synthesis of l-[l,5-dimethyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)indazol-3-yl]-3-[(4- methoxyphenyl)methyl]hexahydropyrimidine-2, 4-dione

[1040]

[1041] Step 1: l-(6-Bromo-l,5-dimethyl-indazol-3-yl)-3-[(4-methoxyphenyl)methyl]hexahydro-pyrimidine-2, 4-dione

[1042]

[1043] To a mixture of 6-bromo-3-iodo-l,5-dimethyl-indazole (1800 mg, 5.13 mmol), 3-[(4-methoxyphenyl)methyl]hexahydropyrimidine-2, 4-dione (1801.97 mg, 7.69 mmol) and K3PO4 (2177.15 mg, 10.26 mmol) in 1,4-dioxane (18 mL) was added Cui (488.35 mg, 2.56 mmol), followed by (lA,2A)-(-)-l,2-diaminocyclohexane (292.8 mg, 2.56 mmol) at rt under argon atmosphere. The resulting mixture was stirred at 100 °C for 7 h. The reaction mixture was

[1044] - 93 - 1107314462\4\AMERICAS

[1045] Attorney Docket No. 119005.00357

[1046] Client Ref. No. NKT-25-003PCT quenched with sat. aq. ammonium chloride solution and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified with silica gel column chromatography, (ethyl acetate / petroleum ether, 0-30%) to afford the title compound as an off-white solid.

[1047] Step 2: l-[l,5-Dimethyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)indazol-3-yl]-3-[(4-methoxyphenyl)methyl]hexahydropyrimidine-2, 4-dione

[1048]

[1049] To a mixture of l-(6-bromo-l,5-dimethyl-indazol-3-yl)-3-[(4-methoxyphenyl)methyl]-hexahydropyrimidine-2, 4-dione (1000 mg, 2.19 mmol), bis(pinacolato)diboron (832.9 mg, 3.28 mmol) and KOAc (321.89 mg, 3.28 mmol) in 1,4-dioxane (15 mL) was added Pd(dppf)C12 (159.84 mg, 0.22 mmol) at rt under argon atmosphere. The resulting mixture was stirred at 100 °C for 2 h. The reaction mixture was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified with silica gel column chromatography, eluted with ethyl acetate / petroleum ether (0-25%) to afford the title compound as a white solid.

[1050] Reference 6

[1051] Synthesis of 3-[6-fluoro-3-methyl-2-oxo-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)- benzimidazol-l-yl]-l-[(4-methoxyphenyl)methyl]piperidine-2, 6-dione

[1052]

[1053] 1107314462\4\AMERICAS

[1054] Attorney Docket No. 119005.00357

[1055] Client Ref. No. NKT-25-003PCT

[1056] Step 1: 3-(5-Bromo-6-fluoro-3-methyl-2-oxo-benzimidazol-l-yl)-l-[(4-methoxyphenyl)methyl]-piperidine-2, 6-dione

[1057]

[1058] Potassium tert-butoxide in THF (3.06 mL, 3.06 mmol) was added to a solution of 5-bromo-6-fluoro-3 -methyl- IH-benzimidazol -2-one (500 mg, 2.04 mmol) in THF (5 mL) at -10 °C.

[1059] [l-[(4-Methoxyphenyl)methyl]-2,6-dioxo-3-piperidyl] trifluoromethanesulfonate (933.65 mg, 2.45 mmol) in THF (5 mL) was added to the above mixture and the resulting mixture was stirred at -10 °C for 1 h. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified with silica gel column chromatography, eluted with ethyl acetate / petroleum ether (0-50%) to afford the title compound.

[1060] Step 2: 3-[6-Fluoro-3-methyl-2-oxo-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzimidazol-1 -y 1] - 1 -[(4-methoxyphenyl)methyl]piperidine-2, 6-dione

[1061]

[1062] A mixture of 3-(5-bromo-6-fluoro-3-methyl-2-oxo-benzimidazol-l-yl)-l-[(4-methoxy-phenyl)methyl]piperidine-2, 6-dione (630 mg, 1.32 mmol), KOAc (389.43 mg, 3.97 mmol), bis(pinacolato)diboron (503.83 mg, 1.98 mmol) and Pd(dppf)C12 (96.78 mg, 0.13 mmol) was stirred at 80 °C for 16 h under Ar. The mixture was concentrated and the residue was purified with silica gel column chromatography, eluted with ethyl acetate / petroleum ether (0-50%) to afford title compound.

[1063] Reference 7

[1064] Synthesis of 3-(2,6-Bis(benzyloxy)pyridin-3-yl)-6-bromo-l,5-dimethyl-lH-indazole

[1065]

[1066] - 95 - 1107314462\4\AMERICAS

[1067] Attorney Docket No. 119005.00357

[1068] Client Ref. No. NKT-25-003PCT

[1069] Step 1: 6-Bromo-3-iodo-5-methyl-lH-indazole

[1070]

[1071] To a stirred solution of 6-bromo-5-methyl-lH-indazole (5.00 g, 23.70 mmol), KOH (3.98 g, 71.10 mmol) in DMF (200.0 mL) was added I2 (12.04 g, 47.40 mmol) and the resulting mixture was stirred at rt for 16 h. The mixture was diluted with water and filtered to afford the title compound as a brown solid.

[1072] Step 2: 6-Bromo-3-iodo-l,5-dimethyl-lH-indazole

[1073]

[1074] To a stirred solution of 6-bromo-3-iodo-5-methyl-lH-indazole (5.50 g, 16.32 mmol) in DMF (100.0 mL) was added NaH (60%) (1.30 g, 32.64 mmol) at 0 °C, and the resulting mixture was stirred at 0 °C for 0.5 h. CH3I (4.63 g, 32.64 mmol) was then added to the above mixture, and the resulting mixture was stirred overnight. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over anhydrous Na2SC>4 and concentrated. The residue was purified by silica gel column chromatography, eluting with PE / ethyl acetate = 3 / 1 to afford the title compound as a yellow solid.

[1075] Step 3: 3-(2,6-Bis(benzyloxy)pyridin-3-yl)-6-bromo-l,5-dimethyl-lH-indazole

[1076]

[1077] To a mixture of 6-bromo-3-iodo-l,5-dimethyl-lH-indazole (2.60 g, 7.40 mmol) in dioxane / H2O (10:1) (50.0 mL) was added CS2CO3 (7.23 g, 22.20 mmol), 2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (3.08 g, 7.40 mmol), Pd(dppf)C12 (541 mg, 0.74 mmol) and the resulting mixture was stirred at 70 °C for 16 h. After cooling to rt, the mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over anhydrous Na2SC>4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE: ethyl acetate = 8: 1 to afford the title compound as a yellow solid.

[1078] Reference 8

[1079] - 96 - 1107314462\4\AMERICAS

[1080] Attorney Docket No. 119005.00357

[1081] Client Ref. No. NKT-25-003PCT

[1082] Synthesis of l-[3-[[4-[(5-chloropyrimidin-2-yl)amino]-l-piperidyl]sulfonyl]phenyl]piperidine-4- carbaldehyde

[1083]

[1084] Step 1: tert-Butyl (l-((3-fluorophenyl)sulfonyl)piperidin-4-yl)carbamate

[1085] N > H

[1086]

[1087] Boc

[1088] To a solution of tert-butyl N-(piperidin-4-yl)carbamate (4.0 g, 20.0 mmol) and TEA (2.1 g, 20.9 mmol) in THF (30 mL) was added 3 -fluorobenzenesulfonyl chloride (3.7 g, 19.0 mmol) in THF (10 mL) dropwise at -10 °C. The resulting mixture was stirred for 2 h at 0 °C. The reaction was quenched with H2O, extracted with ethyl acetate, washed with water and brine, dried over anhydrous Na2SC>4, and concentrated under reduced pressure. The residue was triturated in water / acetonitrile=1:1 to give the title compound as an off-white solid.

[1089] Step 2: tert-Butyl (l-((3-(4-(hydroxymethyl)piperidin-l-yl)phenyl)sulfonyl)piperidin-4-yl)carbamate

[1090]

[1091] A mixture of tert-butyl N-[l-(3-fluorobenzenesulfonyl)piperidin-4-yl]carbamate (5.4 g, 15.1 mmol) and piperidin-4-ylmethanol (5.21 g, 45.2 mmol) in DMSO (54 mL) was stirred for 72 h at 110 °C. The mixture was cooled to room temperature and diluted with water. The resulting mixture was extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over anhydrous Na2SC>4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0 - 100%) to afford the title compound as a light-yellow solid.

[1092] Step 3: (1 -(3 -((4-Aminopiperidin-l-yl)sulfonyl)phenyl)piperidin-4-yl)m ethanol hydrochloride

[1093]

[1094] - 97 - 1107314462\4\AMERICAS

[1095] Attorney Docket No. 119005.00357

[1096] Client Ref. No. NKT-25-003PCT

[1097] A mixture of tert-butyl (l-((3-(4-(hydroxymethyl)piperidin-l-yl)phenyl)sulfonyl)piperidin-4-yl)carbamate (4.0 g, 8.82 mmol) in 4 M HC1 in 1,4-dioxane (40 mL) was stirred for 2 h at room temperature. The resulting mixture was concentrated under reduced pressure to give the title compound as a light-yellow solid.

[1098] Step 4: (l-(3-((4-((5-Chloropyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)phenyl)piperidin-4-yl) methanol

[1099]

[1100] To a solution of (1 -(3 -((4-aminopiperi din- l-yl)sulfonyl)phenyl)piperidin-4-yl)m ethanol hydrochloride (2.1 g, 5.0 mmol) in DMSO (21 mL), was added DIEA (1.95 g, 15.0 mmol) and 2, 5-dichloropyrimidine (1.49 g, 10.0 mmol), the mixture was stirred at 90 °C for 16 h under nitrogen atmosphere. After cooling to room temperature, the mixture was quenched with water, extracted with ethyl acetate, the combined organic layers were washed with water and brine, dried over anhydrous Na2SC>4. After filtration, the organic layer was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with MeOH / DCM (0 - 10%) to afford the title compound as a light-yellow solid.

[1101] Step 5: l-[3-[[4-[(5-Chloropyrimidin-2-yl)amino]-l-piperidyl]sulfonyl]phenyl]piperidine-4-carbaldehyde

[1102]

[1103] To a solution of [l-[3-[[4-[(5-chloropyrimidin-2-yl)amino]-l-piperidyl]sulfonyl]phenyl]-4-piperidyl]methanol (500 mg, 1.07 mmol) in DCM (5 mL) was added Dess-Martin periodinane (910.1 mg, 2.15 mmol) at 0 °C, and the mixture was stirred at rt for 2 h. The mixture was quenched with aq. NaHSCh solution, extracted with DCM. The combined organic layers were washed with water, brine, and dried over anhydrous Na2SC>4. After filtration, the filtrate was concentrated and the residue was purified with flash chromatography, eluted with ethyl acetate / petroleum ester (0-50%) to afford the title compound as colorless oil.

[1104] Reference 9

[1105] - 98 - 1107314462\4\AMERICAS

[1106] Attorney Docket No. 119005.00357

[1107] Client Ref. No. NKT-25-003PCT

[1108] Synthesis of 2-[4-[3-(2,6-dioxo-3-piperidyl)-l-methyl-indazol-6-yl]-5,5-dimethyl-piperazin -2- yl]acetonitrile hydrochloride

[1109]

[1110] Step 1: tert-Butyl 4-benzyl-3, 3 -dimethyl-piperazine-1 -carboxylate

[1111]

[1112] Boc

[1113] To a mixture of tert-butyl 3, 3 -dimethylpiperazine- 1 -carboxylate (2500 mg, 11.67 mmol) and potassium carbonate (4836.45 mg, 35 mmol) in MeCN (25 mL) was added benzyl bromide (2.08 mL, 17.5 mmol) at rt, and the resulting mixture was stirred at rt for 18 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate and concentrated. The residue was purified by silica gel column chromatography to afford the title compound.

[1114] Step 2: tert-Butyl 4-benzyl-2-formyl-5,5-dimethyl-piperazine-l-carboxylate

[1115]

[1116] Boc O Boc

[1117] To a solution of tert-butyl 4-benzyl-3,3-dimethyl-piperazine-l-carboxylate (3450 mg, 11.33 mmol) in THF (25 mL) was added s-BuLi (11.5 mL, 14.73 mmol) at -30 °C and the resulting mixture was stirred at -30 °C for 30 min. DMF (1.82mL, 17 mmol) was then added to the above mixture at -30 °C, and the resulting mixture warmed to rt and stirred for 1 h. The reaction mixture was quenched with sat. aq. ammonium chloride solution and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate and concentrated. The residue was purified by silica gel column chromatography to afford the title compound.

[1118] Step 3: tert-Butyl 4-benzyl-2-(cyanomethyl)-5,5-dimethyl-piperazine-l-carboxylate

[1119]

[1120] To a mixture of toluenesulfonylmethyl isocyanide (1145.22 mg, 5.87 mmol) in THF (1 mL) was added potassium tert-butoxide (1012.6 mg, 9.02 mmol) at -78 °C and the resulting

[1121] 1107314462\4\AMERICAS

[1122] Attomey Docket No. 119005.00357

[1123] Client Ref. No. NKT-25-003PCT mixture was stirred at -78 °C for 10 min. tert-Butyl 4-benzyl-2-formyl-5,5-dimethyl-piperazine-l-carboxylate (1500 mg, 4.51 mmol) in THF (1 mL) was added to the mixture at -78 °C and the mixture was allowed to warm to rt and stirred for 3 h. The mixture was quenched with sat. ammonium chloride aq. solution and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate and concentrated. The residue was purified by silica gel column chromatography to afford the title compound.

[1124] Step 4: tert-Butyl 2-(cyanomethyl)-5,5-dimethyl-piperazine-l-carboxylate

[1125]

[1126] Boc Boc

[1127] To a solution of tert-butyl 4-benzyl-2-(cyanomethyl)-5,5-dimethyl-piperazine-l-carboxylate (690 mg, 2.01 mmol) in ethanol (7 mL) and THF (7 mL) was added Pd(OH)2 / C (140 mg) and Pd / C (140 mg), and the resulting mixture was stirred at rt under 1 atm hydrogen atmosphere for 17 h. The mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to afford the title compound.

[1128] Step 5: tert-Butyl 2-(cyanomethyl)-4-[3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazol-6-yl]-5,5-dimethyl-piperazine-1 -carboxylate

[1129]

[1130] To a mixture of 6-bromo-3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazole (200 mg, 0.4 mmol), tert-butyl 2-(cyanomethyl)-5,5-dimethyl-piperazine-l -carboxylate (202.52 mg, 0.8 mmol) and Pd-PEPPSI-IPentC (34.37 mg, 0.04 mmol) in 1,4-dioxane (2 mL) was added sodium tert-butoxide (115.23 mg, 1.2 mmol) under argon atmosphere, and the mixture was stirred at 90 °C for 10 h. The mixture was diluted with water and ethyl acetate, then filtered through Celite. The filtrate was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by flash chromatography to afford the title compound.

[1131] Step 6: tert-Butyl 2-(cyanomethyl)-4-[3-(2,6-dioxo-3-piperidyl)-l-methyl-indazol-6-yl]-5,5-dimethyl-piperazine-1 -carboxylate

[1132] - 100 - 1107314462\4\AMERICAS

[1133] Attorney Docket No. 119005.00357

[1134] Client Ref. No. NKT-25-003PCT

[1135]

[1136] To a solution of tert-butyl 2-(cyanom ethyl)-4-[3 -(2, 6-dibenzyloxy-3 -pyridyl)- 1-methyl-indazol-6-yl]-5,5-dimethyl-piperazine-l-carboxylate (250 mg, 0.34 mmol) in ethanol (3 mL) and THF (3 mL) was added Pd(OH)2 / C (100 mg) and Pd / C (100 mg), and the resulting mixture was stirred under hydrogen atmosphere at 40 °C for 17 h. The mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to afford the title compound.

[1137] Step 7: 2-[4-[3-(2,6-Dioxo-3-piperidyl)-l-methyl-indazol-6-yl]-5,5-dimethyl-piperazin-2-yl]-acetonitrile hydrochloride

[1138]

[1139] To a solution of tert-butyl 2-(cyanomethyl)-4-[3-(2,6-dioxo-3-piperidyl)-l-methyl-indazol-6-yl]-5, 5-dimethyl -piperazine- 1 -carboxylate (115 mg, 0.23 mmol) in DCM (1.5 mL) was added HCI in dioxane (1 mL, 4.0 M), and the resulting mixture was stirred at rt for 2 h. The solvent was removed under reduced pressure to afford the title compound.

[1140] Reference 10

[1141] Synthesis of 3-[6-(5-fluoro-3,3-dimethyl-2,6-dihydro-lH-pyridin-4-yl)-l-methyl-indazol-3-yl]- piperidine-2, 6-dione hydrochloride

[1142]

[1143] Step 1: 3-(2,6-Bis(benzyloxy)pyridin-3-yl)-l-methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indazole

[1144]

[1145] - 101 - 1107314462\4\AMERICAS

[1146] Attorney Docket No. 119005.00357

[1147] Client Ref. No. NKT-25-003PCT

[1148] To a stirred mixture of 6-bromo-3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazole (2000 mg, 4.0 mmol), bis(pinacolato)diboron (1522.42 mg, 6.0 mmol) and KOAc (784.5 mg, 8.0 mmol) in 1,4-dioxane (20 mL) was added Pd(dppf)C12 (292.17 mg, 0.40 mmol) at 25 °C under argon atmosphere. The resulting mixture was heated to 100 °C for 2 h. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried and concentrated under reduced pressure. The residue was purified with silica gel column chromatography, eluted with ethyl acetate / petroleum ester (0-13%) to afford the title compound as an off-white solid.

[1149] Step 2: 3-[l-Methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)indazol-3-yl]piperidine-2,6-dione

[1150]

[1151] To a stirred solution of 3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)indazole (2000 mg, 3.65 mmol) in EtOH (20 mL) and THF (20 mL) was added Pd / C (600 mg), followed by Pd(OH)2 / C (600 mg) at rt under argon atmosphere. The resulting mixture was purged with hydrogen and stirred for 16 h at 40 °C under 1 atm hydrogen atmosphere. The mixture was diluted with DCM and filtered through Celite. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography, eluted with methanol / dichloromethane (0~3%) to afford the title compound as an off-white solid.

[1152] Step 3: tert-Butyl 3,3-dimethyl-4-trimethylsilyloxy-2,6-dihydropyridine-l-carboxylate

[1153]

[1154] Boc Boc

[1155] To a stirred solution of tert-butyl 3, 3 -dimethyl-4-oxo-piperi dine- 1 -carboxylate (5000 mg, 22 mmol) and TEA (8903.65 mg, 87.99 mmol) in toluene (100 mL) was added TMSOTf (9778.27 mg, 43.99 mmol) dropwise at 0 °C under argon atmosphere. The resulting mixture was stirred at 0 °C for 1 h. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried and concentrated under reduced pressure to afford the title compound as a yellow oil, which was used in the next step without further purification. Step 4: tert-Butyl 5-fluoro-3,3-dimethyl-4-oxo-piperidine-l-carboxylate

[1156] - 102 - 1107314462\4\AMERICAS

[1157] Attorney Docket No. 119005.00357

[1158] Client Ref. No. NKT-25-003PCT

[1159]

[1160] Boc Boc

[1161] To a stirred solution of tert-butyl 3,3-dimethyl-4-trimethylsilyloxy-2,6-dihydropyridine-l-carboxylate (6500 mg, 21.7 mmol) in acetonitrile (130 mL) was added l-chloromethyl-4-fluoro-l,4-diazoniabicyclo[2.2.2]octane bi s(tetrafluorob orate) (8457.57 mg, 23.87 mmol) at 0 °C under argon atmosphere. The resulting mixture was stirred at rt for 16 h. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography, eluted with ethyl acetate / petroleum ester (0-10%) to afford the title compound as an off-white solid.

[1162] Step 5: tert-Butyl 5-fluoro-3,3-dimethyl-4-(((perfluorobutyl)sulfonyl)oxy)-3,6-dihydropyridine-1 (2H)-carboxylate

[1163]

[1164] To a stirred solution of tert-butyl 5-fluoro-3,3-dimethyl-4-oxo-piperidine-l-carboxylate (939 mg, 3.83 mmol) andDBU (1748.38 mg, 11.48 mmol) in THF (20 mL) was added perfluorobutanesulfonyl fluoride (2.07 mL, 11.48 mmol) at 0 °C under argon atmosphere. The mixture stirred at rt for 16 h. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SC>4 and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography, eluted with ethyl acetate / petroleum ester (0~5%) to afford the title compound as a colorless oil. Step 6: tert-Butyl 4-[3-(2,6-dioxo-3-piperidyl)-l-methyl-indazol-6-yl]-5-fluoro-3,3-dimethyl-2,6-dihydropyridine- 1 -carboxylate

[1165]

[1166] To a stirred mixture of 3-[l-methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)indazol-3-yl]piperidine-2, 6-dione (80 mg, 0.22 mmol), tert-butyl 5-fluoro-3,3-dimethyl-4-

[1167] - 103 - 1107314462\4\AMERICAS

[1168] Attorney Docket No. 119005.00357

[1169] Client Ref. No. NKT-25-003PCT

[1170] (((perfluorobutyl)sulfonyl)oxy)-3,6-dihydropyridine-l(2H)-carboxylate (150.58 mg, 0.33 mmol) and K2CO3 (89.84 mg, 0.65 mmol) in 1,4-dioxane (1.6 mL) was added Pd(dppf)C12 (15.84 mg, 0.02 mmol) at rt under argon atmosphere. The mixture was heated to 90 °C and stirred for 16 h. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried and concentrated under reduced pressure. The residue was purified by reverse phase C-18 silica gel column chromatography, eluted with (5% ~ 50% acetonitrile in water with 0.05% formic acid) to afford the title compound as an off-white solid. Step 7: 3-[6-(5-Fluoro-3,3-dimethyl-2,6-dihydro-lH-pyridin-4-yl)-l-methyl-indazol-3-yl]-piperidine-2, 6-dione hydrochloride

[1171]

[1172] To a stirred solution of tert-butyl 4-[3-(2,6-dioxo-3-piperidyl)-l-methyl-indazol-6-yl]-5-fluoro-3,3-dimethyl-2,6-dihydropyridine-l-carboxylate (58 mg, 0.12 mmol) in DCM (1.0 mL) was added HC1 in dioxane (1.0 mL, 4.0 M) at 25 °C and the mixture was stirred for 1 h. The solvent was removed under reduced pressure to afford the title compound as an off-white solid.

[1173] Reference compound 10a was synthesized by proceeding analogously as described in Reference 10.

[1174]

[1175] Reference 11

[1176] Synthesis of 3-[6-(3,3-difluoro-5,5-dimethyl-4-piperidyl)-l-methyl-indazol-3-yl]piperidine-2,6- dione hydrochloride

[1177]

[1178] Step 1: tert-Butyl 4-[3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazol-6-yl]-3,3-dimethyl-2,6-dihydropyridine- 1 -carboxylate

[1179] - 104 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[1180] Client Ref. No. NKT-25-003PCT

[1181]

[1182] A mixture of tert-butyl 3,3-dimethyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,6-dihydropyridine-1 -carboxylate (647.04 mg, 1.92 mmol), 6-bromo-3-(2,6-dibenzyloxy-3-pyridyl)-1-methyl-indazole (800 mg, 1.6 mmol), K3PO4 (1018.06 mg, 4.8 mmol) and Pd(dppf)C12 (30.45 mg, 0.16 mmol), 1,4-dioxane (10 mL) and water (1 mL) was stirred at 100 °C for 4 hr under Ar. After cooled to rt, the mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography, eluted with ethyl acetate / petroleum ester (0-20%) to afford the title compound as a white solid.

[1183] Step 2: tert-Butyl 4-[3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazol-6-yl]-5-hydroxy-3,3-dimethyl-piperidine- 1 -carboxylate

[1184]

[1185] BH3 in Me2S (0.8 mL, 1.9 mmol) was added to the solution of tert-butyl 4-[3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazol-6-yl]-3,3-dimethyl-2,6-dihydropyridine-l-carboxylate (400 mg, 0.63 mmol) in THF (4 mL) at 0 °C and the resulting mixture was stirred at rt for 16 h under Ar. The mixture was quenched with aq. H2O2(0.52 mL, 5.07 mmol) and NaOH (1.26 mL, 5.07 mmol) at 0 °C, and the mixture was stirred for 2 h at rt. The mixture was extracted with ethyl acetate, and the combined organic layers were washed with water, brine, dried and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography, eluted with ethyl acetate / petroleum ester (0-50%) to afford the title compound as a white solid.

[1186] Step 3: tert-Butyl 4-[3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazol-6-yl]-3,3-dimethyl-5-oxo-piperidine-1 -carboxylate

[1187]

[1188] - 105 - 1107314462\4\AMERICAS

[1189] Attorney Docket No. 119005.00357

[1190] Client Ref. No. NKT-25-003PCT

[1191] To a solution of tert-butyl 4-[3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazol-6-yl]-5-hydroxy-3,3-dimethyl-piperidine-l-carboxylate (270 mg, 0.42 mmol) in DCM (5 mL) was added Dess-Martin periodinane (529.35 mg, 1.25 mmol) at 0 °C and the resulting mixture was stirred at rt for 16 h. The mixture was quenched with sat. aq. sodium sulfite and extracted with ethyl acetate. The combined organic phase was washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography, eluted with ethyl acetate / petroleum ester (0-40%) to afford the title compound as brown oil.

[1192] Step 4: tert-Butyl 4-[3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazol-6-yl]-3,3-difluoro-5,5-dimethyl-piperidine- 1 -carboxylate

[1193]

[1194] To the solution of tert-butyl 4-[3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazol-6-yl]-3,3-dimethyl-5-oxo-piperidine-l-carboxylate (130 mg, 0.2 mmol) in DCM (0.5 mL) was added DAST (0.5 mL, 3.78 mmol) at 0 °C, and the mixture was stirred at rt for 6 h. The mixture was quenched with sat. aq. NaHCO3solution at 0 °C and extracted with ethyl acetate. The combined organic phase was washed with brine, dried and concentrated under reduced pressure. The residue was purified by flash chromatography (ethyl acetate / PE: 0-30%) to give the title compound as white solid.

[1195] Step 5: tert-Butyl 4-[3-(2,6-dioxo-3-piperidyl)-l-methyl-indazol-6-yl]-3,3-difluoro-5,5-dimethyl-piperidine-1 -carboxylate

[1196]

[1197] A mixture of tert-butyl 4-[3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazol-6-yl]-3,3-difluoro-5,5-dimethyl-piperidine-l-carboxylate (60 mg, 0.09 mmol), Pd / C (20 mg) and Pd(OH)2 / C (20 mg) in ethanol (2 mL) and THF (2 mL) was stirred at 40 °C for 16 h under 1 atm hydrogen atmosphere. The mixture was then filtered, and the filtrate was concentrated to afford the title compound.

[1198] Step 6: 3-[6-(3,3-Difluoro-5,5-dimethyl-4-piperidyl)-l-methyl-indazol-3-yl]piperidine-2, 6-dione hydrochloride

[1199] - 106 - 1107314462\4\AMERICAS

[1200] Attorney Docket No. 119005.00357

[1201] Client Ref. No. NKT-25-003PCT

[1202]

[1203] To a solution of tert-butyl 4-[3-(2,6-dioxo-3-piperidyl)-l-methyl-indazol-6-yl]-3,3-difluoro-5,5-dimethyl-piperidine-l-carboxylate (44 mg, 0.09 mmol) in DCM (1 mL) was added HCl / dioxane (1 mL, 4.0 M) at rt and the resulting mixture was stirred at rt for 1 hr. The mixture was concentrated to give the title compound as a white solid.

[1204] Reference compound Ila was synthesized by proceeding analogously as described in Reference 11.

[1205]

[1206] Reference 12

[1207] Synthesis of 4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-5,5-dimethyl-l, 2,5,6- tetrahydropyridine-3 -carbonitrile hydrochloride

[1208]

[1209] Step 1: l-(tert-Butyl) 3-methyl 5,5-dimethyl-4-oxopiperidine-l,3-dicarboxylate

[1210]

[1211] Boc l

[1212] Boc

[1213] To a stirred solution of tert-butyl 3, 3 -dimethyl-4-oxopiperi dine- 1 -carboxylate (9 g, 39.6 mmol) in THF (90 mL) was added NaH (4 g, 99 mmol, 60%) in portions at 0 °C under nitrogen atmosphere, and the mixture was stirred at 0 °C for 30 min. To the above mixture was

[1214] added dimethyl carbonate (8.9 g, 99 mmol) dropwise at rt and the resulting mixture was stirred at 60 °C for 16 h. The mixture was diluted with NH4CI aq. solution and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous Na2SC>4 and

[1215] - 107 - 1107314462\4\AMERICAS

[1216] Attorney Docket No. 119005.00357

[1217] Client Ref. No. NKT-25-003PCT concentrated. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0-10%) to afford the title compound as a colorless oil.

[1218] Step 2: l-(tert-Butyl) 3-methyl 5,5-dimethyl-4-(((trifluoromethyl)sulfonyl)oxy)-5,6-dihydro-pyridine-l,3(2H)-dicarboxylate

[1219]

[1220] To a stirred solution of 1 -(tert-butyl) 3-methyl 5,5-dimethyl-4-oxopiperidine-l,3-dicarboxylate (7 g, 24.5 mmol) in DCM (70 mL) was added DIEA (3.5 g, 27 mmol) at 0

[1221] °C under nitrogen atmosphere and the resulting mixture was stirred at 0 °C for 30 min. To the above mixture was added TfzO (8.3 g, 29.4 mmol) dropwise at 0 °C and the resulting mixture was stirred at rt for 4 h. The reaction mixture was quenched with NEUCl aq. solution and then extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0-10%) to afford the title compound as a colorless oil.

[1222] Step 3: l-(tert-Butyl) 3-methyl 4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-5,5-dimethyl-5,6-dihydropyridine-l,3(2H)-dicarboxylate

[1223]

[1224] To a stirred solution of 3-(l-methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indazol-3-yl)piperidine-2, 6-dione (1 g, 2.7 mmol) and 1 -(tert-butyl) 3-methyl 5,5-dimethyl-4-(((trifluoromethyl)sulfonyl)oxy)-5,6-dihydropyridine-l,3(2H)-dicarboxylate (1.13 g, 2.7 mmol) in dioxane (10 mL) and H2O (1 mL) were added Pd(dppf)C12 (0.2 g, 0.27 mmol) and K2CO3 (1.1 g, 8.1 mmol) at rt. The resulting mixture was stirred at 85°C for 2 h under nitrogen atmosphere. After cooling to rt, the reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0-75%) to afford the title compound as a yellow solid.

[1225] Step 4: l-(tert-Butoxycarbonyl)-4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-5,5-dimethyl-l,2,5,6-tetrahydropyridine-3-carboxylic acid

[1226] - 108 - 1107314462\4\AMERICAS

[1227] Attorney Docket No. 119005.00357

[1228] Client Ref. No. NKT-25-003PCT

[1229]

[1230] To a stirred solution of 1 -(tert-butyl) 3-methyl 4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-5,5-dimethyl-5,6-dihydropyridine-l,3(2H)-dicarboxylate (900 mg, 1.763 mmol) in THF (10 mL) was added TMSOK (679 mg, 5.3 mmol) in portions at

[1231] 0°C under nitrogen atmosphere and the resulting mixture was stirred at rt for 16 h. The reaction mixture was diluted with ethyl acetate, and the pH of the mixture was adjusted to 7 with 2 M HC1 aq. solution. The mixture was extracted with ethyl acetate, and the combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with THF / PE (0-40%) to afford the title compound as a yellow solid.

[1232] Step 5: tert-Butyl 5-carbamoyl-4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3-dimethyl-3,6-dihydropyridine-l(2H)-carboxylate

[1233]

[1234] To a stirred solution of l-(tert-butoxycarbonyl)-4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-5,5-dimethyl-l,2,5,6-tetrahydropyridine-3-carboxylic acid (200 mg, 0.4 mmol) and DIEA (208 mg, 1.61 mmol) in DMF (2 mL) were added NH4CI (129 mg, 2.4 mmol) and HATU (230 mg, 0.6 mmol) in portions at r.t. under nitrogen atmosphere. The resulting mixture was stirred for 2 h. The mixture was diluted with water and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with THF / PE (0-75%) to afford the title compound as a yellow solid.

[1235] Step 6: tert-Butyl 5-cyano-4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3-dimethyl-3,6-dihydropyridine-l(2H)-carboxylate

[1236] - 109 - 1107314462\4\AMERICAS

[1237] Attorney Docket No. 119005.00357

[1238] Client Ref. No. NKT-25-003PCT

[1239]

[1240] To a stirred solution of tert-butyl 5-carbamoyl-4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3-dimethyl-3,6-dihydropyridine-l(2H)-carboxylate (144 mg, 0.29 mmol) and TEA (88 mg, 0.87 mmol) in THF (2 mL) was added TfzO (163 mg, 0.58 mmol) dropwise at 0°C under nitrogen atmosphere and the resulting mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with water and then extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with THF / PE (0-60%) to afford the title compound as a yellow solid.

[1241] Step 7: 4-(3-(2, 6-Dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-5, 5-dimethyl-l, 2,5,6-tetrahydropyridine-3 -carbonitrile hydrochloride

[1242]

[1243] To a stirred solution of tert-butyl 5-cyano-4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3-dimethyl-3,6-dihydropyridine-l(2H)-carboxylate (87 mg, 0.18 mmol) in DCM (1 mL) was added 4M HC1 in dioxane (0.8 mL) dropwise at 0°C under nitrogen atmosphere and the resulting mixture was stirred at rt for 1 hr. The reaction mixture was then concentrated under reduced pressure to afford the title compound as a yellow solid.

[1244] Reference compound 12a was synthesized by proceeding analogously as described in

[1245] Reference 12.

[1246]

[1247] Reference 13

[1248] Synthesis of 3-[l-methyl-6-(2, 2,5, 5-tetramethylpiperazin-l-yl)indazol-3-yl]piperidine-2, 6-dione hydrochloride

[1249] - 110 - 1107314462\4\AMERICAS

[1250] Attorney Docket No. 119005.00357

[1251] Client Ref. No. NKT-25-003PCT

[1252]

[1253] Step 1: tert-Butyl 2,2,5,5-tetramethylpiperazine-l-carboxylate

[1254]

[1255] To a mixture of 2, 2, 5, 5 -tetramethylpiperazine dihydrochloride (1.0 g, 4.65 mmol) and TEA (1.9 g, 18.59 mmol) in DCM (10 mL) was added Boc2O (963.6 mg, 4.42 mmol) at r.t. and the resulting mixture was stirred for 2 h. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over anhydrous Na2SC>4 and concentrated. The residue was purified with silica gel flash chromatography, eluted with PE / ethyl acetate (0-100%) to afford the title compound as a yellow oil.

[1256] Step 2: tert-Butyl 4-[3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazol-6-yl]-2,2,5,5-tetramethyl-piperazine- 1 -carboxylate

[1257]

[1258] A mixture of 6-bromo-3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazole (250 mg, 0.50 mmol), tert-butyl 2,2,5,5-tetramethylpiperazine-l-carboxylate (133.2 mg, 0.55 mmol), t-BuONa (95.9 mg, 0.10 mmol) and Pd-PEPPSI-IPentC (43.0 mg, 0.05 mmol) in 1,4-dioxane (3 mL) was stirred at 100 °C for 4 h under argon atmosphere. After cooled to rt, the mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SC>4 and concentrated. The residue was purified by silica gel flash chromatography, eluted with DCM / MeOH (0-5%) to afford the title compound as a brown solid.

[1259] Step 3: tert-Butyl 4-[3-(2,6-dioxo-3-piperidyl)-l-methyl-indazol-6-yl]-2,2,5,5-tetramethyl-piperazine- 1 -carboxylate

[1260]

[1261] To a stirred solution of tert-butyl 4-[3 -(2, 6-dibenzyloxy-3 -pyridyl)- l-methyl-indazol-6-yl]-2, 2, 5, 5-tetramethyl-piperazine-l -carboxylate (240 mg, 0.36 mmol) in EtOH (1.5 mL) and THF

[1262] - Ill - 1107314462\4\AMERICAS

[1263] Attorney Docket No. 119005.00357

[1264] Client Ref. No. NKT-25-003PCT

[1265] (1.5 mL) was added Pd / C (96 mg) and Pd(OH)2 / C (96 mg) at rt under argon atmosphere. The resulting mixture was purged with hydrogen and stirred for 16 h at 40 °C under 1 atm of hydrogen atmosphere. The mixture was diluted with DCM and filtered through Celite. The filtrate was concentrated to afford the title compound as a brown solid.

[1266] Step 4: 3-[l-Methyl-6-(2,2,5,5-tetramethylpiperazin-l-yl)indazol-3-yl]piperidine-2,6-dione hydrochloride

[1267]

[1268] To a stirred solution of tert-butyl 4-[3-(2,6-dioxo-3-piperidyl)-l-methyl-indazol-6-yl]-2,2,5,5-tetramethyl-piperazine-l-carboxylate (170 mg, 0.35 mmol) in DCM (2.0 mL) was added HC1 in dioxane (2.0 mL, 4.0 M) at rt and the resulting mixture was stirred at rt for 1 hr. The solvent was removed under reduced pressure to afford the title compound as a brown solid.

[1269] Reference compound 13a was synthesized by proceeding analogously as described in

[1270] Reference 13.

[1271]

[1272] Reference 14

[1273] Synthesis of 3-[6-(5-fluoro-3,3-dimethyl-4-piperidyl)-l-methyl-indazol-3-yl]piperidine-2, 6-dione hydrochloride

[1274]

[1275] Step 1: tert-Butyl 4-[3-(2,6-dioxo-3-piperidyl)-l-methyl-indazol-6-yl]-5-fluoro-3,3-dimethyl-piperidine- 1 -carboxylate

[1276] - 112 - 1107314462\4\AMERICAS

[1277] Attorney Docket No. 119005.00357

[1278] Client Ref. No. NKT-25-003PCT

[1279]

[1280] A mixture of tert-butyl 4-[3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazol-6-yl]-5-fluoro-3,3-dimethyl-2,6-dihydropyridine-l-carboxylate (150 mg, 0.23 mmol), Pd / C (30 mg, 0.28 mmol) and Pd(OH)2 / C (30 mg, 0.21 mmol) in ethanol (2 mL) and THF (2 mL) was stirred at 40 °C for 16 h under 1 atm of H2 atmosphere. The reaction mixture was filtered and concentrated to give the title compound as yellow oil.

[1281] Step 2: 3-[6-(5-Fluoro-3,3-dimethyl-4-piperidyl)-l-methyl-indazol-3-yl]piperidine-2, 6-dione hydrochloride

[1282]

[1283] To a solution of tert-butyl 4-[3-(2,6-dioxo-3-piperidyl)-l-methyl-indazol-6-yl]-5-fluoro-3,3-dimethyl-piperidine-l-carboxylate (16 mg, 0.03 mmol) in DCM (1 mL) was added HCl / dioxane (4 M, 1 mL) and the mixture was stirred at rt for 1 hr. The reaction mixture was concentrated to afford the title compound as a white solid.

[1284] Reference 15

[1285] Synthesis of 3-[4-(3,3-difluoro-5,5-dimethyl-4-piperidyl)-2-methoxy-anilino]piperidine-2, 6-dione

[1286]

[1287] Step 1: tert-Butyl 4-(4-amino-3-methoxy-phenyl)-3,3-dimethyl-2,6-dihydropyridine-l-carboxylate

[1288]

[1289] - 113 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[1290] Client Ref. No. NKT-25-003PCT

[1291] The title compound was synthesized by proceeding analogously as described in Reference 11, Step 1, using 4-bromo-2-methoxyaniline instead of 6-bromo-3 -(2, 6-dibenzyloxy-3 -pyridyl)- 1-methyl-indazole.

[1292] Step 2: tert-Butyl 4-[4-[(2,6-dibenzyloxy-3-pyridyl)amino]-3-methoxy-phenyl]-3,3-dimethyl-2,6-dihydropyridine- 1 -carboxylate

[1293]

[1294] To a mixture of 2, 6-dibenzyloxy-3 -iodo-pyridine (903.68 mg, 2.17 mmol), cesium carbonate (1764.16 mg, 5.41 mmol) and tert-butyl 4-(4-amino-3-methoxy-phenyl)-3,3-dimethyl-2,6-dihydropyridine-l -carboxylate (600 mg, 1.8 mmol) in tert-butanol (10 mL) was added Pd2(dba)3(165.27 mg, 0.18 mmol) and RuPhos (168.44 mg, 0.36 mmol) under argon atmosphere, and the resulting mixture was stirred at 100 °C for 6 h. The mixture was diluted with water and ethyl acetate, then filtered through Celite. The filtrate was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SC>4 and concentrated. The residue was purified by silica gel flash chromatography to afford the title compound.

[1295] Step 3: tert-Butyl 4-[4-[(2,6-dibenzyloxy-3-pyridyl)amino]-3-methoxy-phenyl]-3,3-difluoro-5,5-dimethyl-piperidine- 1 -carboxylate

[1296]

[1297] The title compound was synthesized by proceeding analogously as described in Reference 11, Steps 2-5, using tert-butyl 4-[4-[(2,6-dibenzyloxy-3-pyridyl)amino]-3-methoxy-phenyl]-3,3-dimethyl-2,6-dihydropyridine-l-carboxylate instead of tert-butyl 4-[3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazol-6-yl]-3,3-dimethyl-2,6-dihydropyridine-l-carboxylate in Step 2.

[1298] Step 4: 3-[4-(3,3-Difluoro-5,5-dimethyl-4-piperidyl)-2-methoxy-anilino]piperidine-2, 6-dione hydrochloride

[1299]

[1300] - 114 - 1107314462\4\AMERICAS

[1301] Attorney Docket No. 119005.00357

[1302] Client Ref. No. NKT-25-003PCT

[1303] To a solution of tert-butyl 4-[4-[(2,6-dioxo-3-piperidyl)amino]-3-methoxy-phenyl]-3,3-difluoro-5,5-dimethyl-piperidine-l-carboxylate (100 mg, 0.21 mmol) in DCM (1 mL) was added HCl-di oxane (1.5 mL, 4 M), and the resulting mixture was stirred at rt for 2 h. The solvent was removed under reduced pressure to afford the title compound.

[1304] Reference 16

[1305] Synthesis of 3 -[2-m ethoxy -4-(2, 2,5, 5-tetramethylpiperazin-l-yl)anilino]piperidine-2, 6-dione hydrochloride

[1306]

[1307] Step 1: tert-Butyl 4-(3-methoxy-4-nitro-phenyl)-2,2,5,5-tetramethyl-piperazine-l-carboxylate

[1308]

[1309] To a stirred solution of 4-iodo-2-methoxy-l -nitro-benzene (300 mg, 1.07 mmol), tert-butyl 2,2,5,5-tetramethylpiperazine-l-carboxylate (521.1 mg, 2.15 mmol) and Cs2CO3(1048 mg, 3.22 mmol) in dioxane (5 mL) was added Pd-PEPPSI-IPentC (92.5 mg, 0.11 mmol) and the resulting mixture was stirred at 100 °C for 3 h under argon atmosphere. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over Na2SC>4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / petroleum ester (0-30%) to afford the title compound as a white solid.

[1310] Step 2: tert-Butyl 4-(4-amino-3-methoxy-phenyl)-2,2,5,5-tetramethyl-piperazine-l-carboxylate

[1311]

[1312] To a stirred solution of tert-butyl 4-(3-methoxy-4-nitro-phenyl)-2,2,5,5-tetramethyl-piperazine-1 -carboxylate (180 mg, 0.457 mmol) in MeOH (3 mL) was added Pd / C (180 mg) and the resulting mixture was stirred for 16 h at 40 °C under 1 atm of hydrogen atmosphere. After

[1313] - 115 - 1107314462\4\AMERICAS

[1314] Attorney Docket No. 119005.00357

[1315] Client Ref. No. NKT-25-003PCT cooling to rt, the mixture was diluted with DCM and filtered through Celite. The filtrate was concentrated under reduced pressure to afford the title compound as a colorless oil.

[1316] Step 3: tert-Butyl 4-[4-[(2,6-dioxo-3-piperidyl)amino]-3-methoxy-phenyl]-2,2,5,5-tetramethyl-piperazine- 1 -carboxylate

[1317]

[1318] To a stirred solution of tert-butyl 4-(4-amino-3-methoxy-phenyl)-2,2,5,5-tetramethyl-piperazine-1 -carboxylate (160 mg, 0.44 mmol), 3-bromopiperidine-2,6-dione (126.8 mg, 0.66 mmol) and Nal (131.9 mg, 0.88 mmol) in DMF (3 mL) was added NaHCO3(147.9 mg, 1.76 mmol). The resulting mixture was stirred at 75 °C for 16 h under argon atmosphere. The reaction mixture was quenched with sat. ammonium chloride aq. solution and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over Na2SC>4 and concentrated. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / petroleum ester (0-80%) to afford the title compound as a white solid.

[1319] Step 4: 3-[2-Methoxy-4-(2,2,5,5-tetramethylpiperazin-l-yl)anilino]piperidine-2,6-dione hydrochloride

[1320]

[1321] To a stirred solution of tert-butyl 4-[4-[(2,6-dioxo-3-piperidyl)amino]-3-methoxy-phenyl]-2,2,5,5-tetramethyl-piperazine-l-carboxylate (160 mg, 0.337 mmol) in DCM (4 mL) was added HC1 in dioxane (2 mL, 4.0 M) at rt and the resulting mixture was stirred for 1 h. The solvent was removed under reduced pressure to afford the title compound as a white solid.

[1322] Reference 17

[1323] Synthesis of l-[6-(3,3-difluoro-5,5-dimethyl-4-piperidyl)-l-methyl-indazol-3-yl]hexahydro- pyrimidine-2, 4-dione

[1324] - 116 - 1107314462\4\AMERICAS

[1325] Attorney Docket No. 119005.00357

[1326] Client Ref. No. NKT-25-003PCT

[1327]

[1328] Step 1: l-(6-Bromo-l-methyl-indazol-3-yl)-3-[(4-methoxyphenyl)methyl]hexahydropyrimidine-2,4-dione

[1329]

[1330] A mixture of l-(6-bromo-l-methyl-indazol-3-yl)hexahydropyrimidine-2, 4-dione (500 mg,

[1331] 1.55 mmol), 4-methoxybenzyl chloride (0.42 mL, 3.09 mmol) and K2CO3 (641.54 mg, 4.64 mmol) in DMF (5 mL) was stirred at rt for 16 h. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over Na2SC>4 and concentrated. The residue was purified with flash chromatography, eluted with ethyl acetate / petroleum ester (0-45%) to afford the title compound as a white solid.

[1332] Step 2: tert-Butyl 3,3-difluoro-4-[3-[3-[(4-methoxyphenyl)methyl]-2,4-dioxo-hexahydro-pyrimidin-l-yl]-l-methyl-indazol-6-yl]-5,5-dimethyl-piperidine-l-carboxylate

[1333]

[1334] The title compound was synthesized by proceeding analogously as described in reference 11, Steps 1-5, using l-(6-bromo-l-methyl-indazol-3-yl)-3-[(4-methoxyphenyl)methyl]hexahydro-pyrimidine-2, 4-dione instead of 6-bromo-3 -(2, 6-dibenzyloxy-3 -pyridyl)- 1-methyl-indazole in Step 1.

[1335] Step 3: l-[6-(3,3-Difluoro-5,5-dimethyl-4-piperidyl)-l-methyl-indazol-3-yl]hexahydropyrimidine-2, 4-dione

[1336] - 117 - 1107314462\4\AMERICAS

[1337] Attorney Docket No. 119005.00357

[1338] Client Ref. No. NKT-25-003PCT

[1339]

[1340] A solution of tert-butyl 3,3-difluoro-4-[3-[3-[(4-methoxyphenyl)methyl]-2,4-dioxo-hexahydropyrimidin-l-yl]-l-methyl-indazol-6-yl]-5,5-dimethyl-piperidine-l -carboxylate (43 mg, 0.07 mmol) in TFA (0.5 mL) and TfOH (0.1 mL) was stirred at 75 °C for 30 min. The reaction mixture was concentrated and the residue was purified by reverse phase flash chromatography, eluted with (5-20% acetonitrile in water with 0.05% ammonium bicarbonate) to give the title compound as a white solid.

[1341] Reference 18

[1342] Synthesis of 3-[5-(3,3-difluoro-5,5-dimethyl-4-piperidyl)-3,3-dimethyl-2-oxo-indolin-l-yl]- piperidine-2, 6-dione

[1343]

[1344] Step 1: 3-(5-Bromo-3,3-dimethyl-2-oxo-indolin-l-yl)-l-[(4-methoxyphenyl)methyl] piperidine-2, 6-dione

[1345]

[1346] To mixture of 5-bromo-3,3-dimethyl-indolin-2-one (500 mg, 2.08 mmol) and [ 1 -[(4-methoxyphenyl)methyl]-2,6-dioxo-3-piperidyl] trifluoromethanesulfonate (952.9 mg, 2.5 mmol) in THF (5 mL) was added a solution of t-BuOK in THF (IM, 3.12 mL, 3.12 mmol) dropwise at -10 °C, and the resulting mixture was stirred at -10 °C for 5 h. The reaction mixture was quenched with sat. NaHCO3aq. solution and then extracted with EtOAc. The combined organic layer was concentrated, and the residue was purified by silica gel column chromatography column to afford the title compound as white solid.

[1347] Step 2: tert-Butyl 3,3-difluoro-4-[l-[l-[(4-methoxyphenyl)methyl]-2,6-dioxo-3-piperidyl]-3,3-dimethyl-2-oxo-indolin-5-yl]-5,5-dimethyl-piperidine-l-carboxylate

[1348] - 118 - 1107314462\4\AMERICAS

[1349] Attorney Docket No. 119005.00357

[1350] Client Ref. No. NKT-25-003PCT

[1351]

[1352] The title compound was synthesized by proceeding analogously as described in Reference 11, Steps 1-5, using 3-(5-bromo-3,3-dimethyl-2-oxo-indolin-l-yl)-l-[(4-methoxyphenyl)methyl] piperidine-2, 6-dione instead of 6-bromo-3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazole in Step 1.

[1353] Step 3: 3-[5-(3,3-Difluoro-5,5-dimethyl-4-piperidyl)-3,3-dimethyl-2-oxo-indolin-l-yl]piperidine-2, 6-dione

[1354]

[1355] To a solution of tert-butyl 3,3-difluoro-4-[1-[1-[(4-methoxyphenyl)methyl]-2,6-dioxo-3-piperidyl]-3,3-dimethyl-2-oxo-indolin-5-yl]-5,5-dimethyl-piperidine-1-carboxylate (113 mg, 0.18 mmol) was added TFA (1 mL) and CF3SO3H (0.2 mL) at rt and the resulting mixture was stirred at 75 °C for 3 h. The reaction mixture was concentrated, and the residue was purified by reverse phase flash chromatography to afford the title compound as white solid.

[1356] Reference 19

[1357] Synthesis of (S)-4-((4-((5-(difluorom ethoxy )pyrimidin-2-yl)amino)piperi din- l-yl)sulfonyl)-2-(2- methyl-3-oxopropyl)benzonitrile

[1358]

[1359] Step 1: Methyl (S)-3-(5-((4-((tert-butoxycarbonyl)amino)piperidin-l-yl)sulfonyl)-2-cyanophenyl)-2-methyl propanoate

[1360] - 119 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[1361] Client Ref. No. NKT-25-003PCT

[1362]

[1363] To a solution of tert-butyl N-[l-(3-bromo-4-cyanobenzenesulfonyl)piperidin-4-yl]carbamate (1 g, 2.25 mmol), pyridine-2-carboximidamide hydrochloride (40 mg, 0.23 mmol), Nal (84 mg, 0.56 mmol), NiCh(dme) (50 mg, 0.23 mmol) in DMA (10 mL) and methyl (2R)-3-bromo-2-methylpropanoate (610 mg, 3.38 mmol) was added Mn powder (250 mg, 4.5 mmol) under nitrogen atmosphere. The resulting mixture was stirred for 3 h at 40 °C under nitrogen atmosphere. The reaction was quenched with water. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SC>4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc / PE (0-100%) to afford the title compound as a light yellow solid.

[1364] Step 2: tert-Butyl (S)-(l-((4-cyano-3-(3-hydroxy-2-methylpropyl)phenyl)sulfonyl)piperidin-4-yl)carbamate

[1365]

[1366] To a stirred solution of methyl (S)-3-(5-((4-((tert-butoxycarbonyl)amino)piperidin-l-yl)sulfonyl)-2-cyanophenyl)-2-methyl propanoate (800 mg, 1.72 mmol) in THF (8 mL) were added 1 M LiAlH4in THF (2.4 mL, 2.4 mmol) dropwise at -60 °C under nitrogen atmosphere. The resulting mixture was stirred for 30 min at -60~-40 °C under nitrogen atmosphere. The reaction was quenched with water, 15% NaOH(aq.) and water at 0 °C. The resulting mixture was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford the title compound as a light-yellow solid.

[1367] Step 3: (S)-4-((4-Aminopiperidin-l-yl)sulfonyl)-2-(3 -hydroxy -2 -methylpropyl)benzonitrile hydrochloride

[1368]

[1369] - 120 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[1370] Client Ref. No. NKT-25-003PCT

[1371] To a stirred solution of tert-butyl (S)-(l-((4-cyano-3-(3-hydroxy-2-methylpropyl)-phenyl)sulfonyl)piperidin-4-yl)carbamate (500 mg, 1.14 mmol) in DCM (3 mL) were added 4M HC1 in 1,4-di oxane (3 mL). The resulting mixture was stirred for 1 h at room temperature. The resulting mixture was concentrated under reduced pressure to afford the title compound as a light yellow solid.

[1372] Step 4: (S)-4-((4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2-(3-hydroxy-2-methyl propyl)benzonitrile

[1373]

[1374] To a stirred mixture of (S)-4-((4-aminopiperidin-l-yl)sulfonyl)-2-(3 -hydroxy -2-methylpropyl)benzonitrile hydrochloride (500 mg, 1.48 mmol) and DIEA (580 mg, 4.49 mmol) in DMSO (5 mL) was added 2-chloro-5-(difluoromethoxy)pyrimidine (400 mg, 2.22 mmol) at room temperature. The resulting mixture was stirred overnight at 100 °C under nitrogen atmosphere. The mixture was quenched by the addition of water. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SC>4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc / PE (0-30%) to afford the title compound as an off-white solid.

[1375] Step 5: (S)-4-((4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2-(2-methyl-3-oxopropyl)benzonitrile

[1376]

[1377] To a stirred solution of (S)-4-((4-((5-(difluoromethoxy) pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2-(3-hydroxy-2-methylpropyl) benzonitrile (170 mg, 0.35 mmol) and DIEA (274 mg, 2.12 mmol) in DCM (2 mL) was added SO3-pyridine (225 mg, 1.4 mmol) in DMSO (2 mL) dropwise at -5-0 °C under nitrogen atmosphere. The resulting mixture was stirred for 10 min at 0 °C under nitrogen atmosphere. The mixture was quenched with water. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The

[1378] - 121 - 1107314462\4\AMERICAS

[1379] Attorney Docket No. 119005.00357

[1380] Client Ref. No. NKT-25-003PCT residue was purified by silica gel column chromatography, eluted with EtOAc / PE (0 - 30%) to afford the title compound as a light yellow oil.

[1381] Reference 20

[1382] Synthesis of (S)-3-(5-((4-((tert-butoxycarbonyl)amino)piperidin-l-yl)sulfonyl)-2-cyanophenyl)-2- methylpropyl methanesulfonate

[1383]

[1384] To a stirred solution of tert-butyl (S)-(l-((4-cyano-3-(3-hydroxy-2-methylpropyl)phenyl)-sulfonyl)piperidin-4-yl)carbamate (240 mg, 0.5 mmol) and TEA (166 mg, 1.5 mmol) in anhydrous DCM (20 mL) at 0 °C was added methanesulfonic anhydride (139 mg, 0.8 mmol). After stirring 1 h at rt, the reaction mixture was quenched with water, and extracted with DCM. The combined organic layers were washed with brine, and dried over anhydrous Na2SC>4. After filtration, the filtrate was concentrated under reduced pressure to afford the crude title compound as a white solid.

[1385] Reference 21

[1386] Synthesis of (S)-2-(3-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)- phenoxy)propanal

[1387]

[1388] Step 1: tert-Butyl(l-((3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)piperidin-4-yl) carbamate

[1389]

[1390] To a stirred solution of tert-butyl (l-((3-bromophenyl)sulfonyl)piperidin-4-yl)carbamate (5 g, 11.92 mmol) and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (3.03 g, 11.92 mmol) in 1,4-dioxane (50 mL) was added Pd(dppf)C12 (0.87 g, 1.19 mmol) and AcOK (3.51 g,

[1391] - 122 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[1392] Client Ref. No. NKT-25-003PCT

[1393] 35.77 mmol) at rt under nitrogen atmosphere, and the resulting mixture was stirred for 2 h at 80 °C. The mixture was quenched with water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford the title compound as a yellow solid. Step 2: tert-Butyl (l-((3-hydroxyphenyl)sulfonyl)piperidin-4-yl)carbamate

[1394]

[1395] To a stirred solution of tert-butyl(l-((3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-phenyl)sulfonyl)piperidin-4-yl) carbamate (9 g, 19.3 mmol) in ACN (90 mL) was added H2O2(30%, 45 mL) at rt. The resulting mixture was stirred for 10 min at room temperature. The mixture was quenched with sat. Na2SO3solution at 0°C and the resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SC>4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc / PE (0-50%) to afford the title compound as a white solid.

[1396] Step 3: Methyl (S)-2-(3-((4-((tert-butoxycarbonyl)amino)piperidin-l-yl)sulfonyl)phenoxy)-propanoate

[1397]

[1398] To a stirred mixture of tert-butyl (l-((3-hydroxyphenyl)sulfonyl)piperidin-4-yl)carbamate (2 g, 5.6 mmol), PPh3(2.2 g, 8.4 mmol) and methyl (2S)-2-hydroxypropanoate (600 mg, 5.78 mmol) in THF (20 mL) was added DIAD (1.36 g, 6.73 mmol) dropwise at 0 °C under nitrogen atmosphere. The mixture was stirred for 2 h at room temperature. The mixture was quenched with water and the resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc / PE (0-25%) to afford the title compound as a white solid. Step 4: tert-Butyl (S)-(l-((3-((l-hydroxypropan-2-yl)oxy)phenyl)sulfonyl)piperidin-4-yl)-carbamate

[1399] - 123 - 1107314462\4\AMERICAS

[1400] Attorney Docket No. 119005.00357

[1401] Client Ref. No. NKT-25-003PCT

[1402]

[1403] To a stirred solution of methyl (S)-2-(3-((4-((tert-butoxycarbonyl)amino)piperidin-l-yl)sulfonyl)phenoxy)propanoate (1.6 g, 3.62 mmol) in THF (16 mL) was added 2 M LiAlH4in THF (3.6 mL, 7.2 mmol) dropwise at 0 °C. The resulting mixture was stirred for 2 h at 0°C. The mixture was quenched with water and 15% NaOH aq. The resulting mixture was diluted with EtOAc, and filtered. The filtrate was concentrated under reduced pressure to give the title compound as a yellow solid.

[1404] Step 5: (S)-2-(3-((4-Aminopiperidin-1-yl)sulfonyl)phenoxy)propan-1-ol hydrochloride

[1405]

[1406] To a stirred solution of tert-butyl (S)-(l-((3-((l-hydroxypropan-2-yl)oxy)phenyl)sulfonyl)-piperidin-4-yl)carbamate (1 g, 2.4 mmol) in DCM (10 mL) was added 4 M HC1 in 1,4-dioxane (5 mL) dropwise at room temperature. The resulting mixture was stirred for 2 h. The mixture was concentrated under reduced pressure to afford the title compound as a light yellow solid.

[1407] Step 6: (S)-2-(3-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-phenoxy)propan- 1 -ol

[1408]

[1409] To a stirred solution of (S)-2-(3-((4-aminopiperidin-l-yl)sulfonyl)phenoxy)propan-l-ol hydrochloride (760 mg, 2.16 mmol) and 2-chloro-5-(difluoromethoxy)pyrimidine (391 mg, 2.16 mmol, 1.0 eq.) in DMSO (7 mL) was added DIEA (560 mg, 4.32 mmol, 2.0 eq.), and the mixture was stirred for 16 h at 90 °C. The mixture was quenched with water and the mixture was extracted with EtOAc. The combined organic layers were washed with water, brine, and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc / PE (0-50%) to afford the title compound as a light yellow solid.

[1410] - 124 - 1107314462\4\AMERICAS

[1411] Attorney Docket No. 119005.00357

[1412] Client Ref. No. NKT-25-003PCT

[1413] Step 7: (S)-2-(3-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-phenoxy)propanal

[1414]

[1415] To a stirred solution of (S)-2-(3-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)phenoxy)propan-l-ol (200 mg, 0.44 mmol) and DIEA (338 mg, 2.62 mmol) in DCM (1 mL) was added SO3-pyridine (278 mg, 1.74 mmol) in DMSO (1 mL) dropwise at -5-0 °C under nitrogen atmosphere, and the mixture was stirred for 10 min at 0 °C. The mixture was quenched by addition of water and the mixture was extracted with EtOAc. The combined organic layers were washed with water, brine, and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc / PE (0-30%) to afford the title compound as a light yellow solid.

[1416] Reference 22

[1417] Synthesis of 2-(5-((4-((5-Chloropyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2- (trifluoromethyl)-phenoxy)acetaldehyde

[1418]

[1419] Step 1: 5-((4-(tert-Butyl)benzyl)thio)-2-(trifluoromethyl)phenol

[1420]

[1421] To a stirred solution of 5-bromo-2-(trifluoromethyl)phenol (1.00 g, 4.15 mmol) in 1,4-dioxane (10.0 mL) was added (4-(tert-butyl)phenyl)methanethiol (972 mg, 5.40 mmol), Pd2(dba)3(385 mg, 0.42 mmol), DIEA (1.61 g, 12.45 mmol) and XantPhos (486 mg, 0.84 mmol) and the mixture was stirred at 100 °C for 12 h. The mixture was diluted with water and extracted with DCM. The combined organic layers was washed with water, brine, and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced

[1422] - 125 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[1423] Client Ref. No. NKT-25-003PCT pressure. The residue was purified by silica gel column chromatography, eluting with PE / EtOAc=20: 1, to afford the title compound as a yellow solid.

[1424] Step 2: tert-Butyl(2-(5-((4-(tert-butyl)benzyl)thio)-2-(trifluoromethyl)phenoxy)ethoxy)dimethyl-silane

[1425]

[1426] To a stirred solution of 5-((4-(tert-butyl)benzyl)thio)-2-(trifluoromethyl)phenol (801 mg, 2.36 mmol), 2-((tert-butyldimethylsilyl)oxy)ethan-l-ol (415 mg, 2.36 mmol) in THF (10.0 mL) was added triphenylphosphine (1.24 g, 4.72 mmol) and stirred at 0 °C for 15 min. Then DIAD was added (953 mg, 4.72 mmol) at 0 °C and the mixture was stirred for 3 h. The mixture was diluted with water and extracted with DCM. The combined organic layers was washed with water, brine, and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE / EtOAc=20: 1, to afford the title compound as a yellow solid. Step 3: 3-(2-((tert-Butyldimethylsilyl)oxy)ethoxy)-4-(trifluoromethyl)benzenesulfonyl chloride

[1427]

[1428] To a stirred solution of tert-butyl(2-(5-((4-(tert-butyl)benzyl)thio)-2-(trifluoromethyl)-phenoxy)ethoxy)dimethylsilane (637 mg, 1.28 mmol) in AcOH (1.0 mL) and ACN / H2O (3.0 mL / 0.4 mL) was added l,3-dichloro-5,5-dimethylimidazolidine-2, 4-dione (504 mg, 2.56 mmol) at rt and the mixture was stirred for 12 h. The mixture was diluted with water and extracted with

[1429] DCM. The combined organic layers was washed with water, brine, and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford the title compound as a white solid.

[1430] Step 4: N-(l-((3-(2-((tert-Butyldimethylsilyl)oxy)ethoxy)-4-(trifluoromethyl)phenyl)-sulfonyl)-piperidin-4-yl)-5-chloropyrimidin-2-amine

[1431]

[1432] To a stirred solution of 5-chloro-N-(piperidin-4-yl)pyrimidin-2-amine (349 mg, 1.41 mmol) and TEA (388 mg, 3.84 mmol) in DCM (5.0 mL) was added 3-(2-((tert-

[1433] - 126 - 1107314462\4\AMERICAS

[1434] Attorney Docket No. 119005.00357

[1435] Client Ref. No. NKT-25-003PCT butyldimethylsilyl)oxy)ethoxy)-4-(trifluoromethyl)benzenesulfonyl chloride (535 mg, 1.28 mmol) at rt and the mixture was stirred for 12 h. The mixture was diluted with water and extracted with

[1436] DCM. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with EtOAc: PE (0 to 100%), to afford the title compound as a white solid.

[1437] Step 5: 2-(5-((4-((5-Chloropyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2-(trifluoromethyl)-phenoxy)ethan- 1 -ol

[1438]

[1439] TBAF (1.0 M in THF, 2.00 mL) was added to a stirred solution of N-(l-((3-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4-(trifluoromethyl)phenyl)sulfonyl)piperidin-4-yl)-5-chloropyrimidin-2-amine (120 mg, 0.20 mmol) at rt and the mixture was stirred for 3 h. The mixture was diluted with water and extracted with DCM. The combined organic layers was washed with water, brine, and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford the title compound as a white solid. Step 6: 2-(5-((4-((5-Chloropyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2-(trifluoromethyl)-phenoxy)acetaldehyde

[1440]

[1441] To a stirred solution of 2-(5-((4-((5-chloropyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2-(trifluoromethyl)phenoxy)ethan-l-ol (100 mg, 0.21 mmol) in DCM (5.0 mL) was added Dess-Martin periodinane (134 mg, 0.32 mmol) at rt and the mixture was stirred for 5 h. The mixture was diluted with water and extracted with DCM. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford the title compound as a yellow oil.

[1442] Reference 23

[1443] Synthesis of 3-[l-methyl-6-(2,2,3,3-tetramethylpiperazin-l-yl)indazol-3-yl]piperidine-2, 6-dione hydrochloride

[1444] - 127 - 1107314462\4\AMERICAS

[1445] Attorney Docket No. 119005.00357

[1446] Client Ref. No. NKT-25-003PCT

[1447]

[1448] Step 1: 5,5,6,6-Tetramethylpiperazine-2,3-dione

[1449]

[1450] To a solution of 2,3-dimethylbutane-2,3-diamine dihydrochloride (3.0 g, 15.86 mmol) and dimethyl oxalate (2.2 g, 19.04 mmol) in MeOH (30 mL) was added sodium methoxide (3.2 g, 31.73 mmol) at rt, then the mixture was stirred at 70 °C for 4 h. The mixture was concentrated under reduced pressure. The residue was purified by reverse column chromatography to afford the title compound as a white solid.

[1451] Step 2: l,4-Dibenzyl-5,5,6,6-tetramethyl-piperazine-2,3-dione

[1452]

[1453] To a solution of 5,5,6,6-tetramethylpiperazine-2,3-dione (1.1 g, 6.46 mmol) in DMF (10 mL) was added NaH (1.0 g, 25.85 mmol) at 5 °C and stirred for 0.5 h, then benzyl bromide (3.3 g, 19.39 mmol) was added to the mixture at 5 °C. The mixture was allowed to stir at rt for 5 h. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over anhydrous sodium sulphate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified with flash chromatography, eluted with ethyl acetate / PE (0-100%) to afford the title compound as a white solid.

[1454] Step 3: l,4-Dibenzyl-2,2,3,3-tetramethyl-piperazine

[1455]

[1456] To a stirred solution of l,4-dibenzyl-5,5,6,6-tetramethyl-piperazine-2,3-dione (2.2 g, 6.28 mmol) in THF (25 mL) was added LiAlH4(1.2 g, 31.39 mmol) at 5 °C under argon atmosphere. The resulting mixture was heated to 70 °C and stirred for 72 h under argon atmosphere. The mixture was quenched with sodium sulfate decahydrate and stirred at rt and the mixture was

[1457] - 128 - 1107314462\4\AMERICAS

[1458] Attorney Docket No. 119005.00357

[1459] Client Ref. No. NKT-25-003PCT stirred for 0.5 h. The mixture was filtered, and the filtrate was concentrated to afford the title compound as a white solid.

[1460] Step 4: 2,2,3,3-Tetramethylpiperazine

[1461]

[1462] To a stirred solution of l,4-dibenzyl-2,2,3,3-tetramethyl-piperazine (1.4 g, 4.34 mmol) in EtOH (7 mL) and THF (7 mL) was added Pd / C (420 mg) at rt. The resulting mixture was heated to 40 °C and stirred for 16 h under H2(ballon). The reaction mixture was diluted with

[1463] di chloromethane and filtered with celite. The filtrate was concentrated to afford the title compound as a yellow oil.

[1464] Step 5: tert-Butyl 2,2,3,3-tetramethylpiperazine-l-carboxylate

[1465]

[1466] To a stirred solution of 2,2,3, 3 -tetramethylpiperazine (610 mg, 4.29 mmol) and TEA (867.9 mg, 8.58 mmol) in DCM (5 mL) was added Boc2O (748.7 mg, 3.43 mmol) at rt and the mixture was stirred for 0.5 h. The mixture was quenched with water and extracted with DCM. The combined organic layers were washed with water, brine, dried over anhydrous sodium sulphate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified with flash chromatography, eluted with ethyl acetate / PE (0-100%) to afford the title compound as a yellow oil.

[1467] Step 6: 3-[l-Methyl-6-(2,2,3,3-tetramethylpiperazin-l-yl)indazol-3-yl]piperidine-2, 6-dione hydrochloride

[1468]

[1469] The title compound was synthesized by proceeding analogously as described in Reference 13, Steps 2-4.

[1470] Reference 24

[1471] Synthesis of 3-[6-[2-(difluoromethyl)-2,5,5-trimethyl-piperazin-l-yl]-l-methyl-indazol-3- yl]piperidine-2, 6-dione hydrochloride

[1472] - 129 - 1107314462\4\AMERICAS

[1473] Attorney Docket No. 119005.00357

[1474] Client Ref. No. NKT-25-003PCT

[1475]

[1476] Step 1: tert-Butyl N-(2-amino-2-methyl-propyl)carbamate

[1477]

[1478] To a solution of 2-m ethylpropane- 1,2-diamine (8.8 g, 99.83 mmol), TEA (10.09 g, 99.83 mmol) in DCM (88 mL) at 0 °C, a solution of Boc2O (10.89 g, 49.91 mmol) in DCM (50 mL) was added dropwise. This mixture was stirred at rt for 16 h. The resulting mixture was quenched with ice / water, diluted with DCM. The organic layer was washed with brine, dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with MeOH / DCM (0-10%) to afford the title compound as a white solid.

[1479] Step 2: tert-Butyl N-[2-(benzylamino)-2-methyl-propyl]carbamate

[1480] l-l

[1481]

[1482] A solution of tert-butyl N-(2-amino-2-methyl-propyl)carbamate (1.88 g, 10 mmol), benzaldehyde (0.96 mL, 9.5 mmol) in DCE (20 mL) were stirred at 25 °C under the argon atmosphere for 1 h. Sodium triacetoxyborohydride (4.24 g, 20 mmol) was added in portions and the mixture was stirred at rt for 16 h. The resulting mixture was quenched with water and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with MeOH / DCM (0-5%) to afford the title compound as a colorless oil.

[1483] Step 3: N2-Benzyl-2-methyl-propane- 1,2-diamine dihydrochloride

[1484]

[1485] To a solution of tert-butyl N-[2-(benzylamino)-2-methyl-propyl]carbamate (2.18 g, 7.83 mmol) in anhydrous DCM (15 mL) was added 4 M HC1 in 1,4-dioxane (15 mL, 60 mmol), and the mixture was stirred for 4 h. The resulting mixture was concentrated under reduced pressure to afford the title compound as a white solid.

[1486] - 130 - 1107314462\4\AMERICAS

[1487] Attorney Docket No. 119005.00357

[1488] Client Ref. No. NKT-25-003PCT

[1489] Step 4: l-Benzyl-3-(difluoromethyl)-3,6,6-trimethyl-piperazin-2-one

[1490]

[1491] To a solution of N2-benzyl-2-methyl-propane-l,2-diamine dihydrochloride (753.6 mg, 3 mmol), l,l-difluoropropan-2-one (564.4 mg, 6 mmol), benzyl triethylammonium chloride (68.33 mg, 0.3 mmol) in chloroform (0.73 mL, 9 mmol) and DCM (7.5 mL) was added 13 N NaOH (3 mL, 39 mmol) dropwise at 0 °C under the argon atmosphere. The resulting mixture was stirred at rt for 16 h. The mixture was diluted with water, extracted with DCM, and the combined organic layers was washed with brine, dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with MeOH / DCM (0-3%) to afford the title compound as a yellow oil. Step 5: l-Benzyl-5-(difluoromethyl)-2,2,5-trimethyl-piperazine

[1492]

[1493] To a solution of l-benzyl-3-(difluoromethyl)-3,6,6-trimethyl-piperazin-2-one (200 mg, 0.71 mmol) in THF (5 mL), BH3-Me2S (0.71 mL, 7.1 mmol) was added dropwise at 0 °C. The mixture was stirred at 75 °C for 16 h. The reaction mixture was cooled to 0 °C and quenched by adding MeOH (1 mL) and HC1 solution (4 N, 0.53 mL) until pH = 3. The mixture was stirred at 50 °C for 1 h, then concentrated under reduced pressure. The residue was diluted with water and DCM / MeOH (10 / 1), then the pH was adjusted to 14 with 4 N NaOH. The resulting mixture was extracted with DCM, washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0-30%) to afford the title compound as a colorless oil.

[1494] Step 6: 6-[4-Benzyl-2-(difluoromethyl)-2,5,5-trimethyl-piperazin-l-yl]-3-(2,6-dibenzyloxy-3-pyridyl)- 1 -methyl-indazole

[1495]

[1496] The title compound was synthesized by proceeding analogously as described in Reference 13, Steps 2.

[1497] - 131 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[1498] Client Ref. No. NKT-25-003PCT

[1499] Step 7: tert-Butyl 5-(difluoromethyl)-4-[3-(2,6-dioxo-3-piperidyl)-l-methyl-indazol-6-yl]-2,2,5-trimethyl-piperazine- 1 -carboxylate

[1500]

[1501] A mixture of 10% Pd / C (24.5 mg), 10% Pd(OH)2 / C (24.5 mg), 6-[4-benzyl-2-(difluoro-methyl)-2,5,5-trimethyl-piperazin-l-yl]-3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazole (100 mg, 0.15 mmol), Boc2O (95.2 mg, 0.45 mmol) in ethanol (3 mL) and THF (3 mL) was stirred at 40 °C under 1 atm hydrogen atmosphere for 16 h. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with MeOH / DCM (0-3%) to afford the title compound as a yellow oil.

[1502] Step 8: 3-[6-[2-(Difluoromethyl)-2,5,5-trimethyl-piperazin-l-yl]-l-methyl-indazol-3-yl]piperidine-2, 6-dione hydrochloride

[1503]

[1504] To a solution of tert-butyl 5-(difluoromethyl)-4-[3-(2,6-dioxo-3-piperidyl)-l-methyl-indazol-6-yl]-2,2,5-trimethyl-piperazine-l-carboxylate (44 mg, 0.08 mmol) in anhydrous DCM (2 mL) was added 4 M HC1 in dioxane (2 mL, 8 mmol), and the mixture was stirred for 4 h. The mixture was concentrated under reduced pressure to afford the title compound as a yellow solid.

[1505] Reference 25

[1506] Synthesis of 3-[6-[2-(difluoromethyl)-5,5-dimethyl-piperazin-l-yl]-l,5-dimethyl-indazol-3- yl]piperidine-2, 6-dione hydrochloride

[1507]

[1508] - 132 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[1509] Client Ref. No. NKT-25-003PCT

[1510] Step 1: tert-Butyl 4-benzyl-2-(hydroxymethyl)-5,5-dimethyl-piperazine-l-carboxylate

[1511]

[1512] To a solution of tert-butyl 4-benzyl-2-formyl-5,5-dimethyl-piperazine-l-carboxylate (1500 mg, 4.51 mmol) in methanol (15 mL) was added sodium borohydride (341.38 mg, 9.02 mmol) at 0 °C, and the mixture was stirred at rt for 1 h. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography to afford the title compound.

[1513] Step 2: (4-Benzyl-5,5-dimethyl-piperazin-2-yl)methanol

[1514]

[1515] To a solution of tert-butyl 4-benzyl-2-(hydroxymethyl)-5,5-dimethyl-piperazine-l-carboxylate (1280 mg, 3.83 mmol) in DCM (10 mL) was added HCl-dioxane (10 mL, 4.0 M), and the mixture was stirred at rt for 2 h. The solvent was removed under reduced pressure to afford the title compound.

[1516] Step 3: (4-Benzyl-5,5-dimethyl-piperazin-2-yl)methoxy-tert-butyl-dimethyl-silane

[1517]

[1518] To a solution of (4-benzyl-5,5-dimethyl-piperazin-2-yl)methanol (890 mg, 3.8 mmol), DMAP (46.33 mg, 0.38 mmol) and triethylamine (1.05 mL, 7.6 mmol) in DCM (6 mL) was added TBSC1 (0.72 mL, 4.18 mmol) at 0 °C and the mixture was stirred at rt for 17 h. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography to afford the title compound.

[1519] - 133 - 1107314462\4\AMERICAS

[1520] Attorney Docket No. 119005.00357

[1521] Client Ref. No. NKT-25-003PCT

[1522] Step 4: [4-Benzyl-l-[3-(2,6-dibenzyloxy-3-pyridyl)-l,5-dimethyl-indazol-6-yl]-5,5-dimethyl-piperazin-2-yl]methoxy-tert-butyl-dimethyl-silane

[1523]

[1524] The title compound was synthesized by proceeding analogously as described in Reference 13, Step 2.

[1525] Step 5: [4-Benzyl-l-[3-(2,6-dibenzyloxy-3-pyridyl)-l,5-dimethyl-indazol-6-yl]-5,5-dimethyl-piperazin-2 -yl]methanol

[1526]

[1527] To a solution of [4-benzyl-l-[3-(2,6-dibenzyloxy-3-pyridyl)-l,5-dimethyl-indazol-6-yl]-5,5-dimethyl-piperazin-2-yl]methoxy-tert-butyl-dimethyl-silane (900 mg, 0.91 mmol) in THF (10 mL) was added TBAF (0.28 mL, 1.82 mmol), and the mixture was stirred at rt for 2 h. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography to afford the title compound.

[1528] Step 6: 4-Benzyl-l-[3-(2,6-dibenzyloxy-3-pyridyl)-l,5-dimethyl-indazol-6-yl]-5,5-dimethyl-piperazine-2-carbaldehyde

[1529]

[1530] To a solution of [4-benzyl-l-[3-(2,6-dibenzyloxy-3-pyridyl)-l,5-dimethyl-indazol-6-yl]-5,5-dimethyl-piperazin-2-yl]methanol (590 mg, 0.88 mmol) and DIPEA (685.05 mg, 5.3 mmol) in DCM (6 mL) was added pyridine sulfur trioxide (421.82 mg, 2.65 mmol) in DMSO (4 mL) at 0 °C, and the mixture was stirred at rt for 1 h. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography to afford the title compound.

[1531] - 134 - 1107314462\4\AMERICAS

[1532] Attorney Docket No. 119005.00357

[1533] Client Ref. No. NKT-25-003PCT

[1534] Step 7: 6-[4-Benzyl-2-(difluoromethyl)-5,5-dimethyl-piperazin-l-yl]-3-(2,6-dibenzyloxy-3-py ri dy 1)- 1, 5 -dim ethyl -indazol e

[1535]

[1536] To a solution of 4-benzyl-l-[3-(2,6-dibenzyloxy-3-pyridyl)-l,5-dimethyl-indazol-6-yl]-5,5-dimethyl-piperazine-2-carbaldehyde (200 mg, 0.3 mmol) in DCM (2 mL) was added DAST (0.08 mL, 0.6 mmol) at -70 °C and the mixture was stirred at rt for 1 h. The mixture was quenched with sodium bicarbonate solution and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography to afford the title compound.

[1537] Step 8: 3-[6-[2-(Difluoromethyl)-5,5-dimethyl-piperazin-l-yl]-l,5-dimethyl-indazol-3-yl]piperidine-2, 6-dione

[1538]

[1539] The title compound was synthesized by proceeding analogously as described in Reference 24, Steps 7-8.

[1540] Reference 26

[1541] Synthesis of 3-[5-(5-fluoro-3,3-dimethyl-2,6-dihydro-lH-pyridin-4-yl)-3-methyl-2-oxo- benzimidazol- 1 -yl]piperidine-2, 6-dione

[1542]

[1543] Step 1: 3-[3-Methyl-2-oxo-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzimidazol-l-yl]-piperidine-2, 6-dione

[1544]

[1545] - 135 - 1107314462\4\AMERICAS

[1546] Attorney Docket No. 119005.00357

[1547] Client Ref. No. NKT-25-003PCT

[1548] To a stirred solution of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (300 mg, 0.89 mmol), bis(pinacolato)diboron (337.93 mg, 1.33 mmol) and KOAc (261.2 mg, 2.66 mmol) in 1,4-dioxane (5 mL) was added Pd(dppf)C12 (64.85 mg, 0.09 mmol). The resulting mixture was heated to 100 °C and stirred for 2 h. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried and concentrated under reduced pressure. The residue was purified with flash chromatography, eluted with methanol / dichloromethane (0~3%) to afford the title compound as an off-white solid.

[1549] Step 2: tert-Butyl 4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]-5-fluoro-3,3-dimethyl-2,6-dihydropyridine-l -carboxylate

[1550]

[1551] To a stirred mixture of tert-butyl 5-fluoro-3,3-dimethyl-4-(l,l,2,2,3,3,4,4,4-nonafluoro-butoxy)-2,6-dihydropyridine-l-carboxylate (270.61 mg, 0.58 mmol), 3-[3-methyl-2-oxo-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzimidazol-l-yl]piperidine-2,6-dione (150 mg, 0.39 mmol) and K2CO3(161.45 mg, 1.17 mmol) in 1,4-dioxane (3 mL) was added Pd(dppf)Cl2(28.49 mg, 0.04 mmol). The mixture was heated to 90 °C and stirred for 16 h. After cooling, the mixture was quenched with sat. aq. ammonium chloride and extracted with ethyl acetate. The combined organic layers were washed with brine, dried and concentrated under reduced pressure. The residue was purified by reverse flash chromatography, eluted with (5% ~ 42% acetonitrile in water with 0.05% formic acid) to afford the title compound as a yellow solid.

[1552] Step 6: 3-[5-(5-Fluoro-3,3-dimethyl-2,6-dihydro-lH-pyridin-4-yl)-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2, 6-dione

[1553]

[1554] To a stirred solution of tert-butyl 4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]-5-fluoro-3,3-dimethyl-2,6-dihydropyridine-l-carboxylate (60 mg, 0.12 mmol) in DCM (1 mL) was added HC1 in dioxane (1.0 mL, 4.0 M), and the mixture was stirred for 1 h. The solvent was removed under reduced pressure and the residue was purified by reverse flash chromatography, eluted with (5% ~ 23% acetonitrile in water with 0.05% ammonium bicarbonate) to afford the title compound as a white solid.

[1555] - 136 - 1107314462\4\AMERICAS

[1556] Attorney Docket No. 119005.00357

[1557] Client Ref. No. NKT-25-003PCT

[1558] Reference 27

[1559] Synthesis of 3-(6-(5-(difluoromethyl)-3,3-dimethyl-l,2,3,6-tetrahydropyridin-4-yl)-l-methyl-lH- indazol-3-yl)piperidine-2, 6-dione

[1560]

[1561] Step 1: Benzyl 4-chloro-5-formyl-3,3-dimethyl-3,6-dihydropyridine-l(2H)-carboxylate

[1562]

[1563] Cbz Cbz

[1564] To a stirred mixture of DMF (10 mL) and DCM (10 mL) was added POCl3(3.8 g, 24.9 mmol, 5 equiv) dropwise at 0°C under nitrogen atmosphere. The resulting mixture was stirred at room temperature for additional 30 min. To the above mixture was added benzyl 3,3-dimethyl-4-oxopiperidine-l -carboxylate (1.3 g, 4.98 mmol, 1 equiv) in DCM (3 mL) dropwise at

[1565] 0°C under nitrogen atmosphere. The resulting mixture was stirred at room temperature for additional 16 h. The reaction was quenched with sat. NH4Cl (aq.) at 0°C. The resulting mixture was extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0-15%) to afford the title compound (700 mg, 45.72%) as a white oil. MS (ES, m / z): [M+H]+= 308.1. Step 2: Benzyl 4-chloro-5-(difluoromethyl)-3,3-dimethyl-3,6-dihydropyridine-l(2H)-carboxylate

[1566]

[1567] Cbz Cbz

[1568] To a stirred solution of benzyl 4-chloro-5-formyl-3,3-dimethyl-3,6-dihydropyridine-l(2H)-carboxylate (700 mg, 2.27 mmol) in DCM (10 mL) was added DAST (1.8 g, 11.37

[1569] mmol) dropwise at 0°C under nitrogen atmosphere, and the mixture was stirred at room temperature for 2 h. The mixture was quenched with sat. NaHCO3(aq.) at 0°C, and the resulting mixture was extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0 - 15%) to afford the title compound as a yellow oil.

[1570] - 137 - 1107314462\4\AMERICAS

[1571] Attorney Docket No. 119005.00357

[1572] Client Ref. No. NKT-25-003PCT

[1573] Step 3: Benzyl 5-(difluoromethyl)-4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3-dimethyl-3,6-dihydropyridine-l(2H)-carboxylate

[1574]

[1575] To a stirred solution of 3-(l-methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indazol-3-yl)piperidine-2, 6-dione (400 mg, 1.08 mmol) and benzyl 4-chloro-5-(difluoromethyl)-3,3-dimethyl-3,6-dihydropyridine-l(2H)-carboxylate (357 mg, 1.08 mmol) in DME (4

[1576] mL) and H2O (0.4 mL) were added Pd(dtbpf)Cl2(141 mg, 0.22 mmol), TBAB (70 mg, 0.22 mmol) and Na2CO3(344 mg, 3.25 mmol), and the mixture was stirred at 90°C for 16 h. After cooling to rt, the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0 - 30%) to afford the title compound as a yellow solid.

[1577] Step 6: 3-(6-(5-(Difluoromethyl)-3,3-dimethyl-l,2,3,6-tetrahydropyridin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione

[1578]

[1579] To a stirred solution of benzyl 5-(difluoromethyl)-4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3-dimethyl-3,6-dihydropyridine-l(2H)-carboxylate (45 mg, 0.08

[1580] mmol) in hexafluoroisopropanol (0.5 mL) was added methanesulfonic acid (24 mg, 0.25 mmol) dropwise, and the mixture was stirred at room temperature for additional 10 min. The crude product was purified by reverse phase flash to afford the title compound as a white solid.

[1581] Reference 28

[1582] Synthesis of 4-(3-(2,6-dioxopiperidin-3-yl)-l,5-dimethyl-lH-indazol-6-yl)-5,5-dimethyl-l, 2,5,6- tetrahydropyridine-3 -carbonitrile hydrochloride

[1583] - 138 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[1584] Client Ref. No. NKT-25-003PCT

[1585]

[1586] Step 1: 1 -(tert-butyl) 3-methyl 4-(3-(2,6-dioxopiperidin-3-yl)-l,5-dimethyl-lH-indazol-6-yl)-5,5-dimethyl-5,6-dihydropyridine-l,3(2H)-dicarboxylate

[1587]

[1588] To a stirred solution of 3-(l,5-dimethyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indazol-3-yl)piperidine-2, 6-dione (500 mg, 1.3 mmol), and 1 -(tert-butyl) 3-methyl 5,5-dimethyl-4-(((trifluoromethyl)sulfonyl)oxy)-5,6-dihydropyridine-l,3(2H)-dicarboxylate (816 mg, 2.0 mmol) in dioxane (5 mL) and H2O (1 mL) were added Pd(dppf)Cl2(191 mg, 0.26 mmol) and K2CO3(541 mg, 3.9 mmol), and the mixture was stirred at 85 °C for

[1589] 3 h under nitrogen atmosphere. After cooling to rt. the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0 - 60%) to afford the title compound as a yellow solid.

[1590] Step 2: l-(tert-Butoxycarbonyl)-4-(3-(2,6-dioxopiperidin-3-yl)-l,5-dimethyl-lH-indazol-6-yl)-5,5-dimethyl-l,2,5,6-tetrahydropyridine-3-carboxylic acid

[1591]

[1592] To a stirred solution of 1 -(tert-butyl) 3-methyl 4-(3-(2,6-dioxopiperidin-3-yl)-l,5-dimethyl-lH-indazol-6-yl)-5,5-dimethyl-5,6-dihydropyridine-l,3(2H)-dicarboxylate (300 mg, 0.57 mmol) in THF (3 mL) was added TMSOK (220 mg, 1.72 mmol) in portions at 0 °C, and the resulting mixture was stirred at rt for 2 h. The mixture was diluted with H2O and acidified to pH 6 with cone. HC1. The resulting mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford the title compound as a white solid.

[1593] - 139 - 1107314462\4\AMERICAS

[1594] Attorney Docket No. 119005.00357

[1595] Client Ref. No. NKT-25-003PCT

[1596] Step 3: tert-Butyl 5-carbamoyl-4-(3-(2,6-dioxopiperidin-3-yl)-l,5-dimethyl-lH-indazol-6-yl)-3,3-dimethyl-3,6-dihydropyridine-l(2H)-carboxylate

[1597]

[1598] To a stirred solution of l-(tert-butoxycarbonyl)-4-(3-(2,6-dioxopiperidin-3-yl)-l,5-dimethyl-lH-indazol-6-yl)-5,5-dimethyl-l,2,5,6-tetrahydropyridine-3-carboxylic acid (210 mg, 0.41 mmol) and NH4Cl (132 mg, 2.5 mmol) in DMF (3 mL) was added HATU (235 mg, 0.62 mmol) and DIEA (213 mg, 1.64 mmol), and the mixture was stirred at rt for 2 h. The resulting mixture was diluted with H2O. The resulting mixture was extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0 - 100%) to afford the title compound as a yellow solid.

[1599] Step 4: tert-Butyl 5-cyano-4-(3-(2,6-dioxopiperidin-3-yl)-l,5-dimethyl-lH-indazol-6-yl)-3,3-dimethyl-3,6-dihydropyridine-l(2H)-carboxylate

[1600]

[1601] To a stirred solution of tert-butyl 5-carbamoyl-4-(3-(2,6-dioxopiperidin-3-yl)-l,5-dimethyl-lH-indazol-6-yl)-3,3-dimethyl-3,6-dihydropyridine-l(2H)-carboxylate (130 mg, 0.25 mmol) and triethylamine (77 mg, 0.77 mmol) in DCM (2 mL) was added trifluoroacetic anhydride (107 mg, 0.51 mmol) dropwise at 0 °C under nitrogen atmosphere, and the mixture was stirred at rt for 2 h. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0-70%) to afford the title compound as a yellow solid.

[1602] Step 5: 4-(3-(2,6-Dioxopiperidin-3-yl)-l,5-dimethyl-lH-indazol-6-yl)-5,5-dimethyl-l, 2,5,6-tetrahydropyridine-3 -carbonitrile hydrochloride

[1603] - 140 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[1604] Client Ref. No. NKT-25-003PCT

[1605]

[1606] To a stirred solution of tert-butyl 5-cyano-4-(3-(2,6-dioxopiperidin-3-yl)-l,5-dimethyl-lH-indazol-6-yl)-3,3-dimethyl-3,6-dihydropyridine-l(2H)-carboxylate (73 mg, 0.15 mmol) in DCM (0.75 mL) was added 4 M HC1 in dioxane (0.75 mL) dropwise at 0 °C. The resulting mixture was stirred at rt for 1 h under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure to afford the title compound as a white solid.

[1607] Example 1

[1608] Synthesis of 3-[6-[l-[[l-[3-[[4-[(5-chloropyrimidin-2-yl)amino]-l-piperidyl]sulfonyl]phenyl]-4- piperidyl]methyl]-3,3-difluoro-5,5-dimethyl-4-piperidyl]-l-methyl-indazol-3-yl]piperidine-2,6- dione

[1609]

[1610] To a solution of 3-[6-(3,3-difluoro-5,5-dimethyl-4-piperidyl)-l-methyl-indazol-3-yl]piperidine-2, 6-dione hydrochloride (40 mg, 0.10 mmol) in DMA (1 mL) was added triethylamine (31.1 mg, 0.31 mmol), the mixture was stirred at rt for 10 mins. AcOH (12.3 mg, 0.21 mmol) and l-[3-[[4-[(5-chloropyrimidin-2-yl)amino]-l-piperidyl]sulfonyl]phenyl]piperidine-4-carb aldehyde (52.3 mg, 0.11 mmol) were added and the resulting mixture was stirred at rt for 30 mins. NaBH(OAc)3 (86.8 mg, 0.41 mmol) was added and the resulting mixture was stirred for 10 h. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried and concentrated under reduced pressure. The residue was purified by flash chromatography to afford the title compound. MS (ES, m / z): [M+H]+= 838.5.

[1611] 1107314462\4\AMERICAS

[1612] Attorney Docket No. 119005.00357

[1613] Client Ref. No. NKT-25-003PCT

[1614] Example 2 was synthesized by proceeding analogously as described in Example 1.

[1615]

[1616] Example 3

[1617] Synthesis of 4-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2-((2S)-3- (4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-2,2,5,5-tetramethylpiperazin-l-yl)-2- methylpropyl)benzonitrile trifluoroacetate

[1618]

[1619] Step 1: tert-Butyl (l-((4-cyano-3-((2S)-3-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-2,2,5,5-tetramethylpiperazin-l-yl)-2-methylpropyl)phenyl)sulfonyl)piperidin-4-yl)carbamate

[1620]

[1621] To a stirred solution of 3-(l-methyl-6-(2,2,5,5-tetramethylpiperazin-l-yl)-lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride (100 mg, 0.24 mmol) and NaHCO3(80 mg, 0.95 mmol) in DMF (1 mL) were added (S)-3-(5-((4-((tert-butoxycarbonyl)amino)piperidin-l-yl)sulfonyl)-2-cyanophenyl)-2-methylpropyl methanesulfonate (123 mg, 0.24 mmol) and Nal (71 mg, 0.48 mmol), and the resulting mixture was stirred at 80°C for 3 h. After cooling to rt, the mixture was diluted with water and extracted with DCM. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0 - 60%) to afford the title compound as a yellow solid.

[1622] - 142 - 1107314462\4\AMERICAS

[1623] Attorney Docket No. 119005.00357

[1624] Client Ref. No. NKT-25-003PCT

[1625] Step 2: 4-((4-Aminopiperidin-l-yl)sulfonyl)-2-((2S)-3-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-2,2,5,5-tetramethylpiperazin-l-yl)-2-methylpropyl)benzonitrile hydrochloride

[1626]

[1627] To a stirred solution of tert-butyl (l-((4-cyano-3-((2S)-3-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-2,2,5,5-tetramethylpiperazin-l-yl)-2-methylpropyl)phenyl)sulfonyl)-piperidin-4-yl)carbamate (90 mg, 0.11 mmol) in DCM (1 mL) was added 4M HC1 in dioxane (0.8 mL) dropwise at room temperature, and the mixture was stirred for 1 h. The mixture was concentrated under reduced pressure to afford the title compound as a yellow solid.

[1628] Step 3: 4-((4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2-((2S)-3-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-2,2,5,5-tetramethylpiperazin-l-yl)-2-methylpropyl)benzonitrile

[1629]

[1630] To a stirred solution of 4-((4-aminopiperidin-l-yl)sulfonyl)-2-((2S)-3-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-2,2,5,5-tetramethylpiperazin-l-yl)-2-methylpropyl)benzonitrile hydrochloride (97 mg, 0.13 mmol) and DIEA (102 mg, 0.79 mmol) in DMSO (1 mL) were added 2-chloro-5-(difluoromethoxy)pyrimidine (36 mg, 0.20 mmol) and CsF (40 mg, 0.26 mmol). The resulting mixture was stirred at 60°C for 16 h. After cool to rt, the resulting mixture was diluted with water and extracted with DCM. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC to afford the title compound as an off-white solid. MS (ES, m / z): [M+H]+= 847.5.

[1631] Example 4

[1632] Synthesis of 4-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2-((2S)-3- ((4S)-4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3-difluoro-5,5- dimethylpiperidin-l-yl)-2-methylpropyl)benzonitrile (A) and 4-((4-((5- (difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2-((2S)-3-((4R)-4-(3-(2,6-

[1633] - 143 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[1634] Client Ref. No. NKT-25-003PCT dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3-difluoro-5,5-dimethylpiperidin-l-yl)-2- methylpropyl)benzonitrile (B)

[1635]

[1636] Step 1: tert-Butyl (l-((4-cyano-3-((2S)-3-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3-difluoro-5,5-dimethylpiperidin-l-yl)-2-methylpropyl)phenyl)sulfonyl)piperidin-4-yl)carbamate

[1637]

[1638] To a stirred solution of 3-(6-(3,3-difluoro-5,5-dimethylpiperidin-4-yl)-l-methyl-lH-indazol-3-yl) piperidine-2, 6-dione hydrochloride (49 mg, 0.12 mmol) andNaHCO3(39 mg, 0.46 mmol) in DMF (1 mL) were added (S)-3-(5-((4-((tert-butoxycarbonyl)amino)piperidin-l-yl)sulfonyl)-2-cyanophenyl)-2-methylpropyl methanesulfonate (89 mg, 0.17 mmol) and Nal (34 mg, 0.23 mmol), and the mixture was stirred at 80 °C for 2 h. After cooling to rt, the resulting mixture was diluted with water and extracted with DCM. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0-70%) to afford the title compound as a yellow solid.

[1639] Step 2: 4-((4-Aminopiperidin-l-yl)sulfonyl)-2-((2S)-3-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3-difluoro-5,5-dimethylpiperidin-l-yl)-2-methylpropyl)benzonitrile hydrochloride

[1640]

[1641] To a stirred solution of tert-butyl (l-((4-cyano-3-((2S)-3-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3-difluoro-5,5-dimethylpiperidin-l-yl)-2-methylpropyl) phenyl)sulfonyl)piperidin-4-yl)carbamate (55 mg, 0.07 mmol) in DCM (1 mL) was added 4M

[1642] - 144 - 1107314462\4\AMERICAS

[1643] Attorney Docket No. 119005.00357

[1644] Client Ref. No. NKT-25-003PCT

[1645] HC1 in dioxane (0.5 mL), and the resulting mixture was stirred for 1 h. Then the resulting mixture was concentrated under reduced pressure to afford the title compound as a white solid.

[1646] Step 3: 4-((4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2-((2S)-3-((4S)-4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3-difluoro-5,5-dimethylpiperidin-l-yl)-2-methylpropyl)benzonitrile (A) and 4-((4-((5-(difluoromethoxy)-pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2-((2S)-3-((4R)-4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3-difluoro-5,5-dimethylpiperidin-l-yl)-2-methylpropyl)-benzonitrile (B)

[1647]

[1648] To a stirred solution of 4-((4-aminopiperidin-l-yl)sulfonyl)-2-((2S)-3-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3-difluoro-5,5-dimethylpiperidin-l-yl)-2-methylpropyl)benzonitrile hydrochloride (60 mg, 0.08 mmol) and 2-chloro-5-(difluoro-methoxy)pyrimidine (22 mg, 0.12 mmol) in DMSO (1 mL) were added DIEA (62 mg, 0.48 mmol) and CsF (24 mg, 0.16 mmol), and the mixture was stirred at 60°C for 2 h. After cooling to rt, the resulting mixture was diluted with water and extracted with DCM. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC to afford a pair of diastereomers, and tentative stereochemistry at benzylic position was assigned as the title compound A and the title compound B. A and B, MS (ES, m / z): [M+H]+= 854.3.

[1649] Example 5

[1650] Synthesis of 3-(6-(l-(3-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)- benzyl)-3,3-difluoro-5,5-dimethylpiperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione

[1651]

[1652] - 145 - 1107314462\4\AMERICAS

[1653] Attorney Docket No. 119005.00357

[1654] Client Ref. No. NKT-25-003PCT

[1655] Step 1: tert-Butyl (l-((3-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3-difluoro- 5,5-dimethylpiperidin-l-yl)methyl)phenyl)sulfonyl)piperidin-4-yl)carbamate

[1656]

[1657] To a stirred solution of 3-(6-(3,3-difluoro-5,5-dimethylpiperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride (160 mg, 0.38 mmol) and tert-butyl ( 1 -((3-formylphenyl)sulfonyl)piperidin-4-yl)carbamate (276 mg, 0.75 mmol) in 1,2-dichloroethane (4 mL) was added NaBH(OAc)3 (159 mg, 0.75 mmol) in portions at 0 °C. The resulting mixture was stirred at 40 °C for 2 h. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with water and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EA / PE (0 - 80%) to afford the title compound as a yellow solid.

[1658] Step 2: 3-(6-(l-(3-((4-Aminopiperidin-l-yl)sulfonyl)benzyl)-3,3-difluoro-5,5-dimethylpiperidin-4-yl)- 1 -methyl- lH-indazol-3 -yl)piperidine-2, 6-dione hydrochloride

[1659]

[1660] To a stirred solution of tert-butyl (l-((3-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3-difluoro-5,5-dimethylpiperidin-l-yl)methyl)phenyl)sulfonyl)piperidin-4-yl)carbamate (81 mg, 0.11 mmol) in DCM (1 mL) was added 4M HC1 in dioxane (1 mL) dropwise at 0 °C. The resulting mixture was stirred at room temperature for 1 h. The resulting mixture was concentrated under reduced pressure to afford the title compound as a white solid.

[1661] - 146 - 1107314462\4\AMERICAS

[1662] Attorney Docket No. 119005.00357

[1663] Client Ref. No. NKT-25-003PCT

[1664] Step 3: 3-(6-(l-(3-((4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-benzyl)-3,3-difluoro-5,5-dimethylpiperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione

[1665]

[1666] A mixture of 3-(6-(l-(3-((4-aminopiperidin-l-yl)sulfonyl)benzyl)-3,3-difluoro-5,5-dimethylpiperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride (86 mg, 0.13 mmol), 2-chloro-5-(difluoromethoxy)pyrimidine (34 mg, 0.19 mmol), CsF (38 mg, 0.25 mmol) and DIEA (98 mg, 0.76 mmol) in DMSO (2 mL) was stirred at 60 °C for

[1667] 16 h under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with H2O and extracted with EA. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC to afford the title compound as a white solid. MS (ES, m / z): [M+H]+=787.2.

[1668] Example 6

[1669] Synthesis of3-(6-(l-(3-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)benzyl)-5-fluoro-3,3-dimethyl-l,2,3,6-tetrahydropyridin-4-yl)-l-methyl-lH-indazol-3-

[1670]

[1671] Step 1: tert-Butyl (l-((3-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-5-fluoro-3,3-dimethyl-3,6-dihydropyridin-l(2H)-yl)methyl)phenyl)sulfonyl)piperidin-4-yl)carbamate

[1672]

[1673] To a stirred solution of 3-(6-(5-fluoro-3,3-dimethyl-l,2,3,6-tetrahydropyridin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride (93 mg, 0.23 mmol) and tert-butyl (1-((3-formylphenyl)sulfonyl)piperidin-4-yl)carbamate (168 mg, 0.46 mmol) in 1,2-dichloroethane (2 mL) was added NaBH(OAc)3 (97 mg, 0.46 mmol) in portions at 0 °C. The resulting mixture

[1674] - 147 - 1107314462\4\AMERICAS

[1675] Attorney Docket No. 119005.00357

[1676] Client Ref. No. NKT-25-003PCT was stirred at 40 °C for 2 h under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with NH4Cl(aq.) and extracted with DCM. The combined organic layers were washed with brine and dried over anhydrous Na2SC>4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EA / PE (0 - 80%) to afford the title compound as a yellow solid.

[1677] Step 2: 3-(6-(l-(3-((4-Aminopiperidin-l-yl)sulfonyl)benzyl)-5-fluoro-3,3-dimethyl-l,2,3,6-tetrahydropyridin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride

[1678]

[1679] To a stirred solution of tert-butyl (l-((3-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-5-fluoro-3,3-dimethyl-3,6-dihydropyridin-l(2H)-yl)methyl)phenyl)sulfonyl)-piperidin-4-yl)carbamate (89 mg, 0.123 mmol) in DCM (1 mL) was added 4M HC1 in dioxane (1 mL) dropwise at 0 °C. The resulting mixture was stirred at room temperature for

[1680] 1 h under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure to afford the title compound as a yellow solid.

[1681] Step 3: 3-(6-(l-(3-((4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-benzyl)-5-fluoro-3,3-dimethyl-l,2,3,6-tetrahydropyridin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione 2,2,2-trifluoroacetate

[1682]

[1683] A mixture of 3-(6-(l-(3-((4-aminopiperidin-l-yl)sulfonyl)benzyl)-5-fluoro-3,3-dimethyl-1,2, 3, 6-tetrahydropyridin-4-yl)-l -methyl- lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride (90 mg, 0.14 mmol), 2-chloro-5-(difluoromethoxy)pyrimidine (37 mg, 0.21 mmol), CsF (41 mg, 0.27 mmol) and DIEA (106 mg, 0.82 mmol) in DMSO (2 mL) was stirred at 40 °C for

[1684] 16 h under nitrogen atmosphere. The mixture was allowed to cool down to room temperature and the resulting mixture was diluted with H2O and extracted with EA. The combined organic layers were washed with brine, dried over anhydrous Na2SC>4. After filtration, the filtrate was

[1685] - 148 - 1107314462\4\AMERICAS

[1686] Attorney Docket No. 119005.00357

[1687] Client Ref. No. NKT-25-003PCT concentrated under reduced pressure. The residue was purified by prep-HPLC to afford the title compound as a white solid. MS (ES, m / z): [M+H]+=767.3.

[1688] Example 7

[1689] Synthesis of 4-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2-((2S)-3- (9-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-6-azaspiro[3.5]non-8-en-6-yl)-2-

[1690]

[1691] Step 1: tert-Butyl (S)-(l-((4-cyano-3-(3-hydroxy-2-methylpropyl)phenyl)sulfonyl)piperidin-4-yl)carbamate

[1692]

[1693] To a stirred solution of methyl (S)-3-(5-((4-((tert-butoxycarbonyl)amino)piperidin-l-yl)sulfonyl)-2-cyanophenyl)-2-methyl propanoate (800 mg, 1.72 mmol) in THF (8 mL) were added 1 M LiAlEU in THF (2.4 mL, 2.40 mmol) dropwise at -78°C under nitrogen atmosphere. The resulting mixture was stirred for 30 min at -78— 40°C under nitrogen atmosphere. The reaction was quenched with 15% NaOH(aq.) and water at 0 °C. The resulting mixture was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford the title compound as a light yellow solid.

[1694] Step 2: (S)-4-((4-aminopiperidin-l-yl)sulfonyl)-2-(3-hydroxy-2-methylpropyl)benzonitrile hydrochloride

[1695]

[1696] To a stirred solution of tert-butyl (S)-(l-((4-cyano-3-(3-hydroxy-2-methylpropyl)-phenyl)sulfonyl)piperidin-4-yl)carbamate (500 mg, 1.14 mmol) in DCM (3 mL) was added 4M HC1 in 1,4-dioxane (2 mL) dropwise, and the mixture was stirred at room temperature for 1 h. The

[1697] - 149 - 1107314462\4\AMERICAS

[1698] Attorney Docket No. 119005.00357

[1699] Client Ref. No. NKT-25-003PCT resulting mixture was concentrated under reduced pressure to afford the title compound as a light yellow solid.

[1700] Step 3: (S)-4-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2-(3-hydroxy-2-methyl propyl)benzonitrile

[1701]

[1702] To a stirred mixture of (S)-4-((4-aminopiperidin-l-yl)sulfonyl)-2-(3 -hydroxy -2-methylpropyl)benzonitrile hydrochloride (500 mg, 1.34 mmol) and DIEA (518 mg, 4.0 mmol) in DMSO (5 mL) was added 2-chloro-5-(difluoromethoxy)pyrimidine (360 mg, 2 mmol). The resulting mixture was stirred for 16 h at 100 °C under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with water and extracted with EA and the combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EA / PE (0-30%) to afford the title compound as an off-white solid.

[1703] Step 4: (S)-3-(2-cyano-5-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-phenyl)-2-methylpropyl methanesulfonate

[1704]

[1705] To a stirred solution of (S)-4-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2-(3-hydroxy-2-methyl propyl)benzonitrile (50 mg, 0.104 mmol) and TEA (32 mg, 0.312 mmol) in DCM (1 mL) was added MsCl (12 mg, 0.15 mmol) dropwise at 0°C under nitrogen atmosphere. The resulting mixture was stirred at room temperature for 10 min and then diluted with water and extracted with DCM. The combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford the title compound as a light yellow solid.

[1706] Step 5: 6-Benzyl-6-azaspiro[3.5]nonan-9-one

[1707] - 150 - 1107314462\4\AMERICAS

[1708] Attorney Docket No. 119005.00357

[1709] Client Ref. No. NKT-25-003PCT

[1710]

[1711] To a stirred solution of 1-cyclobutylethan-l-one (8.4 mL, 73.26 mmol) in EtOH (80 mL) was added concentrated HC1 (6.3 mL, 72.52 mmol) dropwise at room temperature, and the mixture was stirred at 80 °C for 1.5 h. After cooling to rt, benzylamine (8 mL, 75 mmol) and 37% formaldehyde aqueous solution (11.2 mL, 153.8 mmol) in EtOH (80 mL) were added dropwise to above mixture, and the mixture was stirred at 80 °C for 16 h. After cooling to rt, TEA (11.4 mL, 76.22 mmol) and 37% formaldehyde solution (1.6 mL, 21.98 mmol) were added to above mixture dropwise. The resulting mixture was stirred at 80 °C for 24 h. KOH (4.6 g, 82.36 mmol) in H2O (8.4 mL) was added to the mixture dropwise at 0-5 °C and the mixture was concentrated under reduced pressure. The mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc / PE (0-10%) to afford the title compound.

[1712] Step 6: tert-Butyl 9-oxo-6-azaspiro[3.5]nonane-6-carboxylate

[1713]

[1714] To a stirred solution of 6-benzyl-6-azaspiro[3.5]nonan-9-one (5 g, 21.80 mmol) in EtOH (50 mL) were added Pd / C (1 g) and Boc2O (5.7 g, 26.16 mmol) in portions, and the mixture was purged with hydrogen and then stirred at room temperature under 1 atm hydrogen atmosphere for 16 h. The mixture was filtered, and the filter cake was washed with THF. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc / PE (0-15%) to afford the title compound.

[1715] Step 7: tert-Butyl 9-(((trifluoromethyl)sulfonyl)oxy)-6-azaspiro[3.5]non-8-ene-6-carboxylate

[1716]

[1717] To a stirred solution of tert-butyl 9-oxo-6-azaspiro[3.5]nonane-6-carboxylate (2.6 g, 10.86 mmol) in THF (26 mL) was added 1.0 M LiHMDS in THF (16.3 mL) dropwise at -78°C under nitrogen atmosphere, and the resulting mixture was stirred at -78 °C for 1 h. To the above mixture was added l,l,l-trifluoro-N-phenyl-N-(trifluoromethane)sulfonylmethane-sulfonamide (4.7 g, 13.04 mmol) in THF (26 mL) dropwise at -78 °C under nitrogen atmosphere, and the mixture was stirred at room temperature for 5 h. The mixture was quenched with sat.

[1718] - 151 - 1107314462\4\AMERICAS

[1719] Attorney Docket No. 119005.00357

[1720] Client Ref. No. NKT-25-003PCT

[1721] NH4CI (aq.) and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography, eluted with EtOAc / PE (0-5%) to afford the title compound.

[1722] Step 8: tert-Butyl 9-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-6-azaspiro[3.5]non-8-ene-6-carboxylate

[1723]

[1724] To a stirred solution of 3-(l-methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indazol-3-yl)piperidine-2, 6-dione (200 mg, 0.52 mmol) and tert-butyl 9-(((trifluoromethyl)-sulfonyl)oxy)-6-azaspiro[3.5]non-8-ene-6-carboxylate (194 mg, 0.52 mmol) in dioxane (2 mL) and H2O (0.2 mL) were added K2CO3(216 mg, 1.57 mmol) and Pd(dppf)Cl2(76 mg, 0.10 mmol), and the mixture was stirred at 85 °C for 3 h under nitrogen atmosphere. The mixture was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was purified by silica gel column chromatography, eluted with EtOAc / PE (0-70%) to afford the title compound.

[1725] Step 9: 3-(l-Methyl-6-(6-azaspiro[3.5]non-8-en-9-yl)-lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride

[1726]

[1727] To a stirred solution of tert-butyl 9-(3 -(2, 6-dioxopiperi din-3 -yl)-l -methyl- lH-indazol-6-yl)-6-azaspiro[3.5]non-8-ene-6-carboxylate (80 mg, 0.17 mmol) in DCM (1 mL) was added 4 M HC1 in dioxane (0.5 mL) dropwise at room temperature. The mixture was stirred at room temperature for 1 h. The mixture was concentrated under reduced pressure to afford the title compound.

[1728] - 152 - 1107314462\4\AMERICAS

[1729] Attorney Docket No. 119005.00357

[1730] Client Ref. No. NKT-25-003PCT

[1731] Step 10: 4-((4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2-((2S)-3-(9-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-6-azaspiro[3.5]non-8-en-6-yl)-2-methylpropyl)benzonitrile

[1732]

[1733] To a stirred solution of 3-(l-methyl-6-(6-azaspiro[3.5]non-8-en-9-yl)-lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride (40 mg, 0.1 mmol) and NaHCO3(34 mg, 0.4 mmol) in DMF (1 mL) were added (S)-3-(2-cyano-5-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)phenyl)-2-methylpropyl methanesulfonate (55 mg, 0.1 mmol) and Nal (30 mg, 0.2 mmol). The resulting mixture was stirred at 80°C for 6 h under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with water and extracted with EA. The combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC to afford the title compound as an off-white solid. MS (ES, m / z): [M+H]+= 828.5.

[1734] Example 8

[1735] Synthesi s of 3 -(6-(6-(( 1 -(3 -((4-((5 -(difluoromethoxy )pyrimidin-2-yl)amino)piperi din- 1 - yl)sulfonyl)phenyl)piperidin-4-yl)methyl)-6-azaspiro[3.5]non-8-en-9-yl)-l-methyl- lH-indazol-3-yl)piperidine-2, 6-dione

[1736]

[1737] Step 1: (l-(3-((4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)phenyl)-piperidin-4-yl)methanol

[1738]

[1739] - 153 - 1107314462\4\AMERICAS

[1740] Attorney Docket No. 119005.00357

[1741] Client Ref. No. NKT-25-003PCT

[1742] To a stirred mixture of (l-(3-((4-aminopiperidin-l-yl)sulfonyl)phenyl)piperidin-4-yl)methanol (100 mg, 0.26 mmol) and DIEA (132 mg, 1.03 mmol) in DMSO (1 mL) was added 2-chloro-5-(difluoromethoxy)pyrimidine (69 mg, 0.39 mmol) and CsF (79 mg, 0.52 mmol). The resulting mixture was stirred for 16 h at 100 °C under nitrogen atmosphere. The resulting mixture was diluted with water and extracted with EA and the combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EA / PE (0 - 40%) to afford the title compound as an off-white solid.

[1743] Step 2: (l-(3-((4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)phenyl)-piperidin-4-yl)methyl methanesulfonate

[1744]

[1745] To a stirred solution of (l-(3-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)phenyl)piperidin-4-yl)methanol (50 mg, 0.10 mmol) and TEA (31 mg, 0.30 mmol) in DCM (1 mL) was added MsCl (12 mg, 0.15 mmol) dropwise at 0°C under nitrogen atmosphere. The resulting mixture was stirred at room temperature for 10 min. The resulting mixture was diluted with water and extracted with DCM and the combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford the title compound as a light yellow solid.

[1746] Step 3: 3-(6-(6-((l-(3-((4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-phenyl)piperidin-4-yl)methyl)-6-azaspiro[3.5]non-8-en-9-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione

[1747]

[1748] To a stirred solution of 3-(l-methyl-6-(6-azaspiro[3.5]non-8-en-9-yl)-lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride (37 mg, 0.092 mmol) and NaHCO3(31 mg, 0.369 mmol) in DMF (1 mL) were added (l-(3-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)phenyl)piperidin-4-yl)methyl methanesulfonate (53 mg, 0.092 mmol) and Nal (28 mg, 0.184 mmol) at room temperature, and the resulting mixture was stirred at 80 °C for 6 h. The

[1749] - 154 - 1107314462\4\AMERICAS

[1750] Attorney Docket No. 119005.00357

[1751] Client Ref. No. NKT-25-003PCT mixture was allowed to cool down to room temperature and the resulting mixture was diluted with water and extracted with EA. The combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by prep-HPLC to afford the title compound as an off-white solid. MS (ES, m / z): [M+H]+= 844.4.

[1752] Biological Examples

[1753] Biological Example 1

[1754] Phosphorylation of RB protein at S807 / 811 were measured using HTRF phospho-RB cellular kits (Cat# 64RBS807PEG) from Cisbio.

[1755] On Day 1, OVCAR3 (CDK2-dependent cell line) and T47D (CDK4-dependent cell line) cells were seeded into 96-well tissue-culture treated plates at 20,000 cells / well in 200 pL and incubated overnight at 37 °C in CO2atmosphere. On Day 2, the cells were treated with test compounds at concentrations from 0.3 to 3,000 nM using HP D300 digital dispenser. Twenty-four hours after compound treatment, cell culture media was removed by flicking the plate and tapping the plate against clean paper towel. 30 pL IX lysis buffer was supplemented from the kit was added to each well and the plates were then incubated at room temperature on shaker for 30 min. After homogenization by pipetting up and down, 8 pL cell lysate from 96-well cell culture plate was transferred to 384-well small volume white detection plate. 2 pL premixed detection solution was added and the plate was covered with sealer. To prepare the detection solution, d2 conjugated-phospho-RB antibody and Eu-cryptate conjugated phosphor-RB antibody were diluted into detection buffer following manufacturer’s instruction. Detection plates were incubated for 4 h at room temperature and read on ClarioStar (BMG Labtech) in TR-FRET mode (665 nM and 620 nM). The TR-FRET ratio (665 nM / 620 nM) was plotted against the compound concentration and normalized to DMSO controls. Half maximal inhibition concentration (IC50) values were calculated with a four-parameter logistic fit using GraphPad Prism (version 9; La Jolla, CA).

[1756] In the table below, A indicates a IC50of greater than or equal to 1 nM but less than or equal to 100 nM; B indicates a IC50of greater than 100 nM but less than or equal to 500 nM; C indicates a IC50of greater than 500 nM but less than or equal to 2.5 μM; D indicates a IC50of greater than 1 μM.

[1757]

[1758] - 155 - 1107314462\4\AMERICAS

[1759] Attorney Docket No. 119005.00357

[1760] Client Ref. No. NKT-25-003PCT

[1761]

[1762] NT = not tested.

[1763] Biological Example 2

[1764] High-throughput Measurement of Cellular Endogenous CDK1 / 2 / 4 / 6

[1765] Effects of compounds on cellular CDK levels were monitored by a high-throughput HTRF assay.

[1766] To determine half maximal degradation concentration (DC50) and maximum degradation level (Dmax) values of compounds, cellular CDK level can be measured in 96-well format using HTRF total CDK cellular kit (CDK1, Cat# 64CDK1TPEG; CDK2 Cat# 64CDK2TPEG; CDK4 Cat# 64CDK4TPEG; CDK6, Cat# 64CDK6TPEG) from Cisbio / Revvity.

[1767] On Day 1, cells are seeded into 96-well tissue-culture treated plates at 20,000 cells / well in 200 pL and incubated overnight at 37°C in CO2atmosphere. On Day 2 cells are treated with compounds at concentration ranging from 0.1 to 1,000 nM using Tecan D300edigital dispenser (HP Inc., CA, USA). 6 or 24 hours after compound treatment, cell culture media is removed by flicking the plate and tapping the plate against clean paper towel. Immediately 30 pL IX lysis buffer is supplemented from the kit and added to each well and the plate is incubated at room temperature on shaker for 30 min. After homogenization by pipetting up and down, 8 pL cell lysate from 96-well cell culture plate is transferred to 384-well small volume white detection plate. 2 pL premixed detection solution is added and the plate is covered with sealer. To prepare the detection solution, d2 conjugated-CDK antibody and Eu-cryptate conjugated CDK antibody is diluted into detection buffer following manufacturer’s instruction. Detection plates are incubated overnight at room temperature and read on ClarioStar (BMG Labtech) in TR-FRET mode (665 nM and 620 nM). The TR-FRET ratio (665 nM / 620 nM) is normalized to DMSO controls (0% degradation) and lysis buffer controls (100% degradation) to calculate the relative CDK level (%CDK relative to DMSO) which was then plotted against the compound concentration. Half

[1768] - 156 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357

[1769] Client Ref. No. NKT-25-003PCT maximal degradation concentration (DC50) (0% degradation) and maximal degradation values were calculated with a four-parameter logistic fit using GraphPad Prism (version 9; La Jolla, CA).

[1770] Formulation Examples

[1771] The following are representative pharmaceutical formulations containing a compound of the present disclosure.

[1772] Tablet Formulation

[1773] The following ingredients are mixed intimately and pressed into single scored tablets.

[1774] Ingredient Quantity per tablet (mg) compound Formula (I) 400

[1775] cornstarch 50

[1776] croscarmellose sodium 25

[1777] lactose 120

[1778] magnesium stearate 5

[1779] Capsule Formulation

[1780] The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.

[1781] Ingredient Quantity per capsule (mg)

[1782] Compound Formula (I) 200

[1783] lactose spray dried 148

[1784] magnesium stearate 2

[1785] Injectable Formulation

[1786] Compound of the disclosure in 2% HPMC, 1% Tween 80 in DI water, pH 2.2 with MSA, q.s. to at least 20 mg / mL

[1787] Inhalation Composition

[1788] To prepare a pharmaceutical composition for inhalation delivery, 20 mg of a compound disclosed herein is mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% sodium chloride solution. The mixture is incorporated into an inhalation delivery unit, such as a nebulizer, which is suitable for inhalation administration.

[1789] - 157 - 1107314462\4\AMERICAS

[1790] Attorney Docket No. 119005.00357

[1791] Client Ref. No. NKT-25-003PCT

[1792] Topical Gel Composition

[1793] To prepare a pharmaceutical topical gel composition, 100 mg of a compound disclosed herein is mixed with 1.75 g of hydroxypropyl cellulose, 10 mL of propylene glycol, 10 mL of isopropyl myristate and 100 mL of purified alcohol USP. The resulting gel mixture is then incorporated into containers, such as tubes, which are suitable for topical administration.

[1794] Ophthalmic Solution Composition

[1795] To prepare a pharmaceutical ophthalmic solution composition, 100 mg of a compound disclosed herein is mixed with 0.9 g of NaCl in 100 mL of purified water and filtered using a 0.2 micron filter. The resulting isotonic solution is then incorporated into ophthalmic delivery units, such as eye drop containers, which are suitable for ophthalmic administration.

[1796] Nasal spray solution

[1797] To prepare a pharmaceutical nasal spray solution, 10 g of a compound disclosed herein is mixed with 30 mL of a 0.05M phosphate buffer solution (pH 4.4). The solution is placed in a nasal administrator designed to deliver 100 pL of spray for each application.

[1798] - 158 - 1107314462\4\AMERICAS

Claims

Attorney Docket No. 119005.00357Client Ref. No. NKT-25-003PCTWhat is Claimed:

1. A compound of F ormula (I):wherein:R1is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyloxy halo, haloalkyl, haloalkoxy, alkoxy, aryloxy, or cyano and wherein cycloalkyl, either alone or as part of cycloalkoxy, is substituted with one to three halo;R2and R2aare independently hydrogen or deuterium;Hy is cycloalkylene, arylene, heteroarylene, heterocyclylene, bicyclic heterocyclylene, spiro heterocyclylene, bridged heterocyclylene, or fused heterocyclylene, where each of the aforementioned rings is substituted with Ra, Rb, and Rcindependently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, alkoxy, hydroxy, and cyano;Degron is an E3 ubiquitin ligase ligand selected from:(a) a group of formula (i):(i); and(b) a group of formula (ii):(ii);where:Yais CH orN;Zais a bond, -CH2-, -NH-, -O-, or -NHC(O)- where NH of -NHC(O)- is attached to Ya;- 159 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357Client Ref. No. NKT-25-003PCT ring A is a group of formula (a) or (b):where:Raa, Rbb, Rcc, and Rddare independently selected from hydrogen, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, and cyano;R4and R5are independently hydrogen or alkyl; or R4and R5together with the carbon to which they are attached form > C=O; andR6is hydrogen or alkyl;ring B is phenylene, cyclylaminylene, a 5- or 6-membered monocyclic heteroarylene, or a 9- or 10-membered fused bicyclic heteroarylene, wherein each heteroarylene ring contains one to three nitrogen ring atoms and further wherein the phenylene, cyclylaminylene, and each heteroarylene are independently substituted with Reeand Rffindependently selected from hydrogen, alkyl, cycloalkyl, alkoxy, halo, haloalkyl, haloalkoxy, and cyano; andL is -Z1-Z2-Z3-Z4-Z5-Z6- where:where:n is 0 or 1;Z is cycloalkylene, phenylene, monocyclic heteroarylene, heterocyclylene, unsaturated heterocyclylene, bicyclic heterocyclylene, bridged heterocyclylene, unsaturated bridged heterocyclylene, fused heterocyclylene, spiro heterocyclylene, 11 to 13 -membered spiro heterocyclylene, unsaturated spiro heterocyclylene, or 11 to 13 -membered unsaturated spiro heterocyclylene;Rdis alkyl, alkoxy, alkoxyalkyl, halo, haloalkyl, haloalkoxy, cyano, and cyanoalkyl;Reis alkyl, alkoxy, alkoxyalkyl, halo, haloalkyl, or haloalkoxy;Rfis alkyl, alkoxy, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, halo, haloalkyl, haloalkoxy, haloalkoxyalkyl, hydroxy, hydroxyalkyl, alkylsulfonyl, cyano, cyanoalkyl, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonyl, aryl, arylalkyl, heteroaryl,- 160 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357Client Ref. No. NKT-25-003PCT heteroaryl alkyl, heterocyclyl, or heterocyclylalkyl where heteroaryl, heteroaryl of heteroaralkyl, heterocyclyl, and heterocyclyl of heterocyclylalkyl are unsubstituted or substituted with one or two substituents independently selected from halo and alkyl; andRgis deuterium, alkyl, halo, or haloalkyl;Z2is a bond, alkylene, alkynylene, -C(O)-, -C(O)N(R)-, -NR’ (CO)-, -(O-alkylene)b-, -(alkylene-O)b-, -O(CH2)7-, -O(CH2)8-, cycloalkylene, or heterocyclylene, where each ring is substituted with Rjand Rkindependently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, hydroxy, amino, alkylamino, and dialkylamino;Z3is a bond, alkylene, alkynylene, -C(O)NR-, -NR’(CO)-, -O-, -NR”-, -(O-alkylene)c-, -(alkylene-O)c-, cycloalkylene, spiro cycloalkylene, phenylene, -(alkylene)-phenylene-, -phenylene-(alkylene)-, monocyclic heteroarylene, -(alkylene)-monocyclic heteroarylene-, -monocyclic heteroarylene-(alkylene)-, heterocyclylene, -(alkylene)-heterocyclylene-, -heterocyclylene-(alkylene)-, bicyclic heterocyclylene, bridged heterocyclylene, -(alkylene)-bridged heterocyclylene-, -bridged heterocyclylene-(alkylene)-, fused heterocyclylene, spiro heterocyclylene, -(alkyl ene)-spiro heterocyclylene-, -spiro heterocyclylene-(alkylene)-, or 11 to 13 membered spiro heterocyclylene, where each ring, by itself or as part of another group, is substituted with Rmand Rnindependently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, hydroxy, amino, alkylamino, and dialkylamino;Z4is a bond, alkylene, alkynylene, -(alkylene-NR”)-, -(NR”-alkylene)-, -O-, -C(O)-, -NR”-, -(O-alkylene)a-, -(alkylene-O)a-, cycloalkylene, -(alkylene)-cycloalkylene-, -cycloalkylene-(alkylene)-, spiro cycloalkylene, phenylene, heteroarylene, heterocyclylene, -(alkylene)-heterocyclylene-, -heterocyclylene-(alkylene)-, fused heterocyclylene, bridged heterocyclylene, -(alkylene)-bridged heterocyclylene-, -bridged heterocyclylene-(alkylene)-, spiro heterocyclylene, -(alkyl ene)-spiro heterocyclylene, or -spiro heterocyclylene-(alkylene)-, where each ring, by itself or as part of another group, is substituted with R° and Rpindependently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, hydroxy, amino, alkylamino, and dialkylamino;Z5is phenylene, monocyclic heteroarylene, or heterocyclylene, where each ring is substituted with Rqand Rrindependently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, hydroxy, amino, alkylamino, and dialkylamino; andZ6is -S(O)2-;where each R, R’ and R” is independently hydrogen or alkyl, each b, c, and d is independently an integer selected from 1 to 6, and each alkylene of -Z2-, -Z3-, - and-Z4-, by itself or as part of another group, is independently substituted with Rsand R.twhere Rsis- 161 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357Client Ref. No. NKT-25-003PCT hydrogen or deuterium and R.tis hydrogen, deuterium, haloalkyl, hydroxy, alkoxy, cyano, cycloalkyl, heterocyclyl, aryl, or monocyclic heteroaryl, wherein cycloalkyl, heterocyclyl, aryl, monocyclic heteroaryl are substituted with one or two substituents independently selected from hydrogen, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, or cyano;provided that at least one of -Z2-Z3-Z4- is not a bond;or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein at least two of Rd, Re, and Rfare attached to a carbon atom of Z that is adjacent to the carbon atom of Z that is attached to ring A of E3 ubiquitin ligand of formula (i) or to ring B of E3 ubiquitin ligand of formula (ii) and at least one of Rd, Re, and Rfis other than alkyl.

3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein two of Rd, Re, and Rfare other than alkyl.

4. The compound of claim 2 or 3, or a pharmaceutically acceptable salt thereof, wherein the one or two of Rd, Re, and Rfthat is other than alkyl are independently halo.

5. The compound of claim 4, or a pharmaceutically acceptable salt thereof, whereinRdis methyl, ethyl, isopropyl, fluoro, or cyano;Reis methyl, ethyl, fluoro, difluoromethyl, or trifluoromethyl; andRfis methyl, ethyl, methoxy, methoxymethyl, cyclopropyl, cyclopropylmethyl, fluoro, difluoromethyl, trifluoromethyl, difluoromethoxymethyl, trifluoromethoxymethyl, hydroxy, methylsulfonyl, cyano, cyanomethyl, methylaminocarbonyl, phenyl, phenylmethyl, pyrazolyl, pyrazolylmethyl, oxetanyl, or oxetanylmethyl, where phenyl, phenylmethyl, pyrazolyl, and pyrazolyl methyl are unsubstituted or substituted with one or two substituents independently selected from methyl or fluoro.

6. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein:Rdis alkyl;Reis alkyl or halo;Rfis alkyl, halo, cyano, cyanoalkyl, or haloalkyl; andRg, when present, is alkyl.

7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein Z is heterocyclylene.

8. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein Z is unsaturated heterocyclylene.

9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R1is halo, haloalkyl, or haloalkoxy.- 162 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357Client Ref. No. NKT-25-003PCT10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, Hy is:where the N atom of the pyrrolidin- 1,3 -diyl or piperidin-l,4-diyl rings is attached to Z6of L.

11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein the Degron is an E3 ubiquitin ligase ligand of formula (ii):

12. The compound of any one of claims 1 to 6 and 9 to 11, or a pharmaceutically13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein:Z2is a bond;Z3is a bond, alkylene, -C(O)NR-, -NR’ (CO)-, -O-, -NR”-, cycloalkylene, phenylene, monocyclic heteroarylene, heterocyclylene, bicyclic heterocyclylene, bridged heterocyclylene, fused heterocyclylene, or spiro heterocyclylene, where each ring is substituted with Rmand Rn; andZ4is a bond, alkylene, -O-, cycloalkylene, phenylene, monocyclic heteroarylene, heterocyclylene, fused heterocyclylene, or spiro heterocyclylene, where each ring is substituted with R° and Rp; andwherein each alkylene in Z3and Z4is independently substituted with Rsand Rt.

14. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein:- 163 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357Client Ref. No. NKT-25-003PCTZ2is a bond;Z3is a bond, alkylene, or -O-;Z4is heterocyclylene, bridged heterocyclylene, or spiro heterocyclylene, where each ring is substituted with R° and Rpindependently selected from hydrogen, deuterium, alkyl, alkoxy, hydroxy, cyano, halo, haloalkyl, and haloalkoxy;Z5is phenylene or monocyclic heteroarylene, each ring substituted with Rqand Rr, independently selected from hydrogen, deuterium, alkyl, alkoxy, hydroxy, cyano, halo, haloalkyl, and haloalkoxy; andwherein alkylene in Z3is substituted with Rsand R.t.

15. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein -Z3-Z4-Z5-Z6- is:wherein Rqis selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano.

16. The compound of claim 1 to 15, or a pharmaceutically acceptable salt thereof, wherein -Z3-Z4-Z5-Z6- is:

17. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein Degron is the E3 ubiquitin ligase ligand selected from:- 164 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357Client Ref. No. NKT-25-003PCThydrogen, methyl, cyclopropyl, fluoro, cyano, methoxy, difluoromethoxy, trifluoromethoxy, or trifluoromethyl.

18. The compound of claim 17, or a pharmaceutically acceptable salt thereof, whereinDegron is the E3 ligase ligand selected from:

19. The compound of claim 17, or a pharmaceutically acceptable salt thereof, whereinDegron is the E3 ubiquitin ligase ligand:each Reeis hydrogen, methyl,- 165 - 1107314462\4\AMERICASAttorney Docket No. 119005.00357Client Ref. No. NKT-25-003PCT ethyl, cyclopropyl, or 2,2,2-trifluoroethyl and each Rff, when specifically drawn is hydrogen, methyl, cyclopropyl, fluoro, cyano, methoxy, difluoromethoxy, trifluoromethoxy, or trifluoromethyl.

20. A pharmaceutical composition comprising a compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

21. A method of treating cancer mediated by CDK2 and / or CDK4 in a patient which method comprises administering to the patient in need thereof, a therapeutically effective amount a compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 20.- 166 - 1107314462\4\AMERICAS